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Welcome and Introductions 
 
Nancy Bennett, MD, MS 
ACIP Chair 
 
Amanda Cohn, MD 
Executive Secretary, ACIP / CDC 
 
Dr. Bennett called the February 2016 Advisory Committee on Immunization Practices (ACIP) 
meeting to order and welcomed those present.  She introduced Dr. Amanda Cohn, the New 
ACIP Executive Secretary.  Dr. Cohn joins ACIP from the Immunization Services Division (ISD) 
where she was the Deputy Director.  She obtained her medical degree from Emory University, 
completed her Residency in Pediatrics at Boston Children’s Hospital (BCH) and Boston Medical 
Center (BMC).  She came to the Centers for Disease Control and Prevention (CDC) in 2004 as 
an Epidemic Intelligence Service (EIS) Officer, and joined the Meningitis and Vaccine 
Preventable Diseases Branch (MVPDB) in 2006.  She focused on meningococcal disease, and 
served as the CDC Lead for the ACIP Meningococcal Vaccines Work Group (WG) from 2007 
through 2014.  She is Board Certified in Pediatrics and is a Fellow of the American Academy of 
Pediatrics (AAP).  She is also the mother of three daughters, as is Dr. Bennett, so they have 
more in common than just sitting in the front of the room.  
 
Dr. Cohn thanked everyone for welcoming her to the role of ACIP Executive Secretary.  She 
reported that her older daughters have received all doses of Human Papillomavirus (HPV) 
vaccine, and that her youngest daughter is not yet old enough.  She welcomed everyone to the 
February 2016 ACIP meeting.  She indicated that the proceedings of this meeting would be 
accessible to people not in attendance via the World Wide Web, and welcomed those who could 
not attend the meeting in person.  She then recognized several others in the room who were to 
be present throughout the duration of the meeting to assist with various meeting functions:  
Stephanie Thomas, Natalie Greene, Chris Caraway, and Dr. Jean Claire Smith.  She expressed 
appreciation for all of the work these individuals perform every meeting.  She reported that 
because Dr. Rima Khabbaz was unable to attend, Dr. Nancy Messonnier was joining them in 
her place.  Dr. Messonnier is the Deputy Director of the National Center for Immunization and 
Respiratory Diseases (NCIRD). 
 
Dr. Cohn noted that handouts of the presentations were distributed to the ACIP members and 
were made available for others on the tables outside of the auditorium.  Slides presented during 
this meeting will be posted on the ACIP website approximately two weeks after the meeting 
concludes after being made visually accessible to all viewers, including the visually disabled.  
The live webcast will be posted within four weeks following the meeting, and the meeting 
minutes will be available on the website within approximately 90 days following this meeting.  
Members of the press interested in conducting interviews with ACIP members were instructed to 
contact Ian Branam, located at the press table, for assistance in arranging interviews. 
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The next ACIP meeting will be convened at CDC on Wednesday and Thursday, June 22-23, 
2016.  Registration for all meeting attendees is required.  The registration deadline for Non-US 
citizens is May 18, 2016 and for US citizens registration closes June 6, 2016.  Registration is 
not required for webcast viewing.  As a reminder for non-US citizens attending ACIP meetings, 
completion of several forms is required for each meeting at the time of registration.  It is 
important that these forms are submitted within the required time frame.  Stephanie Thomas, 
the ACIP Committee Management Specialist, will be able to help with any questions about the 
process. 
 
Dr. Cohn then introduced and welcomed the following new Ex Officio members and Liaison 
Representatives: 
 







Dr. Narayan Nair replaces Dr. Melissa Houston for the Health Resources and Services 
Administration (HRSA) 
Dr. Jane Kim replaces Dr. Linda Kinsinger for the Department of Veterans Affairs (DVA)  
Dr. Sergienko, Department of Defense (DoD), was unable to attend and was represented by 






Dr. Sean O’Leary, Associate Professor of Pediatric Infectious Diseases and General 
Academic pediatrics at Children’s Hospital Colorado at the University of Colorado School of 
Medicine, replaces Dr. Mark Sawyer for the Pediatric Infectious Diseases Society (PIDS), 
who served as a voting member of ACIP from July 2008 through June 2013, following which 
he joined ACIP as a Liaison Representative 
Dr. Kimberly Martin was in attendance representing the Association of State and Territorial 
Health Officials (ASTHO)  
 
Regarding public comments, Dr. Cohn indicated that topics presented during ACIP meetings 
include open discussion with time reserved for public comment.  She explained that time for 
public comment pertaining to topics on the agenda was scheduled following the end of the day’s 
sessions, and that time for public comments also may be provided prior to specific votes by 
ACIP to enable these comments to be considered before a vote.  During this meeting, there was 
one public comment opportunity scheduled for 4:55 PM.  People who planned to make public 
comments were instructed to visit the registration table at the rear of the auditorium where Ms. 
Stephanie Thomas would record their name and provide information on the process.  People 
making public comments were instructed to provide 3 pieces of information:  name, organization 
if applicable, and any conflicts of interest (COI).  Registration for public comment also was 
solicited in advance of this meeting through the Federal Register.  Given time constraints, each 
comment was limited to 3 minutes.  Participants unable to present comments during this 
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Recommendations and immunization schedules can be downloaded from the ACIP website. 
ACIP has a policy that every three to five years each recommendation is reviewed, and then 
renewed, revised, or retired.  During every meeting, an update is provided on the status of ACIP 
recommendations.  There have been three ACIP publications since October 2015, which are 




Applications for ACIP membership are due no later than November 4, 2016 for the 4-year term 
beginning July 1, 2017.  Detailed instructions for submission of names of potential candidates to 
serve as ACIP members may be found on the ACIP web site: 
 
E-mail:  acip@cdc.gov Web homepage:  http://www.cdc.gov/vaccines/acip/index.html 
 
Nominations:  http://www.cdc.gov/vaccines/acip/committee/req-nominate.html  
 
A current CV, at least one recommendation letter from a non-federal government employee, and 
complete contact information are required.  These may be submitted as e-mail attachments to 
Dr. Jean Clare Smith at jsmith2@cdc.gov 
 
To summarize COI provisions applicable to the ACIP, as noted in the ACIP Policies and 
Procedures manual, members of the ACIP agree to forgo participation in certain activities 
related to vaccines during their tenure on the committee.  For certain other interests that 
potentially enhance a member’s expertise while serving on the committee, CDC has issued 
limited COI waivers.  Members who conduct vaccine clinical trials or serve on data safety 
monitoring boards (DSMBs) may present to the committee on matters related to those vaccines, 
but these members are prohibited from participating in committee votes on issues related to 
those vaccines.  Regarding other vaccines of the concerned company, a member may 
participate in discussions, with the proviso that he/she abstains on all votes related to the 
vaccines of that company.  It is important to note that at the beginning of each meeting, ACIP 
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Dr. Bennett announced that two individuals with long histories with ACIP, Dr. Larry Pickering 




The National Foundation for Infectious Diseases (NFID) will present Dr. Larry Pickering, past 
ACIP Executive Secretary, with the John P. Utz Leadership Award.  The Award is presented to 
individuals who exemplify and support National Foundation for Infectious Diseases (NFID) 
leadership goals through service to NFID and/or the field of infectious diseases.  The second 
award is to Dr. Larry Pickering and Dr. Carol Baker, former ACIP Chair, who will both be 
honored with the 12th Annual Stanley A. Plotkin Lectureship in Vaccinology during the 2016 
Pediatric Academic Societies (PAS) meeting in May.  This lectureship was established to honor 
Dr. Plotkin, PAS’s Founding Father.  Dr. Baker will be presenting A Time to Save: The Vaccine 
Story and Dr. Pickering will be presenting Complexities of Vaccine Recommendations: Lessons 
Learned.  Dr. Bennett invited everyone to join her in congratulating these two important 
members. 
 
Before officially beginning the meeting, Dr. Bennett called the roll to determine whether any 




Dr. Belongia receives research support from Medimmune and has a conflict for influenza. 
The remainder of the ACIP members declared no conflicts. 
 




Centers for Disease Control and Prevention (CDC) 
 
Dr. Messonnier reported that it continues to be a very busy time at CDC.  Apparently, the 
agency has set a new record because there are four simultaneous activations in the Emergency 
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Regarding Ebola, the Sierra Leone vaccine trial has completed vaccination.  Over 8,000 HCP 
and other frontline workers were vaccinated in 5 districts in Sierra Leone.  Current ongoing work 
includes adverse event (AE) monitoring of participants, blood draws at 6 through 12 months 
post-vaccination, and follow-up of pregnancies.  Trial results are expected by Fall 2016. 
 
In terms of polio containment, a major part of the polio eradication effort is containment of 
laboratory samples.  There is an extensive survey underway of laboratories throughout the 
country to determine whether anyone has polio-containing materials, and to ensure that those 
are handled appropriately. 
 
Regarding upcoming meetings, the theme of the 2016 National Adult and Influenza 
Immunization Summit scheduled for May 10-12, 2016 in Atlanta is “Making Vaccination Happen 
in a Changing Environment.”  The Division of Viral Diseases (DVD) is hosting a small meeting in 
May 2016 titled “RSV Disease in the United States: Identifying Gaps in Epidemiology Prior to 
the Advent of Vaccines.” 
 
Centers for Medicare and Medicaid Services (CMS) 
 
Dr. Hance announced that CMS conducted a survey of state Medicaid agencies to try to 
determine exactly what preventive services they are covering for adults, including 
immunizations.  The survey also focused on cost sharing.  CMS will soon release the report on 
this survey, which will be released through the website:  www.Medicaid.gov  
 




Department of Veterans Affairs (DVA) 
 
Dr. Jane Kim reported that the Veterans Information Systems and Technology Architecture 
(VistA), DVA’s nationwide immunization system, has a project known as VistA Immunization 
Enhancements (VIMM) that will be initiating data sharing to state and city immunization 
registries.  Pilot testing will begin later in 2016.  VA is also developing clinical reminder support 
tools for the electronic medical record (EMR) to prompt clinicians to offer tetanus; tetanus 
toxoid, reduced diphtheria toxoid, acellular pertussis (Tdap), and herpes zoster immunizations 
to patients who meet criteria.  These tools will be disseminated nationwide throughout the VA 
system in March 2016. 
 
Food and Drug Administration (FDA) 
 
Dr. Sun reported that since the last ACIP meeting, FDA approved the first adjuvanted seasonal 
influenza vaccine, FLUAD™, for individuals 65 years of age and older.  GARDASIL® 9 received 
supplemental approval for boys 9 through 16 years of age for the prevention of anal cancer, 
genital warts, and anal intraepithelial neoplasia (AIN).  A supplement was also approved for the 
anthrax vaccine, BioThrax®, for post-exposure prophylaxis (PEP).  This is noteworthy because it 
is the first animal rule approval for a vaccine indication.  FDA convened a Vaccines and Related 
Biological Products Advisory Committee (VRBPAC) meeting on November 13, 2015 on the topic 













Use of serologic endpoints as markers for protection 
Safety assessment of infants after maternal immunization 
Duration of follow-up 
Potential immunologic interference of maternal immunization with infant immunization 
Use of observational studies for vaccines recommended by ACIP, such as Tdap and 
influenza, to evaluate the effectiveness of maternal immunization 
 
Health Resources and Services Administration (HRSA) 
 
Dr. Nair reported that the national Vaccine Immunization Compensation Program (VICP) has 
had a busy year processing claims.  As of January 2016, over 375 claims have been filed for the 
current fiscal year.  Thus far in this fiscal year, 127 claims have been adjudicated.  Of those, 
125 were compensable and 2 were dismissed.  Approximately $75 million in awards have been 
paid to petitioners, and $6 million have been paid to attorneys for fees and costs for 
compensated and dismissed claims.  More data about the program can be obtained on the 
HRSA website.  HRSA has completed development of proposed regulations to make changes 
to the Vaccine Injury Table.  The Notice for Proposed Rulemaking was posted for public 
comments in July 2015, and was available for 180 days.  A hearing to obtain comments from 
the public on the proposed changes took place on January 14, 2016.  Comments received from 
the public are still being reviewed.  To date in this fiscal year, the Countermeasures Injury 
Compensation Program (CICP) has compensated 2 claims totaling $125,000.  Both programs 
are involved in outreach programs to inform providers and make the public aware of this safety 
net program. 
 
Indian Health Services (IHS) 
 
Ms. Groom announced that this year, IHS rolled out a mandatory influenza vaccination policy for 
its healthcare personnel (HCP).  Because bargaining had not been completed with unions, IHS 
was able to implement the policy only partially.  However, a 10% increase was observed among 
IHS’s HCP even with partial implementation.  Bargaining was recently completed with the 
largest union, so hopefully there will be more complete implementation of the policy next year.  
In addition, IHS is rolling out two performance measures for the agency that pertain to 
immunizations.  The first is a composite adult immunization measure that will assess the 
proportion of adults 19 years of age and older who have received all age-appropriate 
vaccinations with Tdap, herpes zoster, and pneumococcal vaccines.  The second is a 
developmental measure to assess Tdap and influenza vaccination among pregnant women. 
 
National Institutes of Health (NIH) 
 
Dr. Gorman reported that Dr. Carole Heilman would retire as the Division Director of the Division 
of Microbiology and Infectious Diseases (DMID) on February 12, 2016 following an illustrious 
38-year career at NIH.  Since her 1999 appointment as DMID director, Dr. Heilman has 
managed a highly complex global research program in infectious diseases, providing scientific 
direction and oversight for an extensive extramural research portfolio.  Under her leadership, 
DMID has built a robust research infrastructure encompassing national and regional 
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Known for fostering a collaborative work environment and encouraging open scientific 
discourse, Dr. Heilman has received numerous awards for scientific management and 
leadership.  Her honors include three Department of Health and Human Services (HHS) 
Secretary's Awards for Distinguished Service, recognizing her contributions to developing 
pertussis, biodefense, and AIDS vaccines.  Dr. Irene Glowinski will serve as Acting Director of 
DMID while NIH conducts a national search for Dr. Heilman’s replacement.  Dr. Gorman said 
that when he wonders whether one person can make a difference in a group as large as the 
federal government, he thinks of Dr. Heilman and realizes that it can be done. 
 
In terms of research and publications, Dr. Gorman indicated that Dr. Gellin would provide a 
detailed presentation during the Zika Virus session.  NIH is in the process of collecting serum, 
now on an impromptu and soon on a systematic basis, so that reagents and determinants of 
immune correlates of protection can be studied.  NIH is also considering vaccine development 
and hopes to pivot rapidly from the experience with dengue and Chikungunya to the new virus 
that is vector-borne.  The National Institute of Allergy and Infectious Diseases (NIAID) has 
initiated work on several fronts to address Zika virus including the development of animal 
models to better understand the impact of the virus on the body; in vitro assays to test 
therapeutics for activity against the virus; and improved diagnostics to rapidly identify the virus 
and distinguish it from its close relatives (e.g., dengue).  Several NIAID-supported Zika vaccine 
efforts already are under way, including the use of the following vaccine approaches:  
Deoxyribonucleic acid (DNA) vaccines, live attenuated vaccines, and VSV-vectored vaccines 
[Fauci AS1, Morens DM. Zika Virus in the Americas - Yet Another Arbovirus Threat. N Engl J 
Med. 2016 Jan 13. [Epub ahead of print] http://www.nejm.org/doi/full/10.1056/NEJMp1600297].  
NIAID recently issued a notice to highlight the NIH’s interest in supporting research and product 
development to combat Zika virus.  Areas of high priority include:  diagnostics, therapeutics, 
vaccines, and basic research to better understand infection; pathogenesis; biology of mosquito 
vectors, host-virus interaction and identification of relevant biomarkers [NIH Guide Notice: 
http://grants.nih.gov/grants/guide/notice-files/NOT-AI-16-026.htm]  
 
NIAID is organizing a workshop to be convened March 28-29, 2016 to bring together 
researchers from around the world with HHS entities (CDC, FDA, ASPR/BARDA, and NIH) and 
industry partners.  The discussion will include a review of the latest information on the virology, 
pathogenesis, and epidemiology (including the potential link to microcephaly) of Zika virus, as 
well as efforts toward the development of diagnostics, therapeutics, vaccines, and novel vector 
control strategies. 
 
There has been a recent publication of NIH’s safety and immunogenicity study of sequential 
rotavirus vaccine schedules.  NIAID-supported researchers studied the two rotavirus vaccines 
licensed for infants in the United States (US), RotaTeq® and Rotarix®, to determine whether 
switching from one vaccine product to another works as well as using the same vaccine for all of 
the doses.  According to current recommendations and depending upon which vaccine is used, 
infants receive a series of two or three doses.  In many cases, infants receive the same vaccine 
for all of their doses.  However, in some situations HCPs may switch from one product to the 
other to complete the vaccine series.  In this study, researchers determined that mixed rotavirus 
vaccine schedules are safe and non-inferior in immunogenicity when compared with each 
licensed rotavirus vaccine when administered alone [Libster R, McNeal M, Walter EB, Shane 
AL, Winokur P, Cress G, Berry AA, Kotloff KL, Sarpong K, Turley CB, Harrison CJ, Pahud BA, 
Marbin J, Dunn J, El-Khorazaty J, Barrett J, Edwards KM; Safety and Immunogenicity of 
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Pediatrics. 2016 Jan 28. pii: peds.2015-2603. [Epub ahead of print; 
https://www.clinicaltrials.gov/ct2/show/NCT01266850]. 
 
NIH has a new dengue vaccine entering a Phase 3 trial in Brazil.  This is a large-scale clinical 
trial to evaluate whether a candidate vaccine can prevent the mosquito-borne illness dengue 
fever.  The vaccine, TV003, was developed by scientists in the laboratory of Stephen 
Whitehead, PhD, at NIAID.  The Butantan Institute, a non-profit producer of immunobiologic 
products for Brazil, licensed the NIAID dengue vaccine technology and is sponsoring the 
placebo-controlled, multi-center Phase 3 trial using test vaccine produced in Sao Paulo.  The 
new trial plans to enroll almost 17,000 healthy people 2 through 59 years of age in 13 cities, 
beginning in Sao Paulo [https://clinicaltrials.gov/ct2/show/ NCT02406729]. 
 
An experimental vaccine to protect against the mosquito-borne illness Chikungunya is being 
tested in a Phase 2 trial sponsored by NIH.  Results from an initial trial of the vaccine, which 
was developed by scientists at NIAID, were reported in 2014. In that study, all 25 vaccine 
recipients developed robust immune responses and no safety concerns were noted.  The new 
trial is designed to enroll 400 healthy adult volunteers 18 through 60 years of age at six sites in 
the Caribbean.  It will continue to collect data on the candidate vaccine’s safety and ability to 
elicit immune responses, including antibodies [https://www.clinicaltrials.gov/ct2/show/  
NCT02562482?term=NCT02562482&rank=1]. 
 
There was a special issue of Vaccine:  Advancing Maternal Immunization Programs through 
Research in Low and Medium Income Countries.  This builds upon a long and storied history 
from ACIP in promoting maternal immunizations, and brings together a lot of the research in a 
single area.  This work is ongoing [Volume 33, Issue 47, 25 November 2015, ISSN 0264-410X; 
Guest editors M. Nesin (NIH), J. Read (NIH), M. Koso-Thomas (NIH), M. Brewinski Isaacs (NIH) 
and A. Sobanjo-ter Meulen (B&M Gates Foundation)]. 
 
National Vaccine Advisory Committee (NVAC) 
 
Dr. Orenstein reported that NVAC last met on February 2-3, 2016.  A topic of significant focus 
has been drivers of vaccine innovation, potential ways to incentivize innovation, and possible 
barriers.  They look forward to the June 2016 meeting when an initial landscape analysis will be 
done of what those barriers can be.  They have heard from domestic and global groups, 
including Dr. Seth Berkley, who is the Chief Executive Officer (CEO) of the Global Alliance for 
Vaccines and Immunization (GAVI), and who is talking about creation of a vaccine development 
fund.  During the June 2016 NVAC meeting, there will be a report of selected recommendations 
from NVAC’s Maternal Immunization WG, which is assessing overcoming barriers to developing 
vaccines and vaccine recommendations for existing vaccines for pregnant women.  Another 
major focus is the National Vaccine Plan (NVP) 2010-2020, for which NVAC will be intimately 
involved with a midcourse review.  NVAC is following adult immunization implementation issues, 
and has heard information about efforts pertaining to containment of polioviruses.  Type 2 
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National Vaccine Program Office (NVPO) 
 
Dr. Gellin noted that many had participated in the NVP midcourse review, the purpose of which 
is to determine whether the direction set in 2010 is the same direction that should be continued.  
The National Adult Immunization Plan (NAIP) has been launched.  The NAIP has the following 
four broad goals: 
 
Goal 1: Strengthen the adult immunization infrastructure  
Goal 2: Improve access to adult vaccines 
Goal 3: Increase community demand for adult immunizations 
Goal 4: Foster innovation in adult vaccine development and vaccination-related technologies 
 
In related work with CDC and the Immunization Action Coalition (IAC), NVPO is co-sponsoring 
the National Adult and Influenza Immunization Summit, which will be in Atlanta May 10-12, 
2016. 
 
NVAC issued a vaccine confidence report last summer, which is now the “playbook” for moving 
forward.  NVPO is sponsoring a funding opportunity of up to $250,000 to assess the outlines of 






Allison Kempe, MD, MPH 
Chair, ACIP HPV Vaccines WG  
 
Dr. Kempe reminded everyone that in February 2015, ACIP voted on the 9-valent HPV (9vHPV) 
vaccine recommendations.  In June 2015, the WG reviewed the status of the 9vHPV vaccine 
introduction, reviewed a variety of data, and discussed the issue of potential additional 9vHPV 
vaccination for those who received a different HPV vaccine.  In October 2015, the WG reviewed 
the HPV vaccination program in terms of coverage and implementation, safety, and impact. 
 
To frame the discussion for this session, Dr. Kempe reminded everyone of some historical 
recent dates pertaining to 9vHPV vaccine.  The vaccine was licensed by the FDA in December 
2014 and was recommended by ACIP in February 2015, with a Morbidity and Mortality Weekly 
Report (MMWR) Policy Note published in March 2015.  9vHPV vaccine was recommended as 1 
of 3 HPV vaccines that can be used for females and 1 of 2 for males in the currently 
recommended age groups. 
 
Regarding the male age indications at the time of the first application to FDA, 9vHPV 
immunogenicity trials in males 16 through 26 years of age were not completed.  In December 
2014, the vaccine was licensed for females 9 through 26 years of age and males 9 through 15 
years of age.  On December 14, 2015, FDA extended the age indication to include males 16 
through 26 years of age.  Regarding manufacturer plans, Merck previously reported that they 
intended to maintain 4vHPV in the US market until 9vHPV was approved by the FDA for use in 
males 16 through 26 years of age.  This has now occurred, so Merck plans to retire 4vHPV by 
the end of 2016 in the US. 








Since the last ACIP meeting, the WG has been reviewing data on 2-dose schedules, including 
9-valent HPV vaccine 2- versus 3- dose immunogenicity data and 2-dose trials for other HPV 
vaccines, as well as modeling and cost-effectiveness data.  The WG also has been discussing 
policy considerations related to 2-dose schedules, including what additional data may be 
needed for policy plans, the timeline, and decisions that would go along with those 
considerations. 
 







Data on 2-dose HPV vaccination schedules  
Information and background needed for discussion and decisions about HPV vaccine policy 
options that ACIP will address over the next few meetings 
WG’s future plans 
 
Background: 2-Dose Schedules 
 
Lauri Markowitz, MD 
National Center for Immunization and Respiratory Diseases  
Centers for Disease Control and Prevention 
 
Dr. Markowitz began with some brief background information for the HPV session, including 
general background and previous ACIP considerations of 2-dose schedules. 
 
There are three licensed HPV vaccines.  They are all virus-like particle (VLP) vaccines that are 
made from the L1 protein of the virus, which is the major capsid protein of the virus.  They differ 
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The bivalent vaccine has a different adjuvant, AS04, which has been shown to produce higher 
antibody titers than the adjuvant in the 4vHPV vaccines.  The 4vHPV vaccine and the 9vHPV 
vaccine have the same adjuvant, but there is more adjuvant content in the 9vHPV vaccine.  
There is a higher antigen content for HPV 6, 16, 18 in the 9vHPV compared with 4vHPV.  The 
dates of FDA licensure are shown, as well as the licensed age groups.  All vaccines are 
licensed as a 3-dose schedule as either a 0, 1, 6 month or 0, 2, 6 month schedule.  Although 
there were three licensed vaccines through 2014, almost all vaccine used in the US was 
4vHPV. 
 
For licensure of the HPV vaccines, efficacy and immunogenicity data were obtained.  These 
included efficacy data from trials in 15 through 26 year olds with trial endpoints of cervical pre-
cancer lesions as well as some other pre-cancers and genital warts, and data from bridging 
immunogenicity trials in 9 through 15 year olds.  Licensure in this age group, and age in which 
efficacy trials are not feasible, was based on non-inferior antibody response compared with 
young adult women in the efficacy trials.  This is important as it is obviously relevant for how the 
trials were conducted for the 2- versus 3-dose schedules. 
 
In terms of some brief background about what is known about the immunogenicity of HPV 
vaccines, there is high seroconversion after vaccination at greater than 98%.  In addition, 
vaccination induces higher antibody titers than natural infection.  The main basis of protection is 
neutralizing antibody; however, the minimal protective antibody threshold is not known.  Clinical 
trials used different serologic assays, and the results are difficult to compare across studies or 
HPV types.  For the 4vHPV vaccine, Merck used a competitive Luminex immunoassay (cLIA) 
that measures neutralizing antibody to 1 epitope.  The GlaxoSmithKline (GSK) trials for 2vHPV 
vaccine used an enzyme-linked immunosorbent assay (ELISA), which measures neutralizing 
and non-neutralizing antibody.  Of note in the pre-clinical trials, some 4vHPV vaccinees lost 
detectable HPV 18 antibody as measured by the cLIA, but no loss of protection was detected. 
Vaccination at younger ages results in higher antibody titers.  This last point is illustrated in this 
graphic, which shows the geometric mean titers (GMTs) one month after the third dose of 
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As shown, the GMTs decreased with increasing age at vaccination for all 4 types. [Giuliano, et 
al.  JID 2007]. The same decrease in GMTs with increasing age at vaccination was seen in the 
2vHPV and 9vHPV trials  
 
There has been global interest in simplified schedules for HPV vaccine.  Such schedules could 
facilitate implementation, reduce logistical challenges, and decrease resource needs.  They also 
might increase acceptability for providers, parents, and vaccinees.  Interest in evaluating 2-dose 
schedules in young adolescents was stimulated by data from clinical trials with 3 doses showing 
high efficacy, high serologic response to vaccination, and higher antibody titers in the younger 
age groups. 
 
The 3-dose schedules for which vaccines were originally tested and licensed (0 months, 1 to 2 
months, and 6 months) can be considered a “prime-prime-boost” (PPB), with the first 2 doses 
being the priming doses and the third being the boost.  The 2-dose schedule that has been 
studied is a 0, 6 month schedule.  This schedule can be considered a prime and boost with the 
second prime eliminated.  Memory B cells require at least 4 to 6 months to mature and 
differentiate into high-affinity B cells.  The approximate 6-month interval between the first and 
last dose allows the last dose to reactivate memory B cells efficiently [Siegrist. Chapter 2.  
Vaccine Immunology.  In Vaccines 2013; Stanley et al.  Expert Reviews 2014]. 
 
Based on some of the data that Dr. Markowitz reviewed later during this session, regulatory 
approvals have been obtained for 2-dose vaccination schedules for the 2vHPV and 4vHPV 
vaccines in other countries.  Approval for 2-dose schedules has been based primarily on the 
immunobridging data, which showed non-inferior antibody response with 2 doses (0, 6 months) 
in adolescents compared with a 3-dose schedule in young adult women.  In 2014, the European 
Medicines Agency (EMA) granted marketing authorization for a 2-dose schedule for those 9 
through 14 years of age for 2vHPV and 9 through 13 years of age for 4vHPV.  Following 
regulatory approval by the EMA, in 2014 the World Health Organization (WHO) changed its 
recommendation from a 3-dose to a 2-dose schedule for those starting the vaccination series 
before age 15 [Weekly Epidemiologic Record 2014; 89: 221-236].  Many countries changed 
from a 3- to 2-dose schedule for this age group, including European and Latin American 
countries and some provinces in Canada. 
 
During the June 2014 ACIP meeting, data on 2-dose schedules for 2vHPV and 4vHPV were 
reviewed by ACIP.  At that time, there was no FDA indication for a 2-dose schedule for any HPV 
vaccine, and there were no plans by either manufacturer for submission of 2-dose data to FDA 
for 2vHPV or 4vHPV.  Also at that time, data for the 9vHPV was being considered by ACIP and 
there were no data on 2-dose schedules in the initial Biologics License Application (BLA) under 
review by FDA at that time.  However, a 2- versus 3-doses trial had been initiated by the 
manufacturer for the 9vHPV vaccine.  In 2014, ACIP decided to continue to review 9vHPV as a 
3-dose schedule, and to consider 2-dose schedules after the data from the 2- versus 3-dose 
trial of 9vHPV vaccine and other data become available. 
 
Later that year, 9vHPV vaccine was licensed as a 3-dose schedule and was recommended by 
ACIP in February 2015 as one of the HPV vaccines that could be used for the routine 
immunization schedule.  The 9vHPV vaccine became available through the Vaccines For 
Children (VFC) Program in April 2015.  Approximately 7 million doses were distributed in the US 
through December 2015.  At this point, the 9vHPV 2- versus 3-dose trial data became available 
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Comparison of Immunogenicity of 2-Dose  
and 3-Dose Regimens of 9vHPV Vaccine 
 
Alain Luxembourg, MD, PhD 
Director, Clinical Research 
Merck Research Laboratories 
 
Dr. Luxembourg presented the latest data for Merck’s 2- versus 3-dose trial for 9vHPV vaccine.  
The 3-dose regimen of 9vHPV vaccine was licensed in December 2014 in the US; in 2015 in 
Canada, the European Union (EU), Australia, Chile, and Hong-Kong; and in 2016 in Ecuador, 





Cervical, vulvar, vaginal, and anal cancers caused by HPV 16/18/31/33/45/52/58 
Cervical, vulvar, vaginal, and anal dysplasia caused by HPV 6/11/16/18/31/33/45/52/58 
Genital warts caused by HPV 6/11 
 
In February 2015, ACIP recommended GARDASIL® 9 for routine vaccination.  Licensure of 
9vHPV vaccine is under review in other countries. 
Initial licensure of 9vHPV vaccine was for 3 doses for all age ranges.  WHO changed its 
recommendation for HPV vaccines in terms of dose schedules in October 2014 to 2 doses for 





If dose 2 is administered <5 months after dose 1, a third dose should be given >6 
months after the first dose 
 
No maximum recommended interval (≤12-15 months suggested to complete schedule 
promptly and prior to becoming sexually active) 
 
3 doses in individuals ≥15 years of age and those known to be immunocompromised 
and/or HIV-infected 
 
At this time, there is no current licensure or recommendation of a 2-dose regimen in the US.  
The 2-dose data for 4vHPV vaccine became available around the time when efficacy data 
became available for 9vHPV vaccine.  Considering the imminent submission of the 9vHPV 
vaccine data to FDA, the results of the 2-dose immunogenicity study of GARDASIL® were not 
submitted to FDA.  9vHPV was developed as a 3-dose vaccine because the development 
began in 2007, a year after 4vHPV vaccine was approved.  At that time, the standard regimen 
was 3 doses and 2-dose regimens were not discussed very much.  For that reason, all of the 
trials were conducted with a 3-dose regimen. 
 
Protocol 10 was begun in 2013 to assess a 2-dose regimen of 9vHPV vaccine.  The results of 
the primary immunogenicity analyses (4 weeks post-last dose) are expected to be reviewed by 
the FDA in 2016.  The study will continue for 2 more years for assessment of antibody 
persistence and immune memory, and these results will be presented as soon as they become 
available.  Merck is also planning a separate larger study known as Protocol 025 to assess 
long-term immunogenicity and effectiveness.  Protocol 025 is still in the planning stage.  Merck 
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Protocol 10 is an open-label study with males and females in which all subjects received 9vHPV 
vaccine.  Cohort 1 is comprised of females 9 through 14 years of age who received 2 doses 
administered with a 6-month interval.  Cohort 2 is comprised of males 9 through 14 years of age 
who received 2 doses administered with a 6-month interval.  Cohort 3 is comprised of females 
and males 9 through 14 years of age who received 2 doses with a 12-month interval.  Cohort 4 
is a control group comprised of young women 16 through 26 years of age who received 3 doses 
at 0, 2, and 6 months.  Cohort 4 serves as the control because it uses the population and dose 
regimen that were used to establish vaccine efficacy.  Since there is no immune correlate of 
protection threshold of protective antibody determined for HPV vaccines, the only 
immunogenicity comparison that has clinical significance is a comparison to a group where 
efficacy was established. 
 
Cohort 5 is an exploratory cohort comprised of females 9 through 14 years of age who received 
3 doses to assess the dose effect in the same age range and same gender.  It is exploratory 
because it is scientifically important and interesting, but is not necessarily a comparison for 
which a conclusion can be drawn regarding clinical significance.  There was a 4-week window 
for all of the vaccination dates.  The study will continue for two more years for assessment of 
immunogenicity, including assessment of immune memory at Month 36, with a challenge dose 
administered. 
 
















Demonstrate non-inferiority of GMTs at 1 month after the last dose in girls and boys who 
received a 2-dose regimen versus young women who received a 3-dose regimen 
 
Same approach as that previously accepted for licensure of 3-dose regimen of 
GARDASIL® 
Non-inferiority criterion:  exclude 1.5-fold decrease (2- versus 3-dose) 
 
Perform 3 non-inferiority tests:  
 
Girls (0, 6) vs. Women (0, 2, 6) 
Boys (0, 6) vs. Women (0, 2, 6) 
Girls/Boys (0, 12) vs. Women (0, 2, 6) 
 
The objectives for the exploratory analyses are to: 
 
Compare GMTs 1 month after the last dose in: 
 
Girls (0, 6) vs. Girls (0, 2, 6) 
Girls (0, 12) vs. Girls (0, 2, 6) 
 
Assess antibody persistence at months 24 and 36 
Assess evidence of immune memory (additional dose at month 36) 
 
No hypothesis testing for the exploratory analyses 
 
In terms of the results for the primary objectives, at 1 month post-last dose in 2-dose (0, 6) girls 
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The non-inferiority criterion was met for all 9 HPV types.  The fold difference for girls/women 
was over 2 for most types.  Types 45 and 52 were somewhat lower, but still, the non-inferiority 
criterion was met for all HPV types, with the lower bound of the 95% confidence interval greater 
than 0.67 (thereby excluding a 1.5-fold decrease).  For boys receiving 2-doses (0, 6) versus 
women receiving 3-dose (0, 2, 6), substantially higher immunogenicity was achieved among 
boys receiving 2 doses versus women receiving three doses.  The non-inferiority criterion was 
met for all 9 HPV types.  Types 45 and 52 were in the lower range, while types 16 and 33 were 
among the highest.  For 2-doses (0, 12) for girls and boys versus 3-doses (0, 2, 6) for women, 
the non-inferiority criterion was met for all 9 HPV types. 
 
As part of the objectives, seroconversion rates were also assessed.  It is very clear from the 
following table showing the 5 cohorts and 9 HPV types that all seroconversion rates for any type 






For the exploratory analyses of 2 doses (0, 6) in girls 9 through 14 years of age versus 3 doses 
(0, 2, 6) in girls 9 through 14 years of age, at first glance GMTs look very similar for all 9 HPV 
types.  But looking at the fold difference, the point estimate of the GMT ratio is greater than 1 for 
Types 6, 11, 16, 33, and 58 and lower than 1 for Types 18, 31, 45, and 52.  A fold difference of 
greater than 1 means that the GMT is higher with the 2-dose than the 3-dose regimen, while a 
fold difference of less than 1 means that the GMT is higher with the 3-dose than the 2-dose 
regimen.  For Types 31, 45, and 52 the 95% confidence interval of the GMT ratio does not 
include 1, which indicates a significantly lower GMT for 2-dose than 3-dose. 
 
The same comparison was conducted between girls receiving a 2-dose regimen at 12 months 
(0, 12) versus girls receiving a 3-dose regimen (0, 2, 6).  The GMTs were generally higher with 
the 0, 12 regimen.  The fold difference was greater than 1 for Types 6, 11, 16, 18, 31, 33, 52, 
and 58.  The fold difference was less than 1 for Type 45, and the 95% confidence interval of the 
GMT ratio did not include 1.  Thus, there was a significantly lower GMT for Type 45 and a 
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Given that GARDASIL® 9 is now a licensed product, a vaccination report card was not used and 
injection site and systemic adverse events (AE) were not systematically assessed.  However, 
serious AE (SAE) and discontinuations due to an AE were assessed.  During the study, a few 
SAEs were evenly distributed among the groups.  Among these, there were no vaccine-related 
SAEs and no deaths. One (1) discontinuation due to urticaria was reported at 1 day post-dose 1 
in Cohort 3 that resolved. 
 
In summary, the primary study hypotheses were met.  Non-inferiority was met for HPV 
6/11/16/18/31/33/45/52/58 GMTs at 1 month after last vaccination in girls and boys 9 through 14 
years of age who received 2 doses of 9vHPV vaccine versus women 16 through 26 years of 
age who received 3 doses.  That supports extending the efficacy findings in women who 
received 3 doses to girls and boys who received 2 doses, using the same process that was 
used for 3 doses in boys and girls.  The exploratory analyses showed that for some HPV types, 
GMTs were lower in girls who received 2 doses versus girls who received 3 doses.  The clinical 
significance of this observation is unknown but may deserve further investigation, especially 
based on longer follow-up.  With respect to safety, 9vHPV vaccine was generally well-tolerated 
in all vaccination groups.  There were no vaccine-related SAEs, no deaths, and only 1 
discontinuation due to an AE.  There were no new safety findings compared with previous 
clinical studies of the 9vHPV vaccine. 
 
There are a number of key points and potential limitations to be considered with these results.  
Regarding the time interval between dose 1 and dose 2, per WHO and EMA, if for any reason, 
the interval between doses 1 and 2 is less than 5 months, a third dose should be given 6 
months after dose 1.  There is a single post-marketing effectiveness study of GARDASIL® using 
genital warts as an end point that indicates lower effectiveness if the time interval between 
doses 1 and 2 is less than 5 months [Blomberg et al Clin Infect Dis 2015; 61:676-682].  This 
suggests that there may be less flexibility with a 2-dose regimen than with a 3-dose regimen.  
Though little is known about a single dose, there are post-marketing effectiveness studies of 
4vHPV vaccine that indicate lower effectiveness of a single dose.  Thus, ensuring series 
completion is essential.  Duration of protection provided by 2 doses of 9vHPV vaccine has not 
been assessed, there is no efficacy assessment, and there are no long-term follow-up data.  
Data are forthcoming from the longer term follow-up study that is planned, but they are not 
available at this time.  Immunogenicity assessment will continue through Month 37 in this study 
and a separate, larger, long-term immunogenicity and effectiveness study is planned given the 
absence of an immune threshold of protection. 
 
In conclusion, administration of a 2-dose series of 9vHPV vaccine in girls and boys 9 through 14 
years of age, with the second dose given at 6 or 12 months following the first dose (± 4 week 
window) generates non-inferior GMTs for all 9 HPV types compared with the 3-dose regimen in 
young women 16 through 26 years of age.  The efficacy of the 2-dose regimen, durability of 
responses, and long-term effectiveness remain to be evaluated in long-term follow-up clinical 




Ms. Pellegrini requested clarification regarding whether Merck would be submitting these data to 
FDA, and whether an indication for a 2-dose schedule would be sought based on the data. 
 
Dr. Luxembourg replied that Merck does not plan to submit the 2-dose data of GARDASIL® to 








Dr. Bennett requested clarification of Ms. Pellegrini’s question regarding 9vHPV vaccine. 
 
Dr. Luxembourg clarified that his first reply regarded the 4vHPV vaccine.  FDA is currently 
reviewing the results of the 2-dose study for the 9vHPV vaccine. 
 
Dr. Karron asked how GARDASIL® 9 is being used in the other countries where it has been 
approved. 
 
Dr. Luxembourg responded that at this point, GARDASIL® 9 is commercially available in the US, 
Canada, and a few European countries only as a 3-dose schedule. 
 
Dr. Belongia asked Dr. Luxembourg to comment further on the observation that the GMT ratio 
was higher for the 2-dose schedule at 0, 12 months versus the 2-dose schedule at 0, 6 months, 
and whether Merck would propose to utilize the longer interval in its application for a 2-dose 
schedule licensure. 
 
Dr. Luxembourg explained that the study was designed to conduct a comparison with young 
women who received a 3-dose schedule.  Both of those regimens testing 0, 6 and 0, 12 met the 
non-inferiority criterion, which means that both regimens are equivalent in that regard.  There 
may be differences in GMT levels, but the differences in GMT levels in the HPV vaccine field do 
not have identifiable clinical significance aside from the comparison to an efficacy population.  
Merck’s intent with respect to assessing a 0, 6 regimen and a 0, 12 regimen was not only 
scientific, but also was for practical reasons.  Merck recognizes that depending upon how the 
vaccine is administered (school program, office setting, et cetera), it is important to provide the 
public health community with more flexibility in terms of time interval between the 2 doses. 
 
Dr. Reingold requested further information regarding when results are anticipated from the 
planned long-term effectiveness and post-licensure epidemiological studies. 
 
Dr. Luxembourg replied that Protocol 10 is ongoing, with two more years of follow-up planned.  
The analyses of antibody persistence and immune memory are anticipated to be completed by 
the end of 2017.  The long-term effectiveness study is still in the planning stages and has not 
yet begun, given continued discussions with regulators.  Merck anticipates that the study will 
begin in 2017 and will include at least 10 years of follow-up, and perhaps longer. 
 
Dr. Kelly Moore asked whether there is a biological plausible mechanism by which starting at a 
higher or equivalent GMT with a 2-dose series could result in a more rapid degradation than in a 
3-dose series. 
 
Dr. Luxembourg responded that this will be assessed with the antibody persistence analyses.  
Studies have been conducted with other HPV vaccines, but this does not seem to present a 
concern as there does not seem to be a dramatic decrease over time in GMT ratios between 
girls who received 2 doses versus women who received 3 doses.  Certainly, this is one point 
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Summary: 2-Dose Schedules, Bivalent and Quadrivalent HPV Vaccines 
 
Lauri Markowitz, MD 
National Center for Immunization and Respiratory Diseases  
Centers for Disease Control and Prevention 
 
In this presentation, Dr. Markowitz provided an overview of data on 2-dose vaccination 
schedules for 2vHPV and 4vHPV vaccines.  Data on 2-dose schedules for these vaccines are 
useful to review as ACIP considers data on 2 doses for 9vHPV vaccine for two reasons.  
Although there are some differences between the vaccines, trials of 2vHPV and 4vHPV 
vaccines can provide contributory data to consider related to the 9vHPV decision.  Importantly, 
the 2- versus 3-dose trials of these vaccines have longer follow-up to date than the 9vHPV trial.  
Also, recommendations for 2-dose schedules might be considered for 2vHPV and 4vHPV 
vaccines, and there certainly would be questions regarding persons who received less than 3 
doses of 2vHPV or 4vHPV if 2 doses of the 9vHPV are recommended. 
 
Data on 2-dose schedules of 2vHPV or 4vHPV vaccines include immunogenicity, efficacy, and 
post-licensure effectiveness data.  Dr. Markowitz focused primarily on immunogenicity data in 
this presentation as a complement to the data presented by Dr. Luxembourg on 9vHPV vaccine, 
but briefly mentioned the efficacy and post-licensure effectiveness data. 
 
For the bivalent vaccine, Dr. Markowitz reviewed three trials designed to evaluate 2-dose 
schedules.  The following table shows where each trial was conducted; age groups; number of 





The first two are industry-sponsored studies used to obtain regulatory approval and the third is 
independent.  As noted, all three trials provide a comparison of 2 doses in the younger age 
group with 3 doses in the young adult women, which was the primary comparison.  The first and 
last studies also provided a direct comparison of 2 and 3 doses in the younger age group.  The 
second trial compared two different 2-dose schedules in the younger age group:  0, 6 and 0,12 
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The first study by Romanowski was considered a proof of concept study.  It also included a 
dose ranging component and other groups as well, but Dr. Markowitz showed only the groups of 
interest for ACIP’s discussion during this session.  A follow-up extension study evaluated groups 
that received the licensed formulation through 60 months.  From this proof of concept study, 
there were many findings but the main ones of interest for this discussion were that the 2-dose 
schedule in girls 9 through 14 years of age was immunologically non-inferior to the 3-dose 
schedule in the young adult women.  Within the same age group, GMTs were lower with 2-dose 
schedule given at 0 and 6 months compared with the 3-dose schedule. This was observed for 
both girls 9 through 14 years of age and women 15 through 25 years of age. 
 
In terms of the longer follow-up of two groups of interest, those 9 through 14 years of age who 
received 2 doses and those 15 through 25 years of age who received 3 doses, all subjects 
remained seropositive for HPV 16 and 18 through month 60 after vaccination.  The GMTs over 
time for HPV 16 are shown in the following figure:  
 
 
Romanowski, et al. Hum Vaccin 2016 
 
The antibody kinetics are similar to those seen in all of the HPV vaccine trials, with a peak 
antibody titer after the first dose, a decline, and then a plateau reached at about 24 months.  
GMTs were non-inferior in the 2-dose group compared with 3-dose group through month 60.  
The lines are almost identical, so they are difficult to see.  GMTs were substantially higher than 
after natural infection shown by the lower dotted line through Month 60 of follow-up. 
 
The unpublished trial of the bivalent vaccine was a larger trial that was designed to confirm the 
findings in the proof of concept trial.  Though the results are unpublished, data have been 
presented at meetings and are available online [Clinical Study Report HPV-070 (114700) at 
http://www.gsk-clinicalstudyregister.com Clinicaltrials.gov NCT01381575].  There were two 2-
dose groups of subjects 9 through 14 years of age (0,6 and 0,12 month schedules) and a single 
3-dose group 5 through 25 years of age (0, 1, 6 months—the standard schedule).  Results for 










For the above and subsequent slides, Dr. Markowitz showed the GMT ratios as 2 doses over 3 
doses for consistency though they were presented differently in some of the publications.  Non-
inferiority was defined as the lower 95% CI for the GMT ratio being >.5 in all studies.  On the 
left, the 2-dose 0, 6 month schedule in 9 through 14 year olds is compared with the 3-dose 
schedule in young adult women.  The non-inferiority criterion was met.  On the right is the 
comparison of the 2-dose at 0, 12 month schedule in 9 through 14 olds with the 3-dose 
schedule in young adult women.  GMT ratios are greater than 1 and again, the non-inferiority 
criterion was met.  There was over 99% seroconversion in all groups.  In summary, one month 
after the last dose, GMTs with both 0, 6 and 0,12 schedules in subjects 9 through 14 years of 
age were non-inferior to the 3-dose 0,1,6 schedule in subjects 15 through 15 years of age.  
Recently posted on the GSK website are the results for 36 months, which are very similar to 
these results. 
 
The third bivalent vaccine trial by Lazcano-Ponce was an independent study conducted in 
Mexico.  There were two groups 9 through 10 years of age (0, 6 months and 0, 1, 6—the 
standard schedule) and a group 18 through 24 years of age who received 3 doses in the 
standard schedule.  The group providing data on 2 doses was on a 0-, 6-, 60-month schedule 
with a planned interim analysis at Month 21.  Shown in this table are the data from this trial: 
 
HPV Type 2 dose 9–10 yrs/ 
3 dose 18–24 yrs 
2 dose 9–10 yrs/ 
3 dose 9–10 yrs 
     GMT Ratio       (95% CI)      GMT Ratio     (95% CI) 
HPV 16 1.4             (1.3, 1.4) 0.6          (0.6, 0.7) 
HPV 18 1.4             (1.3, 1.7) 0.6          (0.5, 0.7) 
 
All vaccinees were seropositive when tested at 7 and 21 months.  For the comparison of 2 
doses in subjects 9 through 10 years of age with 3 doses in subjects 18 through 24 years of 
age, the antibody response was generally higher after 2 doses in subjects 9 through 10 years of 
age as noted by GMTs greater than 1.  The non-inferiority criterion was met.  In the comparison 
of 2 doses and 3 doses in subjects 9 through 10 years of age, GMTs were lower in the 2-dose 
schedule.  The GMT ratios were less than 1, but the lower limit of the CI was greater than 0.5.  
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Regarding the data available for 4vHPV vaccine, Dr. Markowitz reviewed the following three 




Data from the Hernandez-Avila and Sankaranarayanan trails were not available when ACIP 
reviewed the data in 2014.  The first two studies included a comparison of 2 doses at 0, 6 
months in the younger age group with 3 doses in young adult women, which was the main 
analysis for these studies.  All studies allowed for a direct comparison of 2 and 3 doses within 
the same age group, although the age ranges differed slightly in these studies.  Follow-up was 
through 36 months in Dobson, 21 months in Hernandez-Avila, and 48 months in 
Sankaranarayanan. 
 
The study conducted in Canada by Dobson has been reviewed with the ACIP previously.  The 9 
through 13 year olds were randomized to receive 2 or 3 doses.  A third group of women 16 
through 26 years of age received 3 doses.  There were 36 months of follow-up.  Although an 
independent study, data from this trial were submitted to regulatory authorities in other countries 
to obtain approval for a 2-dose schedule of 4vHPV vaccine.  The following table shows the 36 
month results: 
 
The main analysis on the left was comparing the 2-dose girls with the 3-dose young adult 
women.  Non-inferiority criteria were met for all types, and the titers were generally higher in the 
9 through 13 year olds shown by the GMT ratios being greater than 1.  In the comparison of the 
2- and 3-dose schedules within subjects 9 through 13 years of age on the right, GMTs were 
generally lower in the 2-dose group and non-inferiority was lost for HPV 6 and 18.  At earlier 
time points in this study not shown on this table, GMTs were lower in the 2-dose group, but the 
non-inferiority criterion was still met for these comparisons.  Non-inferiority was lost by 24 




2 dose 9–13 yrs/ 
3 dose 16–26 yrs 
2 dose 9–13 yrs/ 
3 dose 9–13 yrs 
    GMT Ratio        (95% CI)     GMT Ratio       (95% CI) 
HPV 6 1.36            (0.97, 1.90) 0.64          (0.46*, 0.90) 
HPV 11 1.43            (1.03, 1.99)           0.73          (0.52, 1.02) 
HPV 16 1.70            (1.16, 2.49)           0.81          (0.55, 1.20) 
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The dashed line at the bottom of the above graphic is the serostatus cut off value of the assay.  
Of note, the antibody kinetics were similar in all groups, with the peak antibody titer 1 month 
after the last dose and then declined and a plateau at about 18 to 24 months.  For HPV 18, 
GMTs for the 3-dose, 9 through 13 year old group were higher than the 2-dose girls.  At later 
time points, the lines diverge and this is where GMTs lost non-inferiority.  However, as shown 
here, the GMTs in this 2-dose group were not inferior to the GMTs in the 16 through 26 year 
olds who received 3 doses.  
 
The Hernandez-Avila 4vHPV vaccine was conducted in Mexico.  There were also three groups 
in this trial:  2 groups at age 9 through 10 (a 2-dose and a 3-dose group), and a 3-dose group of 
subjects 18 through 24 years of age.  In this trial, over 98% in all groups were seropositive for 
HPV 16.  For HPV 18, seropositivity was lower in all groups compared with Month 7.  HPV 18 
seropositivity was 56.6% in women 18 through 24 years of age who received 3 doses, 86% 
among the girls who received 3 doses, and 70% among girls who received 2 doses.  The 56% 
seropositivity in women 18 through 24 years of age is consistent with findings in pre-licensure 
efficacy trials of 4vHPV; whereas, HPV 18 seropostivity measured by the cLIA declined over 
time but no loss of protection was detected in these trials.  The following table shows GMTs at 
Month 21 after vaccination: 
 
HPV Type 2 dose 9–10 yrs/ 
3 dose 18–24 yrs 
2 dose 9–10 yrs/ 
3 dose 9–10 yrs 
        GMT Ratio      (95% CI)      GMT Ratio      (95% CI) 
HPV 6 1.29          (1.02 – 1.62) 1.21          (0.96 – 1.52) 
HPV 11 1.52          (1.21 – 1.91) 0.87          (0.69 – 1.10) 
HPV 16 1.49           (1.12 – 1.98) 1.16          (0.88 – 1.55) 
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In the analysis comparing the 2-dose schedule among girls 9 through 10 years of age with the 
3-dose schedule among women at 18 through 24 years of age, the non-inferiority criterion was 
met for all types.  The antibody response was generally higher in girls 9 through 10 years of age 
who received 2 doses, with GMTs ratios greater than 1.  In the comparison of the 2- and 3-dose 
schedules within girls 9 through 10 years of age, the GMT ratios were less than 1 for a few of 
the types, but again, the study’s non-inferiority criteria were still met. 
 
The Sankaranarayanan trial was designed as an immunogencity and efficacy trial of 2 versus 3 
doses of 4vHPV vaccine in India.  Girls 10 through 18 years of age were enrolled.  The design 
was a cluster randomized trial of 2 doses at 0, 6 months versus 3 doses in the standard 3-dose 
schedule.  This was designed to be an efficacy trial assessing pre-cancer outcomes.  However, 
recruitment and vaccination were suspended for reasons unrelated to this study.  Because of 
this, vaccination did not occur as scheduled and the randomized design was lost.  The study 
was analyzed as an observational cohort.  Over 17,000 girls were enrolled and randomized to 









1-Dose Group:  Women who were randomized to the 2 dose or the 3 dose group, but 
only received one dose 
2-Dose Group (0, 2 Months):  Women who were randomized to the 3-dose arm, but did 
not receive the third dose 
2-Dose Group (0, 6 Months) 
3-Dose Group (0, 2, 6 Months) 
 
The following figure shows median fluorescence intensity (MFI) for HPV 16 antibodies, 
expressed as mean MFI: 
  
 
Time after first dose (months) 
 
The number of girls with specimens tested was far less than the number who received vaccine 
in each group, ranging from about 300 to 500.  The dashed line is the seropostivity threshold 
established by the investigators for this assay.  For HPV16, the antibody kinetics of the 2-dose 
0, 6 month schedule was similar to antibody response of the 3-dose group.  The mean MFI of 
the 2- dose group was non-inferior to the 3-dose group at all time points through 48 months. 
The antibody response after 2 doses administered at 0 and 2 months reached lower peak titer 
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were inferior to 3-dose group at 18 and 36 months.  There were some differences, but a similar 
pattern was observed for HPV 18, 6, and 11. 
 
In summary for the immunogenicity of 2-dose schedules of 2vHPV and 4vHPV vaccine, for the 
comparison of 2 doses (0,6 months or 0,12 months) in girls versus 3 doses in young adult 
women, antibody response was non-inferior in the 2-dose group and was generally higher for 
both vaccines.  Antibody kinetics were similar, and these findings were consistent in all trials 
that evaluated the 2 doses (0, 6 months) versus 3 doses in girls the same age.  In the 
comparison of 2 doses (0, 6 months) versus 3 doses (standard schedule) in girls of the same 
age for the 2vHPV vaccine, GMTs were generally lower in the 2-dose group, although formal 
hypothesis testing was not done in some of the studies.  For 4vHPV vaccine, GMTs were lower 
for some types in 2 of the 3 studies. 
 
There are some data on efficacy with 2-dose schedules.  For the bivalent vaccine, there are 
data from a post-hoc analysis of efficacy against incident HPV 16/18 infection.  This is an 
analysis of combined data from two randomized controlled efficacy trials in women 15 through 
25 years of age.  In these 2 trials, participants were randomized to receive a 3-dose vaccine 
schedule or control.  Most, but not all, women completed the 3-dose schedule and there was a 
post-hoc analysis of efficacy against incident infection by number of doses received.  There was 
high efficacy in all groups and no significant difference by number of doses.  There are 
limitations to these data including that in this post-hoc evaluation.  Women who were 
randomized to receive 3 doses but received fewer doses could have been different from those 
who completed the series.  However, these data suggest efficacy with less than 3 doses.  It is 
important to note that the 2-dose schedule in these studies was not a 0, 6 months schedule, but 
instead was a 0, 1 month schedule because the study was designed to evaluate vaccine at 0, 1, 
6 months [Kreimer, et al. Lancet Oncol 2015]. 
 
While the same type of data are not available for 4vHPV vaccine, there are some relevant data 
from the recently published trial in India in which girls 10 through 18 years of age were 
randomized to receive 2 or 3 doses of HPV vaccine.  As mentioned earlier, this trial was 
suspended and lost its randomized design and was analyzed as an observational cohort study.  
Girls were followed up for the immunogenicity evaluation just presented, and with cervical 
samples.  The median time between first vaccination and cervical sample was 3.9 years.  The 
incidence of infection was 0.6% in the 3-dose group and 1% in the 2-dose 0, 6 month group; 2% 
in the 2-dose 0, 2 month group; and 1.6% in the one dose group.  While point estimates varied, 
there was no statistically significant difference between these groups and all groups were lower 
than what was expected from historical data.  Further analyses are needed for this study, which 
hopefully will be forthcoming.  Unvaccinated age and residence matched women are being 
enrolled into a cohort and will be followed to provide incidence data for comparison.  Follow-up 
of women in this study is planned for 20 years [Sankaranarayanan, et al. Lancet Oncol 2016]. 
 
While Dr. Markowitz did not review post-licensure studies of vaccine effectiveness for 2 doses, 
but briefly mentioned the scope of these studies and noted that these data will be reviewed 
during a future ACIP meeting.  There are at least 6 studies that have evaluated post-licensure 
effectiveness after introduction of HPV vaccination programs by number of doses (5 of 4vHPV 









1Gertig BMC Med 2013, 2Crowe BMJ 2014, 3Herwijer JAMA 2014, 4 Blomberg CID 2015, 5Dominiak-Felden PloS One 2015, 6Kavanagh BJC 2014 
 
These studies have mainly been conducted in countries with good national health registries.  
Outcomes evaluated included cervical cytological or histological abnormalities, condyloma, or 
HPV prevalence.  There are a variety of challenges and limitations pertaining to these types of 
studies.  For example, there could have been differences between 2- and 3-dose recipients.  
Most 2-dose recipients did not receive a 0, 6 month 2-dose schedule as these analyses were 
conducted when a 3-dose schedule was recommended and the 2-dose recipients were those 
who did not complete the recommended 3-dose schedule.  Moreover, there are a variety of 
methodologic challenges for these post-licensure studies.  Most of these studies did show lower 
efficacy for those who received less than a 3-dose schedule. As noted, these data will be 
reviewed in more detail during a future ACIP meeting. 
 
To summarize all of these data, the main analyses for immunogenicity and those used by 
regulatory agencies are comparisons of antibody response of 2 doses in young adolescents, 
with 3 doses in young adult women—the age during which efficacy has been demonstrated in 
clinical trials.  This is because there is no established minimum antibody threshold for 
protection.   Two doses (0, 6 months or 0, 12 months) in subjects 9 through 14 years of age 
were non-inferior compared with 3 doses in young adult women.  Follow-up was through 36 
months for 2vHPV and 4vHPV vaccines.  In some trials, antibody titers were lower for some 
types after 2 doses (0, 6 months) compared with 3 doses in the same age group. 
 
There are limited efficacy data.  For 2vHPV vaccine, data are from a post-hoc analysis of 3-
dose RCTs in subjects 15 through 25 years of age.  For 4vHPV vaccine, data are from the 
interrupted RCT of 2- versus 3-dose in vaccination among subjects 10 through18 years of age 
that was analyzed as an observational study.  The studies suggest efficacy with less than 3 
doses, but also raise a variety of interesting questions.  For 2vHPV vaccine in particular, the 
study evaluated an older age group than those who have been the focus of the 2-dose 
immunobridging studies and provided data on a different dose interval, perhaps suggesting 
efficacy for a wider age range and for shorter intervals between doses.  Also, while the criteria 
that have been used and will be used to evaluate reduced dose schedules are non-inferior 
antibody compared to a 3-dose schedule in the age groups in which efficacy was demonstrated 






Design / Study Population 
 
Outcome 
4vHPV   Australia1 Retrospective cohort study using 
linked registry data 
Cytological and histological 
cervical abnormalities 
   Australia2 
      
Case-control study using linked 
registry data 
Histological cervical lesions  
   Sweden3 
      
Open cohort using nationwide 
health registers 
Condyloma 
   Denmark4 
      
Cohort using nationwide health 
registries 
Condyloma  
   Belgium5 
      
Retrospective cohort using 
reimbursement database 
Condyloma 
2vHPV   Scotland6 
      
Women screened for cervical 
cancer  
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protective.  Post-licensure effectiveness, most of which found lower effectiveness with less than 
3 doses, will be reviewed with ACIP during the next meeting. 
 
In summary, data on 2-dose schedules for 2vHPV and 4vHPV vaccines can provide 
supplementary evidence for consideration of 2-dose schedules for 9vHPV vaccine; however, it 
is important to remember that there are some differences between vaccines.  These data also 
could be used for consideration of 2-dose recommendations for 2vHPV and 4vHPV vaccines 
themselves.  The HPV Vaccines WG will further review and evaluate these and other data using 
GRADE, and findings will be presented and discussed at a future ACIP meeting. 
 
Work Group Plans 
 
Elissa Meites, MD, MPH 
Medical Epidemiologist 
National Center for Immunization and Respiratory Diseases  
Centers for Disease Control and Prevention 
 
Dr. Meites summarized that information presented during this session provided background for 
considering 2-dose schedules for HPV vaccines.  New data were presented from the 2-dose 
immunogenicity trial of 9vHPV vaccine in girls and boys, and an overview of current data on 2-
dose schedules for 2vHPV and 4vHPV vaccines.  There are plans to present additional 2-dose 







GRADE for 2-dose schedules 
Review of post-licensure effectiveness data 
Modeling data and cost-effectiveness 
Programmatic considerations  
Additional follow-up data from the 9vHPV vaccine trial  
 
There are a number of issues for ACIP to consider.  One issue pertains to whether a 2-dose 
schedule should be recommended.  If so, the following would need to be addressed: 
 
 The target age or age range for a potential 2-dose recommendation  
 
 The recommended interval or range of intervals (there could be a minimum number of 
months-between-doses in a 2-dose schedule, or a specific interval, such as 0-6 or 0-12)  
 
 Wording of a potential recommendation to clarify whether exactly 2 doses are 
recommended versus allowing for 2 or 3 doses 
 
 Whether special populations should be included in a potential 2-dose recommendation, 
or if three doses would continue to be recommended for some groups, such as 
immunocompromised persons or others  
 
 Which HPV vaccines would be included in a 2-dose recommendation  
 
Another issue to be aware of is FDA approval.  All HPV vaccines currently available in the US 
are FDA-approved as a 3-dose series.  For 9-valent vaccine, data from the 2-dose trial in a 
Supplemental Biologics License Application (sBLA) will be reviewed by the FDA.  A 2-dose 
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4vHPV vaccine, there are no plans for the manufacturer to submit 2-dose data to FDA, so a 2-
dose schedule would be off-label.  Similarly, there are no plans for the manufacturer to submit 
2-dose data to FDA for 2vHPV vaccine, so a 2-dose schedule would be off-label. 
 
A further issue to consider is incomplete series, since currently about 20% of teens starting a 3-
dose series did not complete it.  If a 2-dose recommendation is made, it could specify for each 
HPV vaccine whether and when a 2nd dose or a 3rd dose should be given.  For 4vHPV vaccine, 
the manufacturer plans to retire this vaccine in the US at the end of 2016.  However, if a 2-dose 
recommendation is made, it might still apply to people who began but did not complete a 3-dose 
series. 
 









GRADE for 2-dose schedules, including immunogenicity, efficacy, and post-licensure 
effectiveness data  
Modeling data for cost-effectiveness of 2-dose schedules  
Programmatic considerations  
Initial discussion of potential recommendations 
 
Additional topics that will be presented to ACIP in the future include:  
 
Further follow-up data from the 9-valent vaccine trial, when available 
Decisions from the FDA, if any, that might change the indicated number of doses of 
9vHPV vaccine 




Dr. Reingold noted that according to a New York Times article a couple of days before this 
meeting [summarizing the 2016 research by Markowitz et al published in Pediatrics], current 
coverage seems to be having an even more impressive herd immunity effect than predicted.  He 
wondered whether anything was known about the likely herd effect of a 2-dose schedule versus 
a 3-dose schedule, or whether the fact that the impressive herd effect might give ACIP even 
more impetus to make a 2-dose recommendation given the context of the epidemiologic 
situation.  He also requested that Dr. Bennett comment on the implications of ACIP making an 
off-label recommendation. 
 
Dr. Markowitz replied that in terms of impact, the data suggest that there is either some efficacy 
from less than a complete 3-dose schedule or herd immunity.  It is not possible to say which it 
is.  Certainly, the fact that greater impact is being observed  than expected if a complete 3-dose 
schedule is needed for high efficacy suggests that one or both of those is operating.  In terms of 
whether a similar herd immunity effect would be observed with a 2-dose schedule, if there is 
high efficacy from a 2-dose schedule, the same herd effect would be anticipated from a 2-dose 
as for a 3-dose schedule. It is known from other countries that there is a profound herd effect 
from vaccination programs.  The most compelling data come from Australia where they have 
been able to demonstrate a very large impact on genital warts among males, even though they 
were targeting only females in the vaccination program.  Australia had very high coverage.  
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Regarding the implications of off-label recommendations, Dr. Bennett replied that it is clear that 
ACIP has and will continue to make off-label recommendations.  With respect to how those are 
implemented, particularly in the environment of the new data, she did not believe the 
implications would be negative if ACIP chose to make an off-label recommendation. 
 
Dr. Messonnier added that ACIP has made off-label recommendations in the past, but the 
context of those was quite different from this.  There have been off-label recommendations for 
small subgroups or that have been seen as bridges to something that is not recommended.  The 
programmatic complexities of an off-label recommendation in this setting would be much greater 
in terms of how to communicate that, how providers would implement that given the different 
messages they would be getting from different sources, et cetera.  One of the reasons the 
workgroup outlined further discussion in June 2016 is to allow time to consider some of the 
programmatic considerations.  From the CDC perspective, the hope is that FDA and Merck can 
do an efficient consideration of the BLA and that there will be a rapid response. 
 
Dr. Sun (FDA) responded that the FDA is reviewing the submission pertaining to 2 doses, and a 
regulatory decision will be made in short order.  Given that the review process is ongoing, he 
was not at liberty to say more than that at this point. 
 
Dr. Karron expressed her hope that ACIP could take into consideration any deliberations and 
decisions that occur earlier than June 2016 in terms of timelines for bringing draft 
recommendations forward to ACIP for a vote.  They may not want to wait until the October 2016 
meeting to be making decisions about 2 and 3 doses. 
 
Carol Hayes (ACNM) reminded everyone that every vote ACIP has made regarding 






Lorry Rubin, MD 
Chair, Meningococcal Work Group 
Advisory Committee on Immunization Practices 
 
Dr. Rubin explained that this session would include two parts.  The first part of the session 
would focus on an update pertaining to serogroup B meningococcal vaccines, including newly 
available data.  No discussion of changes to current recommendations was planned.  The 
second part of the session would focus on a discussion of meningococcal disease in HIV-
infected persons and men who have sex with men (MSM).  No vote was anticipated during this 
session. 
 
Additional data for MenB vaccines reviewed by the WG since June 2015 has included safety 
and immunogenicity data from two Phase 3 studies for MenB-FHbp, including immunogenicity 
data on 10 secondary strains and 10 outbreak strains and the results of a mass immunization 
campaign with MenB-4C in Quebec, Canada.  In addition, the WG reviewed reports to the 
Vaccine Adverse Events Reporting System (VAERS) to monitor MenB safety.  No safety signals 









An ad hoc WG comprised of ACIP Meningococcal WG members, ACIP members, state public 
health officials, college health professionals, and CDC reconvened on September 3, 2015 with 
biweekly meetings.  The objectives of this ad hoc WG are to:  1) review available data on the 
recent epidemiology of meningococcal disease and outbreaks; 2) update and harmonize the 
current meningococcal outbreak guidelines for serogroups A, B, C, W, and Y.   The 
Meningococcal Outbreak WG recommendations will be presented in an informational session 
during the June 2016 ACIP meeting.  Harmonized outbreak guidelines will be published on 
CDC’s website. 
 







MenB-FHbp vaccine update 
Results of a mass immunization campaign with MenB-4C in Quebec Canada  
Considerations for use of MenACWY vaccines in HIV-infected persons 
Meningococcal disease among MSM, United States, January 2012-June 2015 
Summary of Work Group Discussions on Meningococcal Disease in MSM 
 
MenB-FHbp Vaccine Update 
 
Dr. Laura York 
Medical Development 
Scientific and Clinical Affairs 
Pfizer 
 
Trumenba®, Pfizer’s MenB-FHbp vaccine, is based on a surface-exposed factor H  
binding protein (FHbp) expressed in over 97% of invasive meningococcal B (MenB) strains.  
The fHbp sequences segregate into two genetically and immunologically distinct subfamilies, A 




         Subfamily B:  71% 
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Pictorially, it is easy to see that this protein extends from the bacteria so that it is readily 
accessible to antibody.  This protein functions as an important meningococcal virulence factor.  
It binds to factor H and down regulates the complement system and, therefore, limits the 
amount of complement-mediated lysis—the protective mechanisms against meningococci.  The 
MenB-FHbp sequences segregate into two genetically and immunologically distinct subfamilies, 
A and B.  Within the subfamilies, these proteins are very similar in their sequence identities, so 
MenB-FHbp contains two lipidated protein variants (A05 and B01), one from each subfamily to 
elicit antibodies that are going to recognize across those FHbps within each subfamily and 
thereby provide a broadly protective response [Madico et al. 2006; Schneider et al. 2006; 
Mascioni et al. 2009; Seib et al. 2009; Ala’Aldeen et al. 2010; McNeil et al. 2009; Jacobson, 
Moellig, Olcen 2009]. 
 




Boxed in green are the trials that supported the accelerated approval in the US.  Part of the 
approval process was to provide ongoing studies to FDA when they are completed as post-
approval commitments.  As the data become available, Pfizer has been providing those data to 
the ACIP WG.  During the considerations, data were provided to ACIP not only from the 7 
licensure trials, but also from the safety and immunogenicity studies of concomitant 
administration of Menactra® and Adacel®, the large-scale Phase 2 safety study, and antibody 
persistence studies from Stage 2 of an early immunogenicity study. 
 
Dr. York indicated that during this session, she would provide an update on the two final studies 
within this clinical development plan for the adolescent indication:  1) a lot consistency, safety, 
and immunogenicity study in adolescents 10 through 18 years of age, and 2) a safety and 
immunogenicity study in young adults 18 through 25 years of age.  She noted that she would 
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trials, referred to as Studies 1 and 2, that provided pivotal immunogenicity, a safety and 
immunogenicity assessment with concomitant Gardasil® conducted in the US referred to as 
Study 3, and Study 4 conducted in Europe to assess 2- and 3-dose schedules.  In total, there is 
now a large database from 11 clinical studies. 
 
Study 1 (B1971009) is a Phase 3 immunogenicity, lot consistency, clinical safety and tolerability 
study of Trumenba® in healthy adolescents 10 through 19 years of age conducted in the US, 
Canada, and Europe.  This study is comprised of approximately 3600 subjects of whom 2693 
received Trumenba® and 897 received HAV/saline.  Study 2 (B1971016) is a Phase 3 
immunogenicity and safety / tolerability study of Trumenba® in healthy adults 18 through 26 
years of age conducted in the US and Europe.  This study is comprised of approximately 3300 
subjects of whom 2471 received Trumenba® and 822 received saline.  In both studies, 
immunizations were administered on a 0, 2, and 6 month schedule. 
 
As post-approval commitment studies, Studies 1 and 2 provide the confirmatory human serum 
bactericidal assay (hSBA) data; that is, they are confirming the data generated in the licensure 
trials in Studies 3 and 4.  These are confirmatory hSBA responses, which is the correlate used 
to predict protection against 4 MenB strains that are agreed to be representative of the 
prevalent strains in the US.  The fHBP variants expressed by these strains are not homologous 
to the vaccine components.  They are A22, A56, B24, and B44.  This is shown on the 




These studies also provide supportive hSBA data, meaning that hSBA responses are shown 
against a panel of 10 additional strains, which are referred to as secondary strains.  They 
express variants that are prevalent and are not homologous to the vaccine components.  In 
total, with the 4 primary strains and the 10 additional strains, these account for about 80% of the 
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As a reminder, there were 5 co-primary endpoints for licensure, meaning that subjects had to 
achieve a 4-fold rise in hSBA titer 30 days post-dose 3 to each of the 4 representative strains 
(A22, A56, B24, and B44).  The fifth primary endpoint was a composite response, looking at the 
subjects who achieved an hSBA titer of greater than or equal to 1:8 and 1:16 on the A22 strain 
for all 4 test strains.  This shows the ability of the antibody within an individual to recognize 
across the diversity of the FHbp being expressed by these 4 representative strains, and inferring 
activity against the FHbp within the same subfamilies.  A high proportion of individuals among 
adolescents and young adults who responded obtained an hSBA titer 4-fold rise against each of 
the 4 strains.  Importantly, a high proportion of these individuals achieved an hSBA titer of 
greater than 1:8 for all 4 test strains. 
 
In terms of comparison across the three studies, there is consistency across the responses with 
a high proportion of individuals who achieved the 4-fold rise in titers after receiving the third 
dose, and also comparable levels of individuals who have a composite response achieving an 
hSBA titer of greater than 1:8 for all 4 test strains.  1:8 is higher than the accepted correlate of 
protection of 1:4.  This consistency of responses to vaccine is, in fact, observed across the 
Phase 1 and Phase 2 studies where this immunogenicity data is available.  There are 
comparable responses across the studies regardless of the geographic area in which the 
studies were conducted.  Therefore, the Phase 2 and 3 studies confirm the data that informed 
the licensure of Trumenba® and provide evidence that Trumenba® will provide a bactericidal 
response which will be active against the diverse MenB strains that are circulating and causing 
disease in the US. 
 
This is supported by the data from the 10 additional strains A06, A07, A12, A15, A19, A29, B3, 
B9, B15, and B16.  Again, a high percent of subjects attained an hSBA titer of greater than 1:8 
which is above the correlate of protection.  The 10 strains are distributed well across the sub-
families and across adolescents and adults, there is a consistent high response and the ability 
of the antibody to recognize across these variants.  These are prevalent variants in the disease-
causing MenB strains. 
 
Pfizer was also asked to provide ACIP with data from an exploratory analysis performed on 
some diverse FHbp variants expressed by outbreak strains B24, A22, B03, B44, B228, and 
B153.  These data are from 10 different isolates from 10 different outbreaks occurring in the US 
and France from 2011 through 2015.  The hSBA titer of the correlate of protection was 1:4. 
 
These 10 strains are diverse in the hSBA variants they express.  They can be prevalent 
variants.  In fact, 5 of these strains express B24.  A22 and other prevalent variant B03 and B44 
are also prevalent variants.  There are also unique variants like B228 and B153.  These data 
were generated with a small number of serum samples with exploratory hSBA assays, which 
sometimes can have challenges in development of the assay.  These data demonstrate that all 
of the strains are susceptible to killing, and that the level of responses observed overall and in 
general are similar to what has been observed in the clinical studies.  In the totality of the 
immunogenicity data to date, these data would be expected to support that Trumenba® would 
be expected to elicit a broadly protective immune response. 
 
In terms of evaluation of safety, the safety profile demonstrated by Trumenba® in Studies 1 and 
2 were consistent with the safety data that supported licensure, and in which the majority of 
local and systemic events were mild to moderate in severity and transient after each 
vaccination.  The most common AEs were pain at the injection site, fatigue, headache, muscle 
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rates were comparable between Trumenba® recipients (1.7%) and controls (1.6%) in 4 
controlled trials.  In both Study 1 and Study 2, Trumenba® was well-tolerated in adolescents and 
young adults.  The reactogenicity profile was consistent with the prior studies, and there is a low 
SAE rate overall of 1.9% versus 2.4%  in the vaccine and control groups, respectively in 
adolescents and 1.3% for both the vaccine and control groups in young adults. 
 
In the total safety database comprised of data from 11 clinical trials, studies have been 
conducted in the US, several European Countries, Canada, Australia, and Chile.  Approximately 
15,000 subjects who have received Trumenba® and approximately 5500 controls are included in 
the database.  Approximately 3000 of these individuals are from the US.  Trumenba® has 
demonstrated an acceptable safety profile.  The most common local and systemic reactions 
were injection site pain, headache, fatigue, and muscle pain.  Reactogenicity events were 
mostly mild and moderate and of short duration.  The median duration was 2 to 3 days for local 
reactions and 1 to 2 days for systemic reactions, and there was no potentiation of reactions with 
subsequent doses.  Trumenba® has demonstrated an acceptable safety profile when co-
administered with other routinely administered adolescent vaccines like MCV4/Tdap, dTaP-IPV, 
or HPV4.  Similar proportions of newly diagnosed chronic medical conditions, autoimmune 
diseases, and neuroinflammatory conditions were reported in Trumenba® recipients and 
controls.  Rates of SAE are similar between Trumenba® recipients (1.6%) and controls (1.9%). 
 
In summary, Trumenba® was designed to provide broad protection against MenB.  The newly 
available hSBA data confirm that Trumenba® elicits bactericidal activity against diverse 
meningococcal serogroup B strains.  Trumenba® demonstrates a favorable safety profile in 
adolescents and young adults.  Spontaneous safety data collected post-approval supports the 
safety profile observed in clinical studies, with reactogenicity events being the most frequent 
events reported.  Trumenba® was recently used in mass vaccination campaigns for outbreak 
control at two US colleges.  One of the colleges with an opt-out policy and a student population 
of approximately 4500 had very good compliance.  The other had an opt-in policy and probably 
less than 50% received the first dose in a target population of around 20,000.  No new safety 
signals have been detected based on post-marketing surveillance.  The data support 
administration with routinely recommended adolescent vaccines.  In total, the data continue to 
support the expectation that immunization with Trumenba® will provide a broadly protective 
response against MenB disease when used both for outbreak control and prevention of endemic 
disease.  The full public health potential of Trumenba® can be realized only with broad 




Regarding protection against outbreaks shown on Slide 9, Dr. Walter noted that two strains 
seemed to show lower protection than others and wondered whether there was something 
different about them. 
 
Dr. York replied that these are small numbers.  Strain-specific differences are observed, and 
some are more difficult to set up in the assays.  In general, overall these data show that there is 
a possibility of killing.  The trend would be toward having the kind of protection that has been 
observed in clinical trials. 
 
Dr. Kempe asked whether there are any immunogenicity data on subsets who received 1 dose, 
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Dr. York responded that with a single dose, there is greater than a 50% response to 3 of the 
strains and approximately 20% to 25% to 1 of the B strains.  In general, there is a response to 
one dose.  Certainly, there is an increase in the response after receiving additional doses.  
There are data from one of the pivotal licensure trials in Europe comparing the 2- versus 3-dose 
schedule (Slide 16), which show the 4-fold response after a 3-dose schedule at 0, 2, 6 and 0, 1, 
6 months and in increasing intervals of two doses at 0, 6; 0, 4; or 0, 2 months.  The responses 
are substantial, but are not as high as if 3 doses had been received.  Clearly, there is still a high 
level of protective response with a longer interval. 
 
Dr. Reingold asked whether the vaccine has any effect on carriage.  Dr. York responded that 
Pfizer is working on those data. 
 
Noting that there had been 3 or more college outbreaks, Dr. Baker wondered whether Pfizer 
had done any testing with its assay against those strains. 
 
Dr. York indicated that the 10 strains she showed include US strains as well as strains from 
France. 
 
Dr. Cohn inquired about the magnitude of the response against the additional 10 strains 
compared to the primary 4 strains in terms of GMTs. 
 
Dr. York responded that as might be expected, there are differences in the GMTs depending 
upon the strain.  But, there is a comparable response within those.  What is typically observed in 
B subfamily strains will be consistent through that, but it may be quite high as well.  The GMTs 
are quite predictable.  It is within the overall range and is not restricted to a particular subfamily. 
 
Results of a Mass Immunization Campaign With 4CMenB  
Vaccine In the Saguenay-Lac-Saint-Jean Region, Quebec, Canada 
 
Gaston De Serres, MD, PhD 
Institut National De Sante Publique 
Du Québec and Laval University 
 
Dr. De Serres described the Canadian experience regarding a mass immunization campaign 
against MenB using the 4-component meningococcal B vaccine, produced by Novartis and 
purchased by GSK.  He indicated that the information he was presenting was funded by the 
Ministry of Health. 
 
Québec has a population of approximately 8 million, but the outbreak occurred within a sub-
region of the province known as Saguenay-Lac-Saint-Jean.  Comparing the number of reported 
cases per year, Quebec has the largest number but is not the largest province.  Ontario has 
nearly twice the population, but the number was much lower.  Canada has an incidence of 
0.33/100 000 and Quebec had an incidence approximately twice that level at 0.76/100 000.  The 
highest incidence was in infants, which rapidly declined in preschoolers, was pretty low between 
5 and 14 years of age, but increased in older teenagers and young adults. 
 
In the early 2000’s, the ST-269 clone emerged.  This was not just a cloncal complex.  It was a 
specific clone that emerged and spread rapidly throughout the province.  The Saguenay-Lac-
Saint-Jean Region 2 is a small region of approximately 270,000 people with nearly 60,000 
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the period 2006 through 2013 was above 10 / 100,000.  For the other regions, the incidence 
was much lower.  Even for adults, the incidence was higher among adults in Saguenay-Lac-
Saint-Jean than in the rest of the regions.  The following table shows all of the invasive 
meningococcal disease (IMD) reported in the region since 1990, with serogroup B beginning to 




In the Saguenay-Lac St-Jean Region, there was high incidence in infants and teenagers.  In 
terms of whether the strain matched the 4CMenB vaccine, nearly 90% of the isolates in that 
region were the ST-269 clone.  None of the isolates antigens were the exact match with the 
MenB-4C components.  Of the MenB ST-269 clonal complex, 96% were predicted to express 
two antigens similar to the vaccine components:  factor H-binding protein (fHbp) peptide 15 
(variant 1) and Neisserial Heparin-Binding Antigen (NHBA) peptide 21. 
 
The vaccine was licensed in December 2013 and in April 2014, the Quebec Immunization 
Committee (CIQ) recommended vaccinating approximately 60,000 children 2 months through 
20 years of age.  The immunization schedule was 4 doses among children 2 through 5 months 
of age, 3 doses among children 6 through 11 months of age, and 2 doses for children 12 
months of age and older.  The campaign began in May and June 2014, during which the first 
dose was administered with the idea of administering the second dose during the following 
school year during September and October 2014.  The campaign ended December 31, 2014.  
The vaccine was offered in schools for primary and high school children, and in public health 
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When the campaign was recommended, there were a lot of data regarding the reactogenicity of 
the vaccine.  A passive VAERS is already in place that is fed by physicians.  In this province, 
adverse events following immunization (AEFI) reporting is mandatory for all physicians.  Active 
surveillance was added so that all vaccinees whose parents provided an email address on the 
consent form were sent a message one week after each dose with a link to a web-based 
questionnaire on a secure server.  The outcomes included AEFI of sufficient severity to cause 
absenteeism or a medical consultation during the 7 days post-vaccination.  In order to assess 
SAEs, another questionnaire was sent six months post-last dose.  Telephone calls were made 
by nurses to validate the information on all hospitalizations, seizures, arthralgia, SAEs 
(hospitalizations, life-threatening sequelae, deaths), and other AEFIs considered severe.  
Coverage was good until 16 years of age, with overall coverage of 83% receiving 1 dose and 




Of the vaccinees, 69% provided an email address.  The participation rate was not large.  For the 
first dose, there was a participation rate of 39% among those sent an email message and 27% 
among all vaccinees.  For the second dose, participation was 32% among those sent an email 
message and 22% among all vaccinees.  Six months post-last dose, participation was 23% 
among those sent an email message. 
 
In terms of fever, that vaccine was associated in clinical trials with a high proportion of fever.  
For Doses 1, 2, 3, and 4 in infants, the onset was primarily the day of vaccination and the 
following day.  By Day 3, fever was largely baseline.  The percentage reporting an AEFI causing 
absenteeism or a medical consultation was consistently more frequent with the second dose 
than the first.  Injection site reaction and general malaise were by far the most predominant 
reasons for absence or consultation.  When the absentees attributable to fever, general 
malaise, or local reactions were calculated with onset on Day 1 or 2, it was 1.8% to 3.4% for 
those younger than 18 years of age.  The province has a generous maternal leave policy, so in 
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However, 3.8% to just under 7% of those 6 through 16 years of age had an absenteeism due to 
those adverse events. 
 
Seizures were less than what was expected based on the clinical trial, but there were 6 febrile 








1 year old 6 hours post-dose 1  
2 year old 8 hours post-dose 2 
4 year old 4 hours 30 minutes post-dose 2 
5 year old 30 minutes post-dose 2 
6 month old 28 hours post-dose 3 
1 year old 48 hours post-dose 3  
 
No clustering was observed in terms of hospitalizations.  The diagnoses of patients are show in 
the following table: 
 
Age Day of Hospital admission Diagnosis 
2 year old Day 2 post dose1  Bronchiolitis 
2 month old Day 2 post dose 1 Fever and dehydration 
1 year old Day 5 post dose 1 Bronchospasm 
1 year old Day 6 post dose 1 URTI and bronchospasm 
6 year old Day6 post dose 1 Viral mesenteric adenitis 
9 year old <15 min. post dose 2 Anaphylaxis (4CMenB + Twinrix)  
Had similar problem with MMR 
4 month old  Day 1 post dose 2  Bronchiolitis 
4 year old Day 1 post dose 2 2 episodes of febrile seizures 
2 year old Day 2 post dose 2 Bronchospasm 
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The most frequent SAEs requiring hospitalization were respiratory problems and other types of 
infections, with all SAEs shown in the following table: 
 
 4 Months 
After Dose 1 
6 months  
after dose 2 
Total 
Respiratory infections /problems 21 31 52 
Infections (urinary, ocular, dental, etc.) 16 22 38 
Surgery 11 4 15 
Trauma 7 1 8 
Fever /dehydration 3 2 5 
Seizures 2 2 4 
Renal lithiasis 0 4 4 
Food allergy 2 1 3 
Nephrotic syndrome 0 3 3 
Anemia 0 3 3 
Epilepsy 1 2 3 
Crohn disease 2 1 3 
Diabetes 1 1 2 
Other 5 9 14 
  
In the targeted cohort, 16 deaths occurred between May 1, 2014 and May 30, 2015.  Of those, 5 
deaths occurred within 6 months of a dose of 4CMenB, 4 were due to motor vehicle accidents, 
and 1 occurred 5 months after a single dose of 4CMenB.  The death that occurred 5 months 
following the single dose of 4CMenB was investigated by a coroner, who concluded that the 
vaccine was not involved. 
 
There were 102 AEFIs reported between May 1, 2014 and August 28, 2015.  The reported rates 
per 10,000 administered doses were as follows: 
 
Overall  10.3 
Fever  2.9 
Local Reaction  2.3 









There was 1 incident of Kawasaki Disease (KD) in a 4-year old child with onset 100 days post-
Dose 2.  In the month preceding KD, the child had received a dose of DapT-Polio (Boostrix-
Polio®) and Flumist®. 
 
In terms of the impact on disease, the upper panel in the following graphic presents the region 
and the green arrow shows the start of the campaign, with only two cases reported after the 




The lower panel in the above table shows the rest of the province, in which the incidence also 
decreased.  In terms of the two cases that occurred in the Saguenay-Lac St-Jean Region in 
March 2015, one case was in an unvaccinated 44 year old who had stayed in an ice fishing 
shelter during the week prior to disease onset.  The second was in an unvaccinated 13 year old 
living outside the Saguenay-Lac St Jean Region that was related to the first case in that the 
child was in the same ice fishing shelter as the first adult case during the week prior to disease 
onset.  Symptom onset occurred two days after those of the first case.  In April 2015, a case 
occurred in an unvaccinated 64 year old who lived in another village in the Saguenay-Lac St-
Jean Region, which was determined  to be unrelated to the other cases.  With regard to vaccine 
effectiveness, no B-IMD cases were observed among the 47,115 vaccinated residents 2 months 
to 20 years of age.  There were 2 cases among 230,444 unvaccinated residents.  Crude 
vaccine effectiveness was 100%, though this was not statistically significant. 
 
In summary, because 4CMenB was recently licensed and there was a limited number of 
participants in the clinical trials, an enhanced surveillance for safety was set-up.  Active 
surveillance was already set up for pandemic influenza by the Canadian Immunization 
Research Network (CIRN).  That surveillance has the advantage to timely inform public health if 
there is any problem.  Participation was not huge, but the hope was that if that was a problem, 
people would be participating and that this may over-estimate the risk but would be unlikely to 
under-estimate it.  The passive surveillance covers all people even if they do not want to 
participate in active surveillence, so there were two ways to assess that.  The safety profile was 
similar to that reported in clinical trials.  There was no signal of unexpected AEFIs and no 
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than expected.  A few cases of KD were reported in the clinical trials, but there was no increase 
in KD.  Only 1 case occurred during the campaign, which was distant from the second dose.  
Most surprising was the rate of absenteeism of 3% to 5.7% of children and adolescents, which 
is quite substantial and affects the societal cost of 4CMenB. 
 
In conclusion, the results suggest direct protection during the 18 months following the 
administration of the first dose of 4CMenB.  There is no evidence of indirect or herd protection in 
adults.  A decrease in incidence also occurred in the rest of the province.  During the mass 
campaign in the Saguenay-Lac St Jean Region, the safety profile of the 4CMenB vaccine was 
as expected.  In terms of local reactions, vaccinees complained that this vaccine was more 
painful than other vaccines.  On the short-term, the vaccine seems to be effective.  Duration of 




Dr. Karron wondered whether there are any data on the prophylactic use of antipyretics or non-
steroidal anti-inflammatories on the safety profile and / or immunogenicity of the vaccine, given 
the information about absenteeism and pain. 
 
Dr. De Serres replied that because he had just 15 minutes, he eliminated his sides about that.  
They recommended anti-pyretic use.  Approximately 80% of children took antipyretics.  Below 2 
years of age, it was 90% plus.  The effect reported was with antipyretics.  Immunogenicity was 
not assessed; however, a greater impact was observed with the first dose in terms of reducing 
fever.  The reduction was about 44% with the first dose and was smaller with the second dose.  
An impact was observed among different age groups, but not above 11 years of age. 
 
Dr. York added that because this was an older age group and fever is observed a very low 
percentage of the time, no studies were set up to assess whether there would be reductions in 
immune responses based on use of antipyretics.  Reporting of whether antipyretics were used 
was assessed, but not to that extent.  Prophylactic use would not be expected in the age group 
in the studies. 
 
Dr. Stephens asked for Dr. De Serres’ for his thoughts about why the disease disappeared in 
the rest of the province, particularly given that a herd immunity effect was not observed. 
 
Dr. De Serres said that he thought meningococcal in general and MenB in particular have 
epidemic cycles with long waves.  It is possible that this outbreak occurred on the declining side 
of the current surge.  However, he said he had no good explanation for why this region was 
specifically affected compared to other regions.  Everyone has asked this question, but it is not 
possible to provide a sound response at this time. 
 
Dr. Moore noted that absenteeism is intriguing to follow, but this finding is not typically reported.  
She wondered whether Canada had experience with other vaccines for which absenteeism 
following immunization was assessed to which this could be compared. 
 
Dr. Serres replied that they do not.  Because of the outcome they selected to follow with active 
surveillance, and they acquired this information.  However, there are no data about absenteeism 
in the overall vaccination program. 
 








Dr. De Serres responded that they do not, but they assessed absenteeism occurring during 
Days 1 and 2 compared to what occurred during the rest of the week.  That is an unusual way to 
set the baseline. 
 
Dr. Rubin asked whether the denominators included just the people who responded from among 
those who provided their email address, or included the entire population. 
 
Dr. De Serres indicated that the results he provided were for those who responded with their 
email address. 
 
Regarding the data suggesting that there might be an increase of absenteeism or medical 
consultation post-vaccination after a subsequent dose, Dr. Rubin asked whether they were able 
to put some error bars around that and if that might have any implications for revaccination. 
 
Dr. De Serres replied that they did not put the bars on this.  Studies were conducted in younger 
children who received more than two doses, and for which there may be some answers.  But it 
is not clear whether that would be the same in someone who received two doses as an 
adolescent and a booster dose 5 to 10 years later.  He has not seen any data about that. 
 
Ms. Pellegrini noted that coverage rates among children were extremely impressive.  She 
wondered whether they were able to execute the school-based vaccination campaign with the 
existing infrastructure or if additional public health personnel or others were tasked for that 
campaign. 
 
Dr. De Serres responded that the existing infrastructure was utilized.  However, some people 
were engaged in other nursing work with the public health system who were rerouted for a few 
weeks to help out. 
 
Considerations for Use of MenACWY Vaccines in HIV-Infected Persons 
 
Jessica MacNeil, MPH 
National Center for Immunization and Respiratory Diseases 
Centers for Disease Control and Prevention 
 
During this presentation, Ms. MacNeil reviewed the use of meningococcal conjugate vaccine in 
human immunodeficiency virus (HIV)-infected persons.  She summarized the evidence of 
increased risk for meningococcal disease in HIV-infected persons, MenACWY vaccine response 
in HIV-infected adolescents, and other considerations. 
 
In terms of background, HIV is an established risk factor for several bacterial infections.  A 
growing body of evidence supports an increased risk of meningococcal disease among HIV-
infected persons.  ACIP does not currently include HIV-infected persons in the 
recommendations for routine vaccination of persons at increased risk of meningococcal 
disease.  However, if an HIV-infected person aged 2 years of age or older is vaccinated, he / 
she should receive a 2-dose primary series. 
 
Data on HIV and meningococcal disease has been limited historically.  An analysis of 
surveillance data from 1988-1993 from the 8-county metropolitan area of Atlanta found that HIV-
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the Group for Enteric, Respiratory, and Meningeal disease Surveillance in South Africa’s 
(GERMS-SA)2 study reported that 45% of 308 meningococcal disease patients were HIV-
infected, the age adjusted relative risk was 11.3 (95%CI 8.9-14.3), and that the case-fatality 
ratio among HIV-infected cases was 20% versus 11% among HIV-uninfected cases [1Stephens 
DS, Hajjeh RA, Baughman WS, Harvey RC, Wenger JD, Farley MM. Sporadic meningococcal 
disease in adults: results of a 5-year population-based study. Ann Intern Med. 1995: 123:937-
40; 2Cohen C, Singh E, Wu HM, Martin S, de Gouveia L, Klugman KP, et al; Group for Enteric 
Respiratory and Meningeal Disease Surveillance in South Africa (GERMS-SA). Increased 
incidence of meningococcal disease in HIV-infected individuals associated with higher case-
fatality ratios in South Africa. AIDS. 2010; 24:1351-60]. 
 
Expanded chart reviews were completed for HIV-infected meningococcal disease cases 
reported through the Active Bacterial Core surveillance (ABCs) system from 2000-2008. 
Incidence calculations from this analysis are limited to cases that met the CDC AIDS 
surveillance case definition, because name-based HIV reporting was not available in all of the 
states during the study years.  In terms of the findings, 33 HIV-infected meningococcal disease 
cases were reported in ABCs during 2000-2008.  Of those cases, 70% were caused by 
serogroup C, W, or Y.  In the 7 years since this review has been completed, an additional 12 
cases of meningococcal disease have been reported in HIV-infected persons in ABCs during 
2009-2015.  Of those cases, 83% were caused by serogroup C, W, or Y [Harris CM et al. 
Meningococcal Disease in Patients with HIV Infection-A Review of Cases Reported Through 
Active Surveillance in the United States, 2000-2008.  Manuscript Under Preparation]. 
 
HIV-related clinical data were collected on meningococcal cases with HIV-infection as part of 
the expanded chart review.  In general, patients presented with a wide range of CD4 counts and 
several met the CDC AIDS surveillance case definition.  The majority were also currently taking 
antiretroviral therapies at the time of meningococcal disease presentation.  Of the cases, 17 met 
the CDC AIDS surveillance case definition and were included in the incidence calculations.  
Meningococcal disease incidence among persons with AIDS was 3.5/100,000 compared to 0.3/ 
100,000 among persons not meeting the CDC AIDS case definition, resulting in a rate ratio of 
12.9.  In this study, an increase in risk was observed for both HIV-infected men and women and 
the rate ratio among men was not significantly different than that among women [Harris CM et 
al. Meningococcal Disease in Patients with HIV Infection-A Review of Cases Reported Through 
Active Surveillance in the United States, 2000-2008.  Manuscript Under Preparation]. 
 
In New York City, meningococcal surveillance data from 2000-2011 was matched to death and  
HIV registries.  As part of this study, an age-matched case-control analysis was also performed 
among HIV-infected persons and included a subset of cases with CD4 count and viral load 
measurements near the time of meningococcal disease.  A total of 40 HIV-infected cases were 
reported in New York City during 2000-2011.  Of those cases, 87% were caused by serogroup 
C, W, or Y.  The incidence of meningococcal disease among persons infected with HIV was 
calculated.  Incidence was 3.4/100,000 in HIV-infected persons compared to 0.34/100,000 
among HIV-uninfected persons, for a risk ratio of 10.  A higher case fatality ratio was observed 
among HIV-uninfected cases compared to HIV-infected cases.  The risk of meningococcal 
disease decreased during the study period for both HIV-infected and HIV-uninfected persons in 
New York City.  Meningococcal disease incidence among HIV-infected persons decreased from 
4.7/100,000 in 2000-2002 to 1.9/100,000 during 2009 through 2011.  In the case-control 
analysis among persons infected with HIV, patients with meningococcal disease were 5.3 times 
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high viral loads [Miller L, Arakaki L, Ramautar A, Bodach S, Braustein S, et al. Elevated Risk for 
Invasive Meningococcal Disease Among Persons with HIV. Ann Intern Med. 2014; 160:30-38]. 
 
The most recent study, which is from the United Kingdom (UK), assessed risk for 
meningococcal disease among HIV-infected children and adults during 2011-2013.  Incidence of 
meningococcal disease was 6.6/100,000 in HIV-infected persons compared to 1.5/100,000 
among HIV-negative persons, for a risk ratio of 4.5 [Simmons RD. et al. Risk of invasive 
meningococcal disease in children and adults with HIV in England: a population-based cohort 
study. BMC Med. 2015; 13: 297]. 
 
All but one of the cases in HIV-infected persons occurred in adults 16 through 64 years of age, 
which meant that there was a 22.7-fold increased risk for HIV-infected adults compared with 
HIV-uninfected adults.  During 2011-2013, 14 HIV-infected cases were reported in the UK.  Of 
these, 71% were caused by serogroup C, W, or Y.  Most of the HIV-infected cases were aware 
of their HIV status and were receiving antiretroviral treatment.  The most common clinical 
presentation was septicemia.  Although intensive care admission was common, none of the 
HIV-infected patients died [Simmons RD. et al. Risk of invasive meningococcal disease in 
children and adults with HIV in England: a population-based cohort study. BMC Med. 2015; 13: 
297]. 
 
To summarize the epidemiologic data, there is an increased risk for meningococcal disease in 
HIV-infected persons.  Among HIV-infected persons, low CD4 count or high viral load increases 
risk.  In some studies, a similar increase in risk was observed for both HIV-infected men and 
women.  However, overall risk is declining along with meningococcal disease incidence in the 
US.  In HIV-infected persons, meningococcal disease is primarily due to serogroups C, W, and 
Y.  Data on the case-fatality ratio for HIV-infected meningococcal disease cases is mixed. 
 
Regarding vaccine response for HIV-infected persons, the data on HIV-infected adolescents is 
based on approximately 300 adolescents included in this study.  The proportion of HIV-infected 
adolescents with more than a 4-fold increased risk in rSBA titers at week 4 was 52% for 
serogroup C and 53% for serogroup Y.  For HIV-infected adolescents who received a single 
dose of MenACWY-D, the response was significantly lower for those with either a low CD4 
count or a high viral load [Phase I/II, Open-Label Trial of Safety and Immunogenicity of 
Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate 
Vaccine in Human Immunodeficiency Virus-Infected Adolescents. Pediatric Infectious Disease 
Journal. 29(5):391-396, May 2010]. 
 
In terms of GMTs against serogroup C at 0, 4, 24, 28, and 72 weeks, despite a second dose of 
vaccine at 24 weeks, response rates remained low through 72 weeks for those with low CD4 
counts at study entry.  For those with higher CD4 counts at study entry who received one dose 
of MenACWY-D, after an initial response at 4 weeks, GMTs waned rapidly.  Persons with higher 
CD4 counts at study entry who received two doses of MenACWY-D, after an initial response at 
4 weeks, GMTs waned rapidly after both Dose 1 and Dose 2.  Overall, the response to 
serogroup Y is higher than for serogroup C, but the same pattern of rapidly waning titers is 
observed.  Regarding the percent of subjects who still had antibodies at week 72 or 
approximately 1.5 years after 1 or 2 doses of MenACWY-D, the primary study endpoint was the 
percent of subjects with rSBA titers ≥1:128.  For serogroup C, titers waned to 21% to 35%.  For 
serogroup Y, titers waned to 63% to 71%.  The proportion of subjects with rSBA titers ≥1:8 are 
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Meningococcal Conjugate Vaccine in Youth Infected with Human Immunodeficiency Virus. The 
Journal of Pediatrics. 161(4):676-681. October 2012]. 
 
In summary, seroresponse to MenACWY-D conjugate vaccine in HIV-infected adolescents is 
suppressed compared to healthy adolescents.  Low CD4 count or high viral load suppresses 
response further.  In addition, the immune response to MenACWY-D wanes rapidly.  Although a 
boost response is seen to a second dose, duration of protection will likely be an issue. 
 
In addition to the evidence of increased risk for meningococcal disease in HIV-infected persons 
and meningococcal vaccine response, the WG also discussed other programmatic 
considerations for the use of meningococcal vaccines in HIV-infected persons.  There are 
approximately 1.2 million persons 13 years of age or older living with HIV in the US1.  An 
additional 50,000 new HIV infections occur each year1.  Only about 50% of persons diagnosed 
with HIV receive regular HIV care2.  Of those retained in care, approximately 89% are 
prescribed antiretroviral therapy and 77% achieve viral suppression2.  For HIV-infected persons 
in care, HIV clinics may already be administering other vaccines recommended for HIV-infected 
persons.  HIV-infected persons in care may be more likely to have CD4 counts and viral loads 
that are favorable for immunogenicity to the meningococcal vaccine [1 http://www.cdc.gov/hiv 
/statistics/overview/ataglance.html; 2 http://www.cdc.gov/hiv/prevention/programs/pwp/ 
linkage.html]. 
 
Although vaccine coverage data specifically for HIV-infected adults is sparse, coverage with 
influenza, hepatitis B, and hepatitis A vaccine has been estimated for HIV-infected persons in 
care through the HIV Outpatient Study (HOPS).  Among active patients in HOPS clinics, annual 
influenza vaccination rates were between 26% and 51% during 1999-20131,2.  Additionally, 32% 
of eligible patients were vaccinated with at least 1 dose of hepatitis B vaccine, and 23% of 
eligible patients were vaccinated with at least 1 dose of hepatitis A vaccine during 1992-20023 
[1Durham MD. Rates and correlates of influenza vaccination among HIV-infected adults in the 
HIV Outpatient Study (HOPS), USA, 1999–2008. Preventive Medicine 53 (2011) 89–94; 
2Durham MD. Seasonal Influenza Vaccination Rates in the HIV Outpatient Study—United 
States, 1999–2013.  CID 60 (2015) 976-7; 3Tedaldi EM. Hepatitis A and B Vaccination Practices 
for Ambulatory Patients Infected with HIV. CID 38 (2004) 1483-9]. 
 
The current consideration is for use of MenACWY conjugate vaccine only.  In HIV-infected 
persons, risk appears to be due primarily to serogroups C, W, and Y.  No safety or 
immunogenicity data is available for use of serogroup B meningococcal vaccines in HIV-infected 
persons.  The current consideration includes all HIV-infected persons 2 months of age and 
older.  Because increased risk from HIV-infection is life long, regular booster doses would be 
recommended for HIV-infected persons similar to other groups at increased risk. 
 
AAP currently recommends MenACWY vaccine for HIV-infected children 2 years of age and 
older.  Here is the language from the 2015 Red Book addressing the use of MenACWY vaccine 







Advisory Committee on Immunization Practices (ACIP)                                               Summary Report                                             February 24, 2016 
 
 
Current AAP and ACIP recommendations are not harmonized for HIV-infected children 2 years 
of age and older. 
 
Regarding risk of meningococcal disease in MSM, of meningococcal disease cases among 
MSM for whom HIV status is known, the majority (59%) are HIV-infected.  This makes 
disentangling the relative contribution of HIV and MSM status to the increase in risk challenging 
in MSM populations.  However, vaccinating HIV-infected persons offers an opportunity also to 
potentially impact meningococcal disease risk among MSM. 
 
In summary, a growing body of evidence supports an increased risk of meningococcal disease 
among HIV-infected persons.  The incidence of meningococcal disease in HIV-infected persons 
is elevated and ranges from 3.4 to 6.6/ 100,000 persons.  That translates to a relative risk of 4.5 
to 12.9 compared to HIV-uninfected persons.  In HIV-infected persons, risk is primarily due to 
serogroups C, W, and Y.  Suboptimal vaccine response and programmatic challenges may limit 
the impact of vaccination on disease burden in HIV-infected persons.  However, HIV-infected 
persons represent a relatively small, defined population who are already recommended to 
receive specialized medical care. 
 
There is strong support from the WG for including HIV-infected persons in the groups at 
increased risk of meningococcal disease.  The primary considerations for the WG included the 
evidence of increased risk of meningococcal disease in HIV-infected persons, the potential 
benefits of vaccination in the targeted group, and the fact that HIV-infected persons represent a 
population who are already receiving specialized medical care.  However, the WG also 
recognizes that there is suboptimal vaccine response and likely issues with duration of 
protection in HIV-infected persons, which may limit the impact of vaccination in this group. 
 
Listed below are the current recommendations for use of MenACWY conjugate vaccine in 










Routine vaccination of persons aged ≥2 months at increased risk of meningococcal 
disease, including: 
Persons with persistent complement component deficiencies1  
Persons with anatomic or functional asplenia2   
Microbiologists who are exposed routinely to isolates of Neisseria 
meningitidis 
Persons at risk during a community outbreak attributable to a vaccine 
serogroup 
Persons who travel to or reside in countries in which meningococcal disease 
is hyperendemic or epidemic 




[1Including inherited or chronic deficiencies in C3, C5-9, properdin, factor D, or factor H; 
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The WG proposes adding persons with HIV infection to the list of groups recommended for 
routine vaccination with MenACWY vaccine.  Guidance for use of MenACWY for HIV-Infected 










Persons aged ≥2 years with HIV who have not been previously vaccinated should 
receive a two dose primary series of MenACWY (0, 2 months) 
Multi-dose schedule for children aged <2 years 
Persons with HIV who have been previously vaccinated should receive a booster dose 
at the earliest opportunity, and then continue to receive boosters at the appropriate 
interval 
Current booster recommendations: 3 years if age <7 years at previous dose and 
5 years if age ≥7 years at previous dose 
 
A cost-effectiveness analysis and a GRADE analysis for routine use of MenACWY in HIV-
infected persons 2 months of age and older are currently in progress and will be shared with 
ACIP as they are completed. 
 
ACIP members were asked to consider the following questions for discussion: 
 
In addition to the cost-effectiveness analysis and GRADE, are there additional analyses 
that ACIP would like to see? 
Is ACIP in agreement with the Meningococcal Vaccines Work Group proposal to 




Based on such a dramatic decline in such a short period of time, Dr. Moore asked whether there 
was discussion in the WG about potentially reducing the interval for booster doses among HIV-
infected adults to 3 years instead of 5 years, or if there are 5-year data on their antibody titers. 
 
Ms. MacNeil replied that the WG did not discuss moving to a shorter interval, given that they 
were thinking about simplicity and harmonization with the current recommendations for other 
groups at increased risk.  However, they could certainly discuss a shorter interval. 
 
Dr. Messonnier asked whether there are any data on more than a single vaccination.  Following 
the rationale Dr. Moore used, if the interval was shortened, what would be done after that.  That 
is, are there any data on multiple doses of conjugate vaccines? 
 
Ms. MacNeil responded that there are not.  For HIV-infected adolescents, the two studies she 
presented are the only data they have for either vaccine. 
 
Given the conversation, Dr. Baker (IDSA) suggested that when the cost-effectiveness study is 
done, boosting on a 3- or 5-year schedule should be considered.  Medically, it makes more 
sense to have a 3-year interval.  Programmatically, it is a nightmare.  However, this might be 
informative. 
 
Dr. Riley asked whether there are any data on co-administration with other vaccines, particularly 








Ms. MacNeil responded that while there are not for HIV-infected persons in particular, there are 
data for healthy adolescents. 
 
Dr. Bennett emphasized that the rates of vaccination among HIV-infected individuals were 
incredibly low, especially since they are among people who are receiving care.  She asked 
whether the WG had considered how this vaccine would be implemented among those groups, 
given the existing poor rates. 
 
Ms. MacNeil indicated that one reason the WG was considering HIV-infected persons was 
because HIV care providers are already providing other vaccines and could provide this vaccine 
as well.  Rates of vaccination in the general adult population are relatively similar. 
 
Dr. Romero asked whether there are any data on the AEs associated with revaccination of 
younger children, and why there is a lower mortality rate in HIV-infected individuals. 
 
Dr. Messonnier responded that there are some CDC data, but it is comparable to healthy 
individuals. 
 
Ms. MacNeil responded that in the two US studies and the UK, the case fatality ratio is lower for 
HIV-infected persons.  There is a variety of reasons.  It could be that people get into care more 
quickly, they are being treated more aggressively perhaps because they are 
immunosuppressed, the disease process is not as severe, et cetera. 
 
Meningococcal Disease Among MSM in the US:  January 2012-June 2015 
 
Temitope A. Folaranmi MBChB, MPH, MPP 
National Center for Immunization and Respiratory Diseases 
Centers for Disease Control and Prevention 
 
For this presentation, Dr. Folaranmi discussed the results of an analysis of surveillance data on 
meningococcal disease among MSM in the US, including instances of community-based 
outbreaks or clusters of invasive meningococcal disease (IMD) among MSM.  The first reported 
outbreak of IMD among this group occurred in Toronto in 2001.  The first reported US outbreak 
occurred in Chicago in 2003. Subsequent clusters/outbreaks have occurred in New York City 
(2010-2013), Los Angeles County (2012-2013), Paris (2013), Belgium (2013), Berlin (2013), and 
Chicago (2015).  All outbreaks were caused by serogroup C ST-11 clonal complex, a common 
invasive strain of Neisseria meningitidis and a frequent cause of outbreak cases.  These 
clusters had between a 25% to 50% case fatality ratio.  These ratios were high when compared 
to 10% to 15% case fatality ratio seen in the general US population.  Similarly, 68% and 75% of 
the cases in New York City and the most recent Chicago outbreak were HIV-infected.  These 
percentages were also high compared to an HIV prevalence of 19% observed in the general US 
MSM population. 
 
These instances of community-based outbreaks and clusters have raised the question as to 














Identify IMD cases reported among MSM within the observation period 
Describe IMD epidemiology and case characteristics among MSM and non-MSM  
Assess rates of IMD and prevalence of known IMD risk factors among MSM 
Estimate the relative risk of IMD among MSM compared to non-MSM 
Estimate the relative risk of IMD among HIV infected MSM compared to HIV uninfected 
MSM 
 
Regarding the methods used in the analyses, meningococcal disease surveillance data are 
reportable in the US.  All US states and territories have passive reporting that includes all 
confirmed and probable cases.  When a meningococcal case is reported, an intensive case 
investigation is conducted by the health department to identify close contacts who may require 
prophylaxis for the disease.  Information on the sex of sex partners and HIV status may be 
captured in case notes, but is not usually reported through surveillance. 
 
To address the first objective to identify IMD cases that occurred among MSM, CDC posted two 
Epi-X calls for cases posted in May 2013 and June 2015.  State health departments, including 
Washington, DC and New York City, were asked to review all meningococcal disease cases 
among men 18 through 64 years of age occurring during the study period of January 2012 
through June 2015.  If MSM cases were identified, case investigation and risk factor data were 
abstracted.  If no MSM case was identified, zero report was requested.  After data abstraction, 







MSM cases in New York City (MSM-NYC) 
MSM cases in Los Angeles County (MSM-LAC) 
MSM cases in Chicago, including those from the metro area (MSM-Chicago) 
MSM sporadic cases and all other MSM cases (MSM-Others) 
Men not known to be MSM (Non-MSM) 
 
Cases within the three jurisdictions (New York City, Chicago, Los Angeles County) were 
grouped separately because they reported an outbreak or cluster during the observation period. 
Not all MSM cases that occurred within the three jurisdictions within the observation period were 
part of a cluster or outbreak.  However, for analysis, all cases that occurred within each 
jurisdiction during the observation period were grouped together. 
 
To address the other four objectives, the denominator was estimated for the disease rate 
calculation.  MSM was defined as “sex with another man in the past five years.”  Similarly, the 
MSM population per jurisdiction was defined as the “population of men aged 18 through 64 
years X MSM prevalence.”  To estimate the population of men 18 through 64 years of age, the 
2012 population estimate data of the American Community Survey (ACS) was utilized.  The 
ACS is a yearly survey conducted by the US Census Bureau.  Using the survey data, the 
number of men 18 through 64 years of age in the US was estimated to be 96,618,006. 
 
To estimate MSM prevalence per jurisdiction, data were used from a recent study conducted by 
subject matter experts (SMEs) from CDC’s Division of STD Prevention (DSTDP) and Emory 
University.  The estimates were 6.8% for Los Angeles County, 7.3% for New York City, 6.6% for 
Chicago, and 3.3% for other US jurisdictions.  The overall prevalence of MSM in the US was 
estimated to be 3.9% [Jeremy Grey, Kyle Bernstein et al, 2015. Estimating the population sizes 
of men who have sex with men (MSM) in the U.S. states and counties using data from the 
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Estimation of the HIV-infected MSM population in each jurisdiction was based on 2012 HIV 
surveillance data1,2,3,4.  The HIV uninfected MSM population per jurisdiction was calculated 
using the formula:  (Population of Men Aged 18-64 Years * MSM Prevalence) – Surveillance 
Estimate of HIV Infected MSM.  MSM-Others’ Cases Estimate was calculated using the formula: 




port.pdf; 3 http://publichealth.lacounty.gov/wwwfiles/ph/hae/hiv/2012AnnualHIVSurveillance 
Report.pdf; 4http://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-
vol-25.pdf]. 
Regarding the results, 527 meningococcal disease cases were identified overall among men 18 
through 64 years of age reported to CDC between January 2012 and June 2015.  Of these 
cases, 74 (14%) were identified as MSM from 17 states and 453 (86%) cases were among non-
MSM from 47 states and Washington, DC.  Before analyzing the data by the jurisdictional 
classifications described earlier, the age group and MSM status was first assessed for all case 
patients to understand whether the case patient would have been eligible for vaccination 
through the vaccination platform.  Case patients 18 through 24 years of age accounted for 31% 
of the non-MSM cases, case patients 26 through 35 years of age accounted for 43% of the 
MSM cases, case patients 36 through 45 years of age accounted for 19%, case patients 46 
through 55 years of age accounted for 16%, and case patients 56 through 64 years of age 
accounted for 1%.  Overall, the median age for all MSM cases was 31 years and the median 
age for non-MSM cases was 34 years. 
This graphic shows the frequency of meningococcal disease cases by month within the 
observation period: 
57 
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Subsequently, the data were analyzed by jurisdiction.  Of the 74 MSM cases identified in this 
study, 23, 14, and 11 MSM cases occurred in New York City, Los Angeles County, and 
Chicago, respectively.  Of the cases, 26 were classified as MSM-Other because they were 
sporadic cases in states and geographic areas outside of the three jurisdictions. 
 
The majority of cases in the MSM and non-MSM categories were non-Hispanic.  However, an 
equal proportion of Hispanic and non-Hispanic cases were observed in Los Angeles County.  
The majority of the MSM-Others, MSM-LAC, and Non-MSM categories were White.  However, 
Blacks accounted for a greater proportion of the cases from New York City and Chicago. 
 
Clinically, meningitis and bacteremia were the two most common presentations.  The clinical 
presentations reported are not mutually exclusive.  About 10% of all MSM cases had both 
meningitis and bacteremia, or either of them and another clinical presentation such as septic 
shock or pneumonia.  Therefore, the percentages may exceed 100%.  Among the MSM cases 
within MSM-Others, MSM-NYC, MSM-LAC, and MSM-Chicago case fatality ratios were 
observed of 39%, 26%, 36%, and 27% respectively.  Among non-MSM cases, the case fatality 
ratio was 24%. 
 
The serogroups included in MenACWY vaccines accounted for most of the MSM cases with 
known serogroup information.  However, serogroup C was predominated among MSM cases.  
On the other hand, a wide distribution of serogroups is observed among the non-MSM cases.  
Serogroup information for about 16% of non-MSM cases was not available.  Between 36% and 
65% of the MSM cases were HIV-infected.  Overall, 59% of all MSM cases with known HIV 
status were HIV-infected.  When the data were restricted to only serogroup C, W, and Y cases, 
the overall HIV prevalence among MSM was 58%.  Across all case patients, serogroup C cases 
were 1.5 times more likely to have a fatal outcome.  When comparing case fatality to MSM 
status, a significant association was not observed between them.  However, outcome data was 
unknown in 15% of the cases of the non-MSM case patients.  Similarly, a significant association 
was not observed between case fatality and HIV status among MSM.  Similar findings were 
observed when data were restricted to only serogroups C, W, and Y cases. 
 
Next, behaviors reported among the MSM cases were assessed.  Of MSM case patients, 33% 
reported smoking; 49% reported use of recreational drugs, including marijuana; 47% reported 
multiple sexual partners or engaged in anonymous sex; 61% reported using dating apps or 
websites to meet partners; and 21% had a history of recent travel.  There are variations in the 
number of cases assessed due to limited availability of data reporting these behaviors. 
 
Regarding the risk of IMD among MSM and non-MSM, first the annualized incidence rates 
among MSM were estimated and compared those to the incidence among non-MSM within 
each jurisdiction.  Overall, the incidence among MSM in the US was 0.59 cases/100,000.  This 
is compared to 0.15 cases/100,000 among non-MSM.  Thus, MSM have 4 times the incidence 
risk of IMD compared to non-MSM.  MSM within the MSM-Others category have 1.8 times the 
incidence risk for IMD when compared to non-MSM cases.  The three MSM cluster categories 
have a relative risk of IMD ranging from 14.6 to 23 when compared to non-MSM cases. 
 
Next, incidence rates were compared between HIV-infected and HIV-uninfected MSM.  Overall, 
it was observed that HIV-infected MSM had 10.1 times the risk of IMD compared to HIV-
uninfected MSM cases.  It was observed that MSM cases within the MSM-Others category had 
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hand, the relative risk for IMD among HIV-infected MSM within the three cluster categories 
ranged from 4.1 to 6.8 compared to HIV-uninfected MSM. 
 
IMD annualized incidence rates among HIV-infected MSM and other men were then compared 
within each jurisdiction.  Other male cases is defined as “all non-MSM and HIV-uninfected MSM 
cases combined.”  Overall, HIV-infected MSM have 16 times the risk of IMD compared to all 
Other Male cases.  HIV-infected MSM within the MSM-Others category have 6.7 times the risk 
of IMD compared to other men cases; whereas, within the cluster categories, HIV-infected MSM 
have a relative risk ranging from 22.5 to 34 when compared to Other Male cases.  In summary 
of relative risk when the data was restricted to only serogroups in MenACWY vaccines, an 
increase was observed in the overall relative risk of IMD among MSM from 4 to 7.3 when 
compared with non-MSM cases having serogroup C, W, and Y infections.  The relative risk for 
IMD among MSM compared to non-MSM in the MSM-Others category was 3.3.  The relative 
risk for IMD among the cluster cases ranged from 21.3 to 38.9 when compared to non-MSM 
cases. 
 
HIV-infected MSM with serogroup C, W, and Y infection had a relative risk of 9.2 when 
compared to the HIV-uninfected MSM overall.  However, within the MSM-Others category, the 
relative risk for IMD increased to 10.3 when compared to HIV-uninfected MSM.  A decline was 
noted in IMD risk among the cluster cases with a relative risk that ranged from 1.8 to 7.7 when 
compared to HIV-uninfected MSM cases.  HIV-infected MSM had a relative risk of 25.7 and 6.7 
in the overall and MSM-Others category respectively.  Among the cluster cases, the relative risk 
ranged from 12.9 to 48.4 when compared to Other Men cases.  Additionally, HIV-uninfected 
MSM were compared to non-MSM cases only.  Overall, a relative risk of 3.0 was observed 
among HIV-uninfected MSM when compared to non-MSM cases.  On the other hand, the 
relative risk in the MSM-Others category was 0.97 when compared to non-MSM cases.  Among 
the cluster MSM cases, the relative risk for IMD among HIV-uninfected MSM ranged from 9.3 to 
22.8.  Finally, it was observed that IMD risk diminished among MSM in non-outbreak settings 
when HIV infection is removed from the equation as shown by the decline in relative risk from 
3.3 to 0.97. 
 
Regarding the salient issues from the analyses, MSM had a higher incidence in terms of IMD 
risk among MSM in both outbreak and non-outbreak settings compared to the general non-MSM 
male population.  It was noted that serogroup C accounted for the majority of the MSM cases 
reported during the observation period.  This is consistent with all previous outbreaks reported 
among MSM; however, the reason for this occurrence remains unclear. 
 
Similarly, HIV prevalence among MSM with IMD was high at 59% when compared to the 
general HIV prevalence of 19% among MSM in the US.1 It is unclear why there is no significant 
association observed between HIV status and case fatality among the MSM cases in the 
analysis.  This may be related to access to HIV care and the care-seeking behavior of the case 
patients.  Unfortunately, there are no data on viral load or CD4 count status that would allow for 
a stratified analysis.  Based on the analyses, it was observed that being MSM combined with 
HIV infection conferred a higher risk for meningococcal disease than being MSM alone. 
Similarly, HIV infection seems to be responsible for most of the increased risk observed among 
MSM-Others [1Prevalence and Awareness of HIV Infection Among Men Who Have Sex With 
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In terms of high risk behaviors among MSM with IMD, a high prevalence of recreational drug 
use among MSM with IMD of 48% was observed compared with a recreational drug use 
prevalence of 10%1 among US adults.  A high prevalence of smoking was observed among 
MSM with IMD of 30% compared with an 18%2 prevalence among US individuals 12 years of 
age and older.  The reasons for increased IMD risk in outbreak settings are unclear, but may 
include an increase in the number of contacts and/or higher-risk behaviors.  MSM with these 
behaviors may also be at increased risk of being infected with HIV [1Jamal A, Agaku I, O'Connor 
E, King B, Kenemer J, Neff L. Current Cigarette Smoking Among Adults — United States, 
2005–2013. (MMWR). 2014;63(47):1108-12; 2Center for Behavioral  Health Statistics and 
Quality. Behavioral health trends in the United States: Results from the 2014 National Survey on 
Drug Use and Health. 2015]. 
The analysis is not without limitations.  Ascertainment of MSM and HIV status during case 
investigations is still a challenge.  The estimates are conservative, and it is likely that 
misclassification of MSM status may underestimate the rate.  Systematic collection of 
information on sexual behavior by health departments will help reduce misclassification in future 
analyses.  Similarly, IMD incidence may vary depending upon the accuracy of denominator 
estimates.  CDC recommended that all health departments routinely assess MSM and HIV 
status for cases that occur in men 16 years of age and older.  It remains unclear how broadly 
and completely this recommendation has been implemented.  Given the lack of a proper control 
population and missing/incomplete data, assessment of risk factors is difficult. 
 
The key messages from this analysis are that MSM had increased incidence of IMD, but the 
overall incidence remains low in both outbreak and non-outbreak settings compared to the 
general population.  Incidence increases with HIV infection and was higher among serogroups 
C, W, and Y infections in case patients.  Also, most MSM case patients are in the older age 
groups and would not have been vaccinated as part of the current adolescent vaccination 
platform for MenACWY. 
 
Considerations for Use of MenACWY Vaccines in MSM 
 
Jessica MacNeil, MPH 
National Center for Immunization and Respiratory Diseases 
Centers for Disease Control and Prevention 
 
Ms. MacNeil presented a summary of the WG discussions on meningococcal disease among 
MSM.  The ongoing clusters and outbreaks of meningococcal disease among MSM have 
increased awareness of meningococcal disease cases occurring in MSM.  However, 
understanding the risk for meningococcal disease in MSM is challenging given the associations 
with HIV-infection and higher-risk behaviors and the limited data available to evaluate and tease 
apart these potential risk factors. 
 
During the clusters and outbreaks among MSM in New York City, Los Angeles County, and 
Chicago, MenACWY vaccines were used as part of outbreak response, with local vaccination 
recommendations targeting either a subgroup of MSM1 or all MSM.  In these jurisdictions, 
vaccination recommendations for MSM continue to remain in place.  ACIP recommendations 
support the use of meningococcal vaccines in response to outbreaks.  However, these reactive 
vaccination campaigns often require considerable resources and effort on the part of the 
affected health department.  Despite these challenges, the initial vaccination response was 
demonstrated to be cost-effective in New York City2 [1MSM, regardless of HIV status, who 
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application ("app"), or at a bar or party; 2Simons et. al. Cost-Effectiveness of Meningococcal 
Vaccination Among Men Who Have Sex With Men in New York City. J Acquir Immune Defic 
Syndr. 2016 Feb 1;71(2):146-54]. 
 
As the WG reviewed the available data on the epidemiology of meningococcal disease among 
MSM, the key discussion points were that outbreaks of meningococcal disease continue to 
occur among MSM; MSM had higher incidence rates than non-MSM in both outbreak and non-
outbreak settings; and in non-outbreak settings, HIV infection appears to be the main driver of 
increased risk for MSM.  The reasons for outbreaks among MSM are unclear, but may include 
close social networks, an increased number of contacts, and/or higher risk behaviors. 
 
As presented earlier, it is estimated that approximately 3.9% of the US adult male population is 
MSM, which translates to a population size of approximately 3.8 million people.  To evaluate the 
potential programmatic issues and challenges for vaccinating MSM with meningococcal 
vaccines, the WG looked at other vaccines currently recommended by ACIP for MSM or 
subgroups of MSM, including HPV, Hepatitis A, and Hepatitis B vaccines.  These vaccines may 
be administered to MSM in a variety of settings and requires disclosure of MSM status to health 
care providers (e.g., primary care, STD clinics, et cetera). 
 
The National HIV Behavioral Surveillance (NHBS) surveyed over 10,000 US adult MSM in 2014.  
Of these, 82.2% visited a health care provider in past year1.  Among HIV-infected MSM, 97% 
had used health care.  Among other MSM, 80% had used health care.  Approximately 80% 
disclosed MSM activity to a healthcare provider.  The locations of usual care included doctor’s 
office or HMO (55.6%), clinic or health center (28.1%), hospital emergency room (13.5%), and 
other (2.4%) [1Unpublished data, courtesy S. Oliver and E. Meites]. 
 
Many STD clinics providing health care to populations which include MSM offer vaccines, 
including meningococcal vaccine.  In a survey from the National Coalition of STD Directors 
(NCSD) of 78 STD clinics from 46 US states, three-quarters stocked at least one vaccine and 
nearly half stocked a meningococcal vaccine [Unpublished data, courtesy E. McGinnis and 
NCSD]. 
 
The NHBS survey also provides estimates of HPV vaccine coverage among MSM.  In the 2011 
NHBS survey1, only 5% of MSM 18 through 26 years of age reported receiving at least 1 dose 
of HPV vaccine, with 13% coverage among HIV-infected MSM.  In late 2011, the ACIP 
recommendation for HPV vaccine for males and MSM was changed from permissive to routine.  
In the next NHBS cycle in MSM in 20142, 17% of MSM 18 through 26 years of age reported 
receiving any HPV vaccine, with 37% coverage among HIV-infected MSM [1Meites, E et al. HPV 
vaccine coverage among men who have sex with men – National HIV Behavioral Surveillance, 
United States 2011; Vaccine 2014; 2 Unpublished data, courtesy S. Oliver and E. Meites]. 
 
After reviewing the available data, no consensus was reached by the WG for including MSM or 
a particular sub-group of MSM in the groups at increased risk for meningococcal disease.  The 
primary reasons include the low absolute risk for meningococcal disease currently in non-
outbreak settings and potential programmatic challenges for implementing a vaccination 
program in MSM.  The WG feels that continued study is needed to better understand 
transmission and risk factors for this population.  In terms of meningococcal disease cases, the 
prevalence of HIV is high, with nearly 60% of MSM meningococcal diseases cases co-infected 
with HIV.  This is compared to an overall HIV prevalence in the general US MSM population of 
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important proportion of MSM meningococcal disease risk [1Prevalence and Awareness of HIV 
Infection Among Men Who Have Sex With Men—21 Cities, United States, 2008. Morbidity and 
Mortality Weekly Report (MMWR). 2010;59(37):1201-7]. 
 
MenACWY vaccines will continue to be used to vaccinate at risk populations if additional 
outbreaks of meningococcal disease among MSM occur.  In addition, enhanced surveillance for 
cases of meningococcal disease in MSM and HIV-infected persons is ongoing.  Updates will be 




In terms of changing the recommendations, it seemed key to Dr. Kempe to understand how 
much of the MSM risk is due to HIV.  Dr. Folaranmi’s slide 49, “Relative Risk of IMD among 
MSM with Serogroup C, W, and Y Infections” seemed to contain the most salient information.  
There are no 95% confidence intervals.  The last line appeared to be the comparison between 
non-HIV MSM with non-MSM.  She asked Dr. Folaranmi to expand on this. 
 
Dr. Folaranmi explained that for the first line, the general MSM population was compared to the 
non-MSM population.  The goal was to tease out the effect of HIV infection, which is why HIV-
infected MSM were compared to non-MSM.  The risk is almost 1, meaning that the majority of 
risk observed among MSM compared to non-MSM is likely due to HIV infection in the sporadic 
setting.  That effect was not seen in the clusters.  Most of the cases in the clusters were due to 
outbreaks. 
 
Regarding why more is not known about risk factors for meningococcal disease in MSM and 
potential problems with not having proper controls, Dr. Reingold pointed out that many case-
control studies have been conducted on MSM to assess numbers of partners, going to bath 
houses, and various other risk factors for HIV infection.  He was curious as to whether or not 
having controls was a resource problem or if there was a plan to conduct case-control risk factor 
studies.  In terms of this type of analysis, he suggested that it might be better to calculate 
population attributable risks instead of simply trying to compare relative risks in terms of trying to 
sort out how much of this is HIV and how much is MSM. 
 
Dr. Folaranmi replied that the population attributable risk was not calculated, but it is something 
to consider for further analysis.  With respect to the control group, the group referred to as non-
MSM cannot be confidently said to be all non-MSM, which is why the term “Other men not 
known to be MSM” is used.  They are not a perfect control group to use to analyze the data.  He 
did not know of any studies that assessed risk factors between MSM and non-MSM.  One study 
was conducted in New York City that attributed one possible risk factor, STDs in the past year 
before infection and HIV infection.  Those two risk factors were identified in that particular case-
control study.  CDC’s population was very small, comparing approximately 50 MSM cases to 
about 50 controls. 
 
Dr. Reingold clarified that he was talking about case-control studies comparing MSM who have 
meningococcal versus those who do not to assess risk factors among MSM (going to bath 
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Ms. Martin (SME) responded that CDC has discussed conducting a risk factor study.  Part of the 
problem is that the number of cases is low, so it would have to be a national study.  New York 
City conducted a study, but their comparison group is somewhat different from the case group 
and raises some questions pertaining to the validity of the findings. 
 
Ms. Pellegrini said she was struggling most with the limitations of ACIP’s mandate.  This is a 
very complex population with a lot of confounding risk factors.  It is not clear whether vaccine is 
the right public health intervention to achieve this goal.  Can IMD actually be reduced by 
reducing HIV infection, promoting condom use, et cetera?  She wondered whether their CDC 
colleagues could discuss how these conversations occur within the agency, because she is very 
concerned about potentially sending a recommendation to Dr. Frieden and putting the agency in 
a position of deciding whether to support the recommendation and essentially divert public 
health resources to this less effective intervention simply because ACIP is not tasked with 
determining how to reduce meningitis. 
 
To clarify any misunderstanding, Dr. Messonnier noted that the place the WG came to on this 
issue was not moving toward a vaccine recommendation.  Given all of the complexities, they 
recognize that this is not what the current science says at this point.  The larger issue is an 
interesting one.  Before meningococcal vaccines were available, a number of studies evaluated 
smoking as a risk factor for meningococcal disease that found that active and passive smoking 
had an attributable risk of 25% to 30% of cases of meningococcal disease.  However, no one 
was going to make passive smoking regulations based on this.  Fortunately, there were many 
other drivers of that.  This is a very specific, very small subgroup and it is difficult to determine 
whether that is going to drive the public health conversation.  The team is working with those in 
the STD and HIV worlds’ and this is part of it.  However, Dr. Reingold and Ms. Pellegrini raised 
another important issue as well:  Given the many other issues in this population, even launching 
research studies focused on this or nesting the issue in other studies is difficult. 
 
Something that troubled Dr. Bennett regarded where the estimates for the percentage of the 
population that engage in MSM come from and whether they are accurate.  This population may 
or may not want to disclose, and the rates in that population are quite dependent upon the 
denominator.  Therefore, it concerned her that the denominator may be underestimated. 
 
With respect to the outbreak comments, Dr. Moore thought in addition to the denominator 
having a significant effect on conclusions, the outbreaks themselves skew the perspective as 
this demonstrates.  There is the allusion on slide 3 of Ms. MacNeil’s second presentation to the 
fact that the outbreak response in New York City was demonstrated to be cost-effective.  She 
requested that Dr. Zucker from New York City discussed what sort of cost-effectiveness they 
observed. 
 
Dr. Zucker (NYC) said she would need to pull up the precise numbers to bring back to the 
group, but recalled that it was under $100,000 and was within or less than the cost-
effectiveness range used for the meningococcal recommendations.  It was surprising to her 
from the New York City perspective that it was clear that HIV is an increased risk factor—the 
data supported that.  They showed, at least in that setting, that it was cost-effective to conduct 
the vaccine campaign in the outbreak setting.  Relative to what they just heard in terms of 
numbers and increased risk, having a recent vote with over $1 million to prevent one case of 
IMD-B, perhaps they should have GRADE numbers to show what a national campaign would 
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MSM or a subgroup.  She was surprised that there was not more discussion about moving 
toward a routine recommendation, at least for some of the subgroups. 
 
Ms. MacNeil indicated that the cost-effectiveness analysis performed for GRADE would be 
presented in June 2016 for HIV-infected persons. 
 
Dr. Duchin (NACCHO) said he wanted to further explore some of the incidence numbers in the 
various sub-strata presented.  For the HIV-infected cohorts, particularly in the three cities, the 
incidence rates are much higher than they are for adolescents for whom meningococcal 
vaccination is routinely recommended.  Even for some of the HIV-uninfected populations, they 
are comparable.  He requested further information about what the WG thought about that issue, 
and whether it would be appropriate to consider vaccination where it has been established that 
the rate of disease is so much higher than it is for other populations for whom the vaccine is 
already recommended. 
Ms. MacNeil responded that the three jurisdictions that had outbreaks or clusters recommended 
vaccination of MSM, and those recommendations remain in place for those jurisdictions. 
 
Dr. Duchin (NACCHO) asked whether she was saying that there would be a different policy for 
jurisdictions in which outbreaks are occurring versus where they have not yet occurred. 
 
Ms. MacNeil replied that the WG did not discuss this because the recommendations are already 
in place in response to the outbreaks. 
 
Dr. Baker (IDSA) congratulated the presenters for summarizing information that took days for 
her to hear repeatedly.  This is very complex and difficult to tease out.  It would be great to 
conduct a case-control study, but it would cost a prohibitive amount.  She thinks the HIV data 
are very clear and compelling.  The AAP recommended MenACWY many years ago when the 
vaccine became available to drop down to two years with booster doses.  HIV-infected people is 
a subgroup.  They are a larger subgroup than children born with congenital complement 
deficiencies, which are on the list of high risk individuals.  When attempting to add, tear apart, 
figure out, or analyze MSM, it is complicated.  She thinks the HIV data are clear and that a 
policy group should not care about what proportion are being vaccinated.  Does ACIP 
recommend influenza vaccine for everyone 6 months of age and older?  Yes.  Is it a good policy 
decision?  Yes.  Do we have some groups that are well below 50%?  Yes.  It is not bad policy.  
ACIP is not in charge of implementing.  There is no reason not to add vaccine to public health 
measures to reduce risk.  Influenza vaccine recommendations are added to hand-washing, 
cough etiquette, and other measures.  It is not either / or. 
 
Dr. Zucker (NYC) clarified that New York City is focused on HIV-positive persons.  A person is 
MSM, but is high risk MSM high risk as defined from an outbreak cluster in terms of increased 





National Meningitis Association, Inc. (NMA) 
 
Thank you.  Hi.  I’m Lynn Bozof, President of the National Meningitis Association (NMA).  Most 
of you are familiar with my story of losing my son, Evan, to meningococcal disease as a college 
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scheduled.  But, I’m getting constant phone calls and emails from people with major difficulties 
finding serogroup B vaccines.  So, I felt I needed to say something.  Then with the recent 
outbreak at Santa Clara University and the MenB case at Yale, this is obviously an issue that 
we still need to think about.  Thank goodness there were no fatalities from those cases.  The 
Category B recommendations seemed like a really great place to start.  We saw people that 
wanted to fully protect their children who would just talk to their health care provider and let 
them know this is important to them.  Unfortunately, that is really not working out.  We hear from 
parents that their child’s doctors aren’t aware of the MenB recommendations.  Even fewer are 
carrying it, and they don’t know where to send people for it.  The other day, we had a workshop 
and one of the moms whose son contracted serogroup B at Princeton had to make 12 phone 
calls to find the vaccine for her younger son.  We had another college-age survivor that had to 
make 5 phone calls to find the vaccine.  These are people that are motivated.  These are people 
that want to be vaccinated.  If it’s so difficult for them, what is the average person going to do?  
They are going to give up.  So, when we have someone who wants to be vaccinated, yet can’t 
find the vaccine, it’s a bad situation.  When health care providers don’t know how to deal with a 
vaccine request, that’s a bad situation.  We really need to do better.  Most people want to send 
their children off to college fully protected.  We should make this easy.  It should be a “no-
brainer.”  But, it’s really turning out to be a challenge to get vaccinated for serogroup B.  So, I’m 






Lorry Rubin, MD 
ACIP, Workgroup Chair  
 
Dr. Rubin reminded everyone that inactivated vero cell culture-derived Japanese encephalitis 
vaccine (JE-VC; IXIARO®) is the only JE vaccine available in the US.  JE-VC is manufactured 
by Valneva, formerly Intercell.  Inactivated mouse brain–derived JE vaccine (JE-MB; JE-VAX®) 
is no longer available in the US. 
 
In terms of how ACIP recommendations for the use of JE-VC have evolved, in 2009 the FDA 
licensed JE-VC for use in adults and ACIP approved recommendations for a primary series in 
adults.  In 2010, the MMWR Recommendations and Reports from 1993 were updated.  In 2011, 
ACIP approved recommendations for use of a booster dose in adults based on new information 
and a Policy Note was published in the MMWR.  In 2013, ACIP approved recommendations for 
use of a primary series in children and an additional Policy Note was published in the MMWR. 
 
The JE Vaccine WG’s objectives are to:  1) review newly available safety and immunogenicity 
data for JE-VC; 2) review epidemiology and risk of JE in travelers; 3) review ACIP 
recommendations for use of JE vaccine in consideration of updated safety, immunogenicity, and 
traveler risk data; and 4) update the MMWR Recommendations and Reports published in 2010. 
 
Presentations during this session focused on duration of protection following the primary series 
and a booster dose in adults, duration of protection and consideration of need for a booster 
dose in children, and the JE Vaccine WG’s summary and plans.  
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Duration of Protection Following Primary  
Series and Booster Dose of IXIARO® in Adults 
 
Dr. Katrin Dubischar 
Senior Scientist, Clinical Research 
Valneva Austria GmbH 
 
Dr. Dubischar reminded everyone that the IXIARO® primary series was approved by FDA in 
2009 for use in persons 17 years of age and older.  Initial data on antibody persistence after a 
primary series of IXIARO®, the immunogenicity and safety of a booster dose, and duration of 
protection after the booster were added to the IXIARO® prescribing information in 2010.  The 
data were presented to ACIP and a booster recommendation was issued in 20111. In 2013, the 
IXIARO primary series indication was expanded to include children from 2 months of age, and 
ACIP issued a respective recommendation.  Data on need for and timing of a booster in children 
were not available at the time.  New clinical data are now available on duration of protection 
after primary series and after a booster dose, in both adults and children [1MMWR, May 27, 
2011, Vol. 60, No. 20]. 
 
Three clinical trials in adults provide data relevant to persistence of antibodies.  New clinical 







(Reviewed by ACIP) 
Follow-Up  








IC51-303 36 months 60 months Not Done  
IC51-311 15 months  
12 months  
(all subjects) 
76 months  
(subgroup) 
IC51-305 24 months  13 months  
 
Trial IC51-303 was a long-term immunogenicity and safety study.  The design was a single-arm 
Phase 3 follow-up study, with no treatment administered.  The study population was comprised 
of 181 subjects 18 years of age and older for the first 24 months after the first dose, with 152 
subjects included in the analysis up to Month 60 after the first dose.  Follow-up was at 2, 6,12, 
24, 36, 48, and 60 months after the first vaccination.  There were 4 study sites in Austria, 







Primary endpoint of SCR at Month 24 after first vaccination 
Secondary endpoint of GMT at Month 24 after first vaccination 
Immunogenicity (SCR and GMT) at Months 2, 6,12, 36, 48, and 60 
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The seroprotection rate was defined as the rate of subjects with a protective titer (PRNT50 
≥1:10).  There was a decrease in seroprotection from 99% down to about 80% within the first 12 
months.  Seroprotection then remained stable at approximately 80% for up to 5 years after the 
first dose.  The GMT decreased markedly in the first year, then remained stable at 
approximately 40 for up to 5 years.  The study was conducted in an area where tick-borne 
encephalitis (TBE) vaccine is relatively common.  It was observed in the pivotal studies that a 
response to a first dose of JE vaccine is enhanced in people who have had a prior TBE 
vaccination.  For that reason, a post-hoc analysis was performed to assess the impact of TBE 
vaccination on the seroprotection rate.  Subjects were grouped by their TBE virus vaccination 





No TBE vaccination up to the specific time point before the JE series 
TBE vaccination prior to the first dose of IXIARO®, but no TBE vaccination during the study 
TBE vaccination during the study after IXIARO® vaccination 
 
Among the subjects without any TBE vaccination before or during the study, the seroprotection 
rate decreased to approximately 60% at the end of 5 years follow-up; whereas, people with prior 
or concomitant TBE vaccination tended to show higher seroprotection rates over time [Schuller 
et al 2008, Dubischar-Kastner et al. Abstract LB-2357, American Society of Tropical Hygiene 
2011]. 
 
Trial IC51-311 was the main booster dose trial for XIARO® to assess the effect of a booster 
dose on long-term immunity.  This was a single-arm, open-label follow-up study conducted in 
198 subjects 18 years of age and older.  The treatment group received a 0.5 mL booster of 
IXIARO® intramuscularly at Month 15 after primary immunization.  Follow-up occurred at 1, 6, 





A primary endpoint of SCR at Month 12 after the booster vaccination 
Main secondary endpoints of SCR at Day 28 and Month 6 after the booster vaccination; 
GMTs at Day 28, Month 6, and Month 12; and solicited and unsolicited AEs up to Month 12 
 
In this trial, the seroprotection rate dropped from 97% to 69% by 15 Months after the start of the 
primary series.  GMT after primary immunization declined from about 170 to 23 [Eder et al, Long 
term immunity following a booster dose of the inactivated Japanese Encephalitis vaccine 
IXIARO®, IC51. Vaccine 2011,29;2607–2612]. 
 
Trial IC51-305 was an open-label, Phase 3 supportive booster / long-term immunogenicity 
follow-up study.  The objectives of the trial were to determine long-term immunogenicity, and 
response to a booster dose in subjects without measurable antibody titers.  The study 
population consisted of 356 subjects 18 years of age and older who received one of three 
different doses / schedules of IXIARO® in a preceding trial.  Dr. Dubischar showed only data for 
the standard schedule group during this session.  A 0.5 mL booster of IXIARO® was 
administered to seronegative subjects only.  Subjects who were seronegative at Month 6 were 
boosted at Month 11.  Subjects who were seronegative at Month 12 were boosted at Month 23.  
Follow-up was at 2 years after the primary series and up to 12 months after the booster.  There 
were 2 study sites in Germany and Northern Ireland where TBE vaccination is not practiced at 
all.  The primary endpoint was seropositivity at Month 24.  Seronegative subjects received a 
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The main secondary endpoints included seroprotection at Month 6, 12, and 24; GMTs at Month 
6, 12, 24; and SAEs and medically attended AEs and local and systemic tolerability of the 
booster. In this trial, the seroprotection rate dropped from 97% to 58% by Month 12 after start of 
the primary series.  By Month 24 after the primary series, only 48% of the subjects retained 
protective titer levels.  A stronger decline was observed in the GMTs from 219 to 16 by Month 
24 [Dubischar-Kastner et al Vaccine 2010]. 
 
For Trial IC51-311, the main booster dose trial, neutralizing antibodies also were assessed at 1, 
6, and 12 months after booster.  The seroprotection rate increased from about 70% at the pre-
booster time point to 100% within 1 month of the booster dose, and remained at 99% for at least 
12 months after the booster dose.  There was about a 40-fold increase in GMTs with the 
booster dose.  Up to about Month 12 after the booster dose, GMTs were retained at higher 
levels than observed after the primary series. 
 
A study was conducted as an extension of the IXIARO® main booster trial that assessed 
neutralizing antibodies 6 years after the booster dose in a subset of the original study population 
at 2 of the 3 original study centers.  For this study, the investigators were able to call back 67 of 
the original 198 subjects from main booster trial for serological sampling on average 76 months 
from their booster dose.  Among these subjets, the seroprotection rate remained at 96% 
approximately 6 years after the booster dose and the GMTs were about 150.  The data from 
that study also were used for mathematical modeling of the antibody decline.  A PRNT50 titer of 
1:10 was defined as the limit for protection.  Duration of protection depends upon the titer level 
after the booster dose.  The modeling estimated that about 75% of subjects will be protected for 
a minimum of 10 years.  The average duration of protection is projected to be 14 years, with a 
range 2 to 25 years.  The authors concluded that a second booster dose should be scheduled 
after 10 years for this vaccine [Paulke-Korinek et al, Persistence of Antibodies Six Years after 
Booster Vaccination with Inactivated Vaccine against Japanese Encephalitis. Vaccine 2015]. 
 
To summarize the data on boosting in adults, based on waning neutralizing antibody titers and a 
seroprotection rate range of 83% to 58% in the clinical trials, a booster of IXIARO® should be 
considered or recommended at 12 months after the primary series.  Clinical data demonstrate 
that a booster dose of IXIARO® will elicit a memory response at least until 23 months after the 
primary series.  After an IXIARO® booster dose, clinical data demonstrate high levels of 
seroprotection for 6 years.  Mathematical modelling suggests seroprotection may persist for at 
least 10 years after the booster dose of IXIARO® in 75% of vaccinees.  Safety data for a booster 
dose of IXIARO® were presented to ACIP for the booster recommendation vote in 2011.  No 
safety concerns were identified, and the AE profile was in-line with the primary series. 
 
In conclusion of the discussion regarding an adult booster dose, Dr. Dubischar presented 
information about the regulatory status and outlook for an IXIARO® booster dose 
recommendation in adults. 
 
In Europe, the Summary of Product Characteristics gives clear guidance for HCP for the first 
booster dose: 
 
“A booster dose (third dose) should be given within the second year (i.e., 12 - 24 months) after 
primary immunization, prior to potential re-exposure to JEV. Persons at continuous risk for 
acquiring Japanese encephalitis (laboratory personnel or persons residing in endemic areas) 
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A recommendation for a second booster dose after 10 years is currently under review by the 
EMA. 
 
In the US, both the Prescribing Information and the ACIP recommendations use less 
prescriptive language than Europe for first booster dose: 
 
“Individuals 17 years of age and older: If the primary series of two doses was completed 
more than 1 year previously, a booster dose may be given if ongoing exposure or re-
exposure to JEV is expected.” 
 
FDA indicated that without actual safety and immunogenicity data instead of mathematical 
modeling, no recommendation for a second booster would be granted in the label.  Therefore, 
Valneva has no current plans to submit additional antibody persistence data for IXIARO® to 
FDA. 
 
Duration of Protection and the Need for 
A Booster Dose of IXIARO® in Children 
 
Dr. Katrin Dubischar 
Senior Scientist, Clinical Research 
Valneva Austria GmbH 
 
Dr. Dubischar next presented an overview of clinical data pertaining to duration of protection 
after a primary series and booster dose of IXIARO® in children.  Two clinical trials in children 
provide data relevant to persistence of antibodies, and one clinical trial provides data on 
antibody persistence following a booster dose.  This presentation provided a comprehensive 















ety and immunogenicity study of IXIARO® in a JE vaccine naïve, pediatric travelers population 
comprised of children and adolescents 2 months or older through less than 18 years of age.  
This was an open-label, single-arm trial with an extension study and 100 children were 
evaluated for safety and 64 children were evaluated for immunogenicity. There were 23 children 
enrolled in the extension study IC51-324.  The treatment group was comprised of 12 children 
less than 3 years of age who were given a 0.25 mL dose of IXIARO®, and 88 children 3 years of 
age to 18 years of age who were given a 0.5 mL dose of IXIARO®.  Follow-up was at Day 56 
and Month 7 in the parent study and at Months 12, 24, and 36 in the extension trial.  There were 
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enpoint was rate of SAEs and medically-attended AEs until Day 56.  The secondary endpoint 
was immunogenicity (SCR/ GMT) up to Month 36. 
 
Long-term data are limited in traveling children due to recruitment issues.  In children aged 3 
years of age or less at primary immunization, the seroprotection rate decreased in the first 6 
months, then remained stable at approximately 90% for up to 3 years.  One child less than 3 
years of age was enrolled in the extension study, and retained a protective titer.  The GMTs 
declined in the first 7 months, and then remained fairly stable over time [Dubischar-Kastner et 
al., Abstract P 2.7, 5th Northern European Conference on Travel Medicine, June 5-8 2014 
Bergen, Norway; and Dubischar-Kastner et al., Abstract FC2.04, Presented at the 14th 
Conference of the International Society of Travel Medicine, May 25-28 2015, Quebec, Canada]. 
 
Trial IC51-325 was an antibody persistence / booster study in Philippine children to assess long-
term persistence of immunity and the safety and immunogenicity of an IXIARO® booster dose in 
children from JE endemic regions.  The study population was comprised of 300 children and 
adolescents 2 months through 17 years of age who were vaccinated in a preceding trial..  This 
was an open-label, randomized, Phase 3 study.  Subjects were randomized 1:1 into a booster 
group (12 months after first vaccination) and non-booster group of 150 subjects each.  Follow-
up occurred at Month 13 after the first immunization (4 weeks after booster dose) and Month 24 
for safety and immunogenicity.  There were 3 study sites in the Philippines.  The primary 
endpoint was seroconversion rate at 1 month after the booster dose.  The secondary endpoints 
included GMTs at 1 month after the booster dose and SAEs and medically attended AEs 1 
month after the booster dose. 
 
Of the children in this study, 149 were followed for a maximum of 3 years with a mean age of 
4.6 years at the time of primary vaccination.  The seroprotection rate decreased in the first 6 
months, then remained stable at approximately 90% for up to 3 years based on combined data 
for all ages / doses.  Though marginal, there was a constant increase in GMTs.  Looking at the 
individual titers of the subjects, titer increases that were suggestive of natural boosting were 
observed in 24 of 150 children during follow-up.  Children 1 to less than 3 years of age and 3 to 
less than 12 years of age showed a stronger decline in seroprotection rate down to 
approximately 80% at Month 7, although the numbers are limited in some of the age cohorts.  A 
booster dose was received by 148 children 12 months after the primary series, with a mean age 
of 5.6 years at the time of the booster.  The booster increased the seroprotection rate to 100% 
and this level was sustained for 2 years.  As in adults, GMTs increased about 40-fold after the 
booster, and remained higher compared with GMTs 2 months after the primary series. 
 
In terms of safety, the booster dose in children was very well-tolerated.  Most AEs were mild or 
moderate, and the AE rate with the booster was lower than with the primary series.  The most 
common AEs were local reactions, fever, loss of appetite, and headache.  All of these were 
reported in less than 10% of children.  Two SAEs occurred within 4 weeks after booster, 
including an abscess of the right flank and dengue fever) [Dubischar-Kastner et al., Abstract P 
2.8, 5th Northern European Conference on Travel Medicine, June 5-8 2014 Bergen, Norway; 
Dubischar-Kastner et al., Abstract FC2.04, Presented at the 14th Conference of the 
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In summary, in a small, mainly adolescent pediatric cohort from JEV non-endemic regions, 
antibody titers declined considerably up to Month 36 after vaccination with IXIARO®, but the 
seroprotection rate was still high at 89.5% in 17/19 subjects.  In a larger pediatric cohort from a 
JEV-endemic country, antibody titers also declined considerably up to Month 36.  
Seroprotection rates remained greater than 80% in all age groups.  Natural boosting through 
JEV virus exposure may have contributed to persistence of antibodies in this trial.  Together, 
data suggest that booster dose administration may not be absolutely necessary in any pediatric 
age group for a minimum of 3 years after the primary series.  However, titers in children 
declined substantially within the first year after the primary series, and the long-term 
seroprotection rate was enhanced by a booster dose, which was well-tolerated.  Valneva 
considers administration of a booster dose in children 12 months after primary series justified for 
programmatic reasons in terms of uniformity of medical use for adults / children and optimization 
of long-term protection. 
 
In Europe, a first booster recommendation for IXIARO® in children is currently under regulatory 
review.  There is indication that the adult booster recommendation will be extended for children:  
 
“A booster dose (third dose) should be given within the second year (i.e., 12 - 24 
months) after primary immunization, prior to potential re-exposure to JEV ...” 
  
In the US, the FDA is currently reviewing the pediatric booster data on IXIARO®, which were 
submitted as part of the post-marketing commitment.  Valneva plans to file a supplemental BLA 
with the FDA in 2016 with proposed edits to the prescribing information for a first booster dose 
of IXIARO® in children.  The proposed wording for a pediatric booster dose of IXIARO could 
resemble the adult language in the prescribing information: 
 
“If the primary series of two doses was completed more than 1 year previously, a 
booster dose may be given if ongoing exposure or re-exposure to JEV is expected.” 
  
In Europe and the US, there will not be a recommendation for a second booster dose of 
IXIARO® in children. 
 
JE Vaccine WG Summary and Plans 
 
Dr. Susan Hills 
Medical Epidemiologist 
National Center for Emerging and Zoonotic Infectious Diseases 
Centers for Disease Control and Prevention 
 
Dr. Hills presented on behalf of the JE Vaccine WG a summary of the new safety, 
immunogenicity, and other data presented during this session.  She also discussed plans and 
the timeline for presentation and discussion of additional data and topics. 
 
As a reminder, when the JE Vaccine WG was reformed in March 2015, its objectives were to:  
1) review newly available safety and immunogenicity data for JE-VC; 2) review updated data on 
the epidemiology and risk of JE in travelers; 3) review ACIP recommendations for use of JE 
vaccine in consideration of updated safety, immunogenicity, and traveler risk data; and 4) 
prepare a revised MMWR Recommendations and Reports to update the document that was 





Advisory Committee on Immunization Practices (ACIP)                                               Summary Report                                             February 24, 2016 
 
 
As a reminder, ACIP approved the JE-VC booster dose recommendation in 2011 which states: 
 
“If the primary series of JE-VC was administered >1 year previously, a booster dose may 
be given before potential JE virus exposure.” 
  
Data supporting the booster dose recommendation came from three clinical trials that provided 
data on persistence of protective neutralizing antibodies after a primary 2-dose JE-VC series.  
At 12 through 15 months after the 2-dose primary series, 58% to 83% of subjects were 
seroprotected based on these 3 studies.  At 24 months after the 2-dose primary series, 48% to 
82% of subjects were seroprotected in the 2 studies with data.  Thus, the results of the 
percentage of subjects with protective JE titers were quite variable.  In the study that had an 
82% seroprotection rate at 24 months, subjects were followed up for 60 months.  At 5 years, 
82% (124/152) of subjects were seroprotected.  The neutralizing antibody GMT was 43.  In 
addition, a post-hoc analysis was done for this study that stratified subjects by TBE vaccination 
status.  Seroprotection rates and GMTs were higher if TBE vaccine was administered after 
commencement of JE-VC vaccination.  The seroprotection rate at 24 through 60 months was 
90% to 100% in the TBE vaccine group and 64% to 72% in the vaccine group who did not 
receive TBE vaccine.  GMTs in the TBE vaccine group were significantly higher than GMTs in 
the non-TBE vaccine group at 24, 36, and 48 months. 
 
The WG reviewed and assessed these data.  The WG’s assessment and summary of the 
duration of protection following a JE-VC primary series in adults are that after a 2-dose primary 
series, long-term seroprotection rates and GMTs are lower in those not administered TBE 
vaccine compared with those administered TBE vaccine.  TBE vaccine is not available in the US 
and other flavivirus vaccines, such as YF vaccine, are not routinely administered with JE-VC.  
Therefore, JE seroprotection rates and GMTs for US travelers are likely to be most similar to the 
lower rates and GMTs in the study group not administered TBE vaccine.  Following the WG’s 
review, two options were considered.  The first was to make no change to the current booster 
dose recommendations.  The second was to strengthen the existing permissive ACIP 
recommendation from 2011.  The WG concluded that the data were sufficient to consider a 
strengthened booster dose recommendation.  The suggested recommendation would be as 
follows: 
 
“If the primary series of JE-VC was administered >1 year previously, a booster dose should 
be given before potential JE virus exposure.” 
 
The WG would be interested in feedback on this suggested change.  Depending upon feedback, 
the WG would consider putting the recommendation up for a vote during the next ACIP meeting. 
 
The second topic presented by Dr. Dubischar regarded new data on duration of protection 
following a booster dose in adults.  In summary, in observational study, at approximately 6 years 
after booster dose, 96% (64/67) of subjects were seroprotected and the neutralizing antibody 
GMT was 148.  This study was conducted in areas where TBE vaccine is not routinely 
administered.  In one modeling study, and estimated 75% of subjects would be seroprotected at 
10 years or later. 
 
The WG reviewed and discussed these data and its assessment was that after a 2-dose primary 
series and a booster dose, seroprotection rates were high for at least 6 years.  In addition, FDA 
has indicated that there will be no recommendation for a second booster dose as there are no 
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review, two options were considered.  The first was to make an off-label recommendation for a 
second booster dose.  The second was no off-label recommendation, but incorporation of the 
data into an updated MMWR Recommendations and Report document to make information 
available for vaccine providers.  The WG concluded that the data were not sufficient to support 
an off-label recommendation for a second booster dose.  The plan is to incorporate the data into 
an updated MMWR Recommendations and Reports document. 
 
The final topic presented by Dr. Dubischar pertained to duration of protection following a 2-dose 
primary series in children.  One study was conducted among pediatric travelers from non-
endemic countries.  The long-term study cohort included only 23 children, including 1 child in 
the 2 month to 2 year age group who received two 0.25mL doses of vaccine, 3 children in the 3 
to 11 year age group who were administered two 0.5mL doses of vaccine, and 19 children in 12 
to 17 year age group who received two 0.5mL doses of vaccine.  At 36 months, 89% (17/19) 
children were seroprotected and the GMTs were 58.  Although seroprotection rates and GMTs 
decreased between 1 and 6 months following the primary series, seroprotection rates and 
GMTs were then maintained at similar levels from Months 6 through Month 36.  In the long-term 
duration of protection studies, seroprotection rates at 36 months were higher in the pediatric 
study compared with the adult study.  At 36 months, 89% (17/19) were children seroprotected 
compared with 72% (41/57) of adults in the non-TBE vaccine group in the adult study. 
 
Data on duration of protection in children were also available from one study conducted among 
children in the Philippines, which is a JE-endemic country.  At 36 months after a 2-dose primary 
series, 90% (128/142) of children were seroprotected and the GMT was 59.  While 
seroprotection rates were variable by age group, in all age groups at least 81% of children were 
seroprotected.  At 24 months after a booster dose, 100% (143/143) of children were 
seroprotected and the GMT was 350. 
 
The WG discussed these data from the pediatric studies.  The WG’s assessment and summary 
of the need for a booster dose in children was as follows.  There are limited safety and 
immunogenicity data on the need for a booster dose in children.  The available data suggest 
high seroprotection rates at 3 years following a 2-dose primary series.  The data have been 
submitted to FDA and are under review.  Following the WG’s review, two options were 
considered.  The first was an off-label recommendation for a booster dose while awaiting FDA 
review of data.  The second was no off-label recommendation, but incorporation of the data into 
an updated MMWR Recommendations and Reports document while awaiting FDA review of 
data.  The WG concluded that no off-label recommendation would be requested.  The plan is to 
incorporate the data into an updated MMWR Recommendations and Reports document to make 
the information available for providers, and to await FDA review of the data. 
 
To complete the ACIP JE Vaccine WG objectives, the following topics will be addressed during 






A presentation of updated post-licensure safety data 
A review of the epidemiology and risk of JE in travelers 
A review of the ACIP recommendations for use of JE vaccine in consideration of the 
updated safety, immunogenicity, and traveler data presented to ACIP during this and 
previous ACIP meetings 
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In conclusion, Dr. Hills noted that a new WG member and Chair will be identified to replace Dr. 







Ruth Karron, MD 
Chair, Influenza Work Group 
 
Dr. Karron reported that since the October 2015 ACIP meeting, the Influenza WG has 
considered recent data pertaining to duration of protection following vaccination, and discussion 
of recommendations regarding timing of vaccination; data pertaining to egg allergy and 
influenza vaccination, particularly use of live attenuated influenza vaccine (LAIV) for egg-allergic 
persons; and clinical data for quadrivalent recombinant influenza vaccine (RIV4).  She indicated 
that the topics for this session would focus on an influenza surveillance update, RIV4, influenza 
vaccination and egg allergy, and proposed recommendations for 2016-2017. 
 
Influenza Surveillance Update 
 
Lynnette Brammer, MPH 
National Center for Immunization and Respiratory Diseases 
Centers for Disease Control and Prevention 
 
Ms. Brammer presented an influenza surveillance update and interim estimates of 2015–2016 
seasonal influenza VE against medically-attended influenza from the US Flu VE Network.  In 
terms of the number and percent of specimens testing positive for influenza at approximately 
250 clinical laboratories across the country that report to CDC each week, the most recent week 
was Week 6 that ended on February 13, 2016.  At that time, 12% of specimens tested were 
positive for influenza.  The previous week, it was about 2.5%.  To put that into perspective, 
activity is still very low.  At the peak of influenza activity last year, 27% of clinical laboratory 
specimens tested positive for influenza.  To date for this season, 75% of the influenza tests at 
public health laboratories were influenza A viruses and 25% were influenza B viruses.  Among 
the influenza A viruses tested, 71.5% were A (H1N1)pdm09 viruses.  The remainder of the As 
were A (H3N2) viruses.  Among the influenza B viruses, 75% of those tested for lineage were in 
the B/Yamagata-lineage and the remaining 25% were in the B/Victoria-lineage. 
 
The public health laboratories sent a subset of the viruses they tested to CDC for further 
characterization.  Among those viruses, all 181 influenza A (H1N1)pdm09 viruses were 
antigenically characterized as A/California/7/2009-like contained in the current vaccine.  All 228 
H3N2 viruses genetically sequenced belonged to genetic groups for which a majority of the 
viruses antigenically characterized were similar to the cell-propagated A/Switzerland/ 
9715293/2013 contained in the current vaccine.  A subset of 107 H3N2 viruses were also 
antigenically characterized, and 100 (93.5%) were A/Switzerland/9715293/2013-like by HI 
testing or neutralization testing.  All 88 B/Yamagata-lineage viruses antigenically characterized 
were B/Phuket/3073/2013-like, which is included as an influenza B component of the 2015-2016 
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viruses antigenically characterized were B/Brisbane/60/2008-like, which is included as an 
influenza B component of the 2015-2016 Northern Hemisphere quadrivalent influenza vaccines. 
 
CDC receives reports of outpatient illness from approximately 2000 primary care sites across 
the country.  During Week 6, 3.1% of those visits were for influenza-like illness (ILI).  This year 
has been later with less activity than the previous two seasons, but not as mild as the 2011-
2012 influenza season.  Hospitalization data reported through FluServ-NET reflect a similar 
picture.  The current rate of hospitalizations is 4.1/100,000, which is much lower than observed 
during the previous three seasons and just slightly higher than the 2011-2012 influenza season.  
As would be expected given the low rate of hospitalizations and illness, influenza-associated 
pneumonia and influenza mortality reported to the National Center for Health Statistics (NCHS) 
has also been relatively low.  The percentage of deaths that had pneumonia or influenza listed 
anywhere on the death certificate that occurred as of the week ending January 30th was 6.5%, 
which is well below the epidemic threshold of 7.6%.  Influenza-associated deaths in children 
less than 18 years of age is a nationally notifiable condition.  Thus far this year, 13 influenza-
associated pediatric deaths have been reported to CDC. 
 
The following map shows the geographic distribution of influenza within states and territories, 




The map shows that influenza activity across the US has not been simultaneous this year.  
There has been more widespread activity in the Southwest and Northeast, and less activity in 
the center of the country thus far.  However, that is expected to progress in the coming weeks. 
 
Regarding next season, the WHO Consultation on the Composition on Influenza Virus Vaccines 
for the Northern Hemisphere 2016-2017 is being held February 22-24, 2016.  Announcement of 
their decision will be made on February 25, 2016.  FDA’s VRBPAC will meet on March 4, 2016 
to make recommendations on the selection of vaccine virus strains for the US vaccines. 
 
In summary, influenza activity to date is low compared to the previous three seasons.  The rate 
of influenza associated hospitalizations is low, and pneumonia and influenza mortality have not 
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viruses of both lineages have co-circulated.  The majority of circulating viruses are similar to the 
vaccine strains. 
 
Interim estimates of influenza vaccine effectiveness for this season were presented to ACIP, but 
have not been published.  These interim estimates included patients enrolled from November 2, 
2015 through February 12, 2016.  The methods are similar to previous years and have been 
described previously.  Methods used to produce these interim estimates were the same as 
those used for interim estimates in previous seasons.  Briefly, outpatients 6 months of age and 
older with acute respiratory illness and cough of 7 or fewer days duration were enrolled at five 
US Flu VE Network sites from November 2, 2015 through February 12, 2016.  A test-negative 
design was used to estimate vaccine effectiveness by comparing vaccination odds among 
influenza RT-PCR positive cases and RT-PCR negative controls.  Vaccination status was 
defined as “receipt of at least one dose of any 2015-16 seasonal influenza vaccine according to 
medical records, immunization registries, and/or self-report.”  Vaccine effectiveness is estimated 
as one minus the adjusted odds ratio times 100.  Variables included in the models for 
adjustment are study site, age, self-rated general health status, race/Hispanic ethnicity, interval 
(days) from onset to enrollment, and calendar time. 
 
From November 2, 2015 through February 12, 2016, a total of 3,333 outpatients were enrolled 
at the five network sites.   Of those, 92% (3,081) were RT-PCR negative for influenza and 8% 
(252) of enrolled patients were influenza-positive.  The contribution of each of the viruses 




Both influenza A and B viruses circulated, with a majority of influenza A viruses being 
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The following epi curve shows the number of enrolled participants with RT-PCR-confirmed 
influenza A or B by epidemiologic week of enrollment and the percent positivity for any influenza 
type by week.  Note that laboratory testing is incomplete for patients enrolled during the most 
recent week, but the percent positivity continues to increase.  Very few positive cases were 
enrolled before the first week of January, with a low percentage of those enrolled testing 




Interim adjusted estimates of VE against medically-attended influenza for all patients aged 6 
months and older was 59% with a 95% confidence interval from 44% to 70%.  Interim adjusted 
VE against H1N1pdm09 for all ages combined was 51%, with a 95% confidence interval from 
25% to 69%.  Adjusted estimates of VE against influenza B for all ages combined was 76%, 
with a confidence interval from 59% to 86% and was similar against B/Yamagata lineage 
viruses with an adjusted VE of 79%. 
 
In summary, interim results from the US Flu VE Network for the 2015-2016 season through 
February 12, 2016 indicate that VE was 59% against medically-attended influenza.  The interim 
estimate for this season is similar to previous seasons when vaccine was well-matched to 
circulating influenza viruses.  Significant protection against circulating influenza H1N1pdm09 
and B viruses was observed for all ages combined, while VE was not estimated against H3N2 
viruses due to the small number of cases.  The enrollment in VE studies for this year continues.  
Interim estimates may be less precise due to low numbers of flu cases enrolled, and the end-of-




Dr. Reingold asked whether there was any suggestion so far regarding whether the LAIV 
vaccine is performing any better this season. 
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Quadrivalent Recombinant Influenza Vaccine 
 
Wayne Hachey DO, MPH 
Protein Sciences 
 
Dr. Hachey reported on a recent study that demonstrated the improved efficacy of a 
recombinant influenza vaccine versus an inactivated vaccine during the influenza season 
marked by a vaccine mismatch.  The study was designed to demonstrate the clinical efficacy 
and safety of Flublok® Quadrivalent (RIV4) versus an inactivated quadrivalent vaccine (IIV4  
Fluarix® Quadrivalent). 
 
Flublok® is the first licensed recombinant hemagglutinin protein influenza vaccine.  Because it 
does not require passage in eggs and therefore does not require an egg-adapted strain, the HA 
for recombinant influenza vaccines matches the wild type of the FDA-specified strain.  The 
2014-2015 influenza season was particularly unpleasant for adults 65 years of age and older. 
This was primarily due to widespread circulation of an H3N2 strain that was not antigenically 
matched to the vaccine, with over 80% of the identified H3N2 strains representing this 
mismatch.  This mismatch lead to low vaccine effectiveness estimated at less than 20% overall, 
as well as high rates of laboratory-confirmed hospitalizations for pneumonia and influenza. 
During this good season, Protein Sciences conducted a double-blind RCT that compared 
Flublok® Quadrivalent (RIV4) versus a licensed quadrivalent inactivated vaccine (Fluarix®  
Quadrivalent). 
 
Flublok® quadrivalent attack rates were significantly lower than the IIV comparator at 2.2% 
versus 3.3%.  These lower attack rates persisted throughout the season.  Although viral cultures 
did not yield sufficient titers to test for antigenic similarity, the improved efficacy in the face of a 
mismatch is inferred from the fact that more than 80% of the circulating H3N2 viruses in that 
season were antigenically mismatched to the vaccines.  In regard to safety, AEs were similar for 
both vaccines, with the exception of a lower incidence of local reactions, specifically pain and 
tenderness at the injection site in the Flublok® Quadrivalent group.  
 
The study hypothesis was that the relative vaccine efficacy for Flublok® Quadrivalent would be 
non-inferior to that of IIV4 in adults 50 years of age and older.  Non-inferiority was specified by 
the lower bound of the 95% confidence interval for relative VE to be greater than -20%. 
Superiority determined in pre-specified exploratory analysis was determined by the threshold of 
the lower bound of the 95% confidence interval for relative VE at greater than 9%.  Sample size 
was powered for the primary endpoint as well as pre-specified secondary analysis of subgroups. 
Between October 22 and December 23, 2014 9003 subjects were vaccinated.  They were 
subsequently followed through May 22, 2015.  ILI symptomatic subjects had nasopharyngeal 
(NP) swabs for both PCR and culture.  The protocol-defined ILI required at least one respiratory 
symptom and at least one systemic symptom (temperature >99, chills, fatigue, headache or 
myalgia) occurring at least 14 days after vaccination.  The protocol definition was identical to 
that used for the High Dose IIV3 study in adults 65 years of age and older.  HAI serology was 
tested in 613 subjects, reactogenicity was monitored for 7 days post-vaccination, and safety 
monitoring continued for 6 months post-vaccination. 
 
The antigenic composition of Flublok® Quadrivalent was 45 mcg per antigen of H1N1: 
A/California/07/2009, H3N2: A/Texas/50/2012, B/Massachusetts/2/2012 (B/Yamagata-lineage), 
and B/Brisbane/60/2008 (B/Victoria-lineage).  The antigenic composition of IIV4 was 15 mcg 
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A/Texas/50/2012, B/Massachusetts/2/2012, and B/Brisbane/60/2008.  Both vaccines contained 
the HAs representing the strains selected by the WHO and VRBPAC for the 2014-2015 season.  
However, the Flublok® Quadrivalent contained a strain that was matched to the reference strain 
wild type. 
 
This map depicts the geographic distribution of enrollment and shows the wide distribution 




A total of 9003 participants were enrolled.  After exclusions, the RIV4 group was comprised of 
4303 (96.2%) in the efficacy population, 314 (7%) in the immunogenicity population, 4328 
(96.7%) in the safety population, and 4228 (94.5%) completing the study.  The IIV4 group began 
with 4489.  Of those, 4301 (95.8%) were in the efficacy population, 300 (6.7%) were in the 
immunogenicity population, 4344 (96.8%) were in the safety population, and 4236 (94.4%) 
completed the study.  Withdrawals were relatively rare and were evenly distributed between the 
two study populations. 
 
In terms of demographics, the study included adults 50 years of age or older.  Subjects were 
stratified to age categories of 50 through 64, 65 through 74, and 75 and older prior to being 
randomly assigned in a 1:1 ratio to receive a single dose of either vaccine.  Distribution was 
even in terms of gender race and ethnicity. 
 
Post-vaccination HAI antibody GMTs at Day 0 and Day 8 for A/H1 and B/ Massachusetts and 
B/Bisbane were comparable between the two vaccine groups, with the B/Brisbane titers being 
quite low for both vaccine groups.  HAI antibody GMTs were significantly higher for the H3 
component after vaccination with Flublok® RIV4 than with IIV4. 
 
For efficacy against rtPCR-confirmed protocol-defined ILI, 234 participants met the primary 
endpoint representing 96 or 2.2% of the RIV4 subjects and 138 or 3.2% of the IIV4 recipients. 
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IIV4.  B strains represented rather small number of individuals at 23 and 24 subjects, 
respectively.  Of the 102 individuals with culture-confirmed ILI, 38 were in the RIV4 group and 
64 were in the IIV4. 
 
The efficacy of RIV4 relative to the traditional IIV4 for the primary endpoint was 31% with a 
lower bound of the two-sided 95% confidence interval for relative vaccine efficacy of 10%, which 
satisfied the non-inferiority and superiority criteria.  As the predominant circulating strain was 
H3N2, a post-hoc analysis of VE against influenza A and B was conducted.  Relative VE of 
RIV4 versus IIV4 was 37% for type A and 17% for type B.  Efficacy against cell culture-
confirmed influenza was important to evaluate since this was a more rigorous assessment of the 
true cause of ILI.  Relative VE of RIV4 versus IIV4 was more pronounced at 43%.  Of note is the 
wide confidence intervals for the B stains due to the relatively small number of individuals. 
 
This Kaplan-Meier curve presents the cumulative incidence of RT-PRC confirmed influenza over 
the season and displays the relative efficacy of the two study vaccines for influenza types A and 






In a review of the primary and secondary endpoint analyses for PCR-confirmed protocol-defined 
ILI for all types of influenza, relative VE was about 31%.  For those 50 through 64 years of age, 
VE was 41%.  For those 65 years of age and older, VE was 0.17.  However, the more rigorous 
culture-confirmed protocol-defined ILI for those over 65 was 0.43 and remained significant.  Of 
note is the enhanced protective effect in individuals who have not received a prior influenza 
vaccine, although this cannot be explained thus far. 
 
Moving to safety, individuals were followed for 6 months post-immunization.  Medically-attended 
ILI included 19 individuals, 6 in the RIV4 group and 13 in the IIV4 group.  Hospitalizations were 
rare with a total of 4, 1 in the RIV4 group and 3 in the IIV4 group.  No SAEs or AEs were 
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vaccine group and included cough, ILI, oropharyngeal pain, headache, upper respiratory tract 
infection, fatigue, myalgia, and productive cough. 
 
In terms of reactogenicity, the study participants were particularly compliant with reporting 
whether they experienced specifically solicited reactions to the vaccine.  Memory aids that 
included both local and systemic reactions were returned by more than 96% of subjects in both 
treatment groups.  The only difference between the two vaccine groups were with respect to 
local injection site pain and tenderness that were reported significantly more frequently by the 
IIV4 recipients, and injection site erythema was more commonly reported by RIV4 recipients. 
 
In conclusion, Flublok® Quadrivalent met criterion for non-inferior efficacy against PCR-
confirmed ILI, as well as the pre-specified criterion for superior efficacy over IIV4.  Superiority 
possibly was driven by the efficacy against largely antigenically drifted influenza A.  This is 
inferred because more than 80% of the circulating H3N2 viruses in 2014-2015 were 
antigenically mismatched to the vaccines.  Efficacy against influenza B was similar to IIV4, 
which was observed with the trivalent vaccine.  HAI antibody responses after Flublok® were 
especially high for A/H3, which is also consistent with previous trivalent vaccine data.  Both 
vaccines had similar safety profiles.  Injection site pain and tenderness were significantly less 





Dr. Moore noted that in the study, vaccination occurred during the influenza season and the 
relatively early arriving influenza season.  She wondered if Dr. Hachey could address how the 
study design prevented any confounding due to prior influenza infection among those who were 
enrolled, or particularly geographic differences in influenza disease activity during the period of 
vaccination with IIV4 or RIV4. 
 
Dr. Hachey explained that the individuals were medically screened before entering the study, so 
anyone with any febrile or any illness at that time was excluded from enrollment.  If 
asymptomatic at the time of enrollment, it is possible that someone could have had influenza 
already prior to enrolling in the study. 
 
Dr. Belongia noted that there is not a clear understanding of the relative importance of egg-
induced mutations and how that might impact clinical effectiveness.  There was a unique 
opportunity in a season with a mismatch and a vaccine not based on an egg-adapted virus.  
There was some suggestion that even in a mismatch, virus circulating relative to the vaccine 
strain that egg-induced mutations perhaps might make an additional contribution.  He thought 
they had a gold mine of data in terms of evaluating the viruses from the H3N2 cases in the RIV4 
and IIV4 groups.  He thought it would be interesting to sequence those viruses to assess the HA 
and specifically evaluate the people who received RIV4 versus IIV 4 to see if there are different 
clades, and also to look at the people who received the prior vaccine and those who did not to 
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Dr. Ornstein (NVAC) said striking to him was the improved immunogenicity against the H3N2 
component with RIV4 versus IIV4.  He wondered whether they had been able to study any of 
the drifted strains and done any serology to determine whether there are differences in 
immunogenicity against the actual drifted strains that occurred during that season. 
 
Dr. Hachey responded that while they did not characterize the viruses, they do know that at 
least 80% of them were drifted.  In previous studies with trivalent vaccine, also during 
mismatched years, particularly with H3 strains, vaccines tended to do much better.  This was 
approximately 5 years ago. 
 
Dr. Orenstein (NVAC) said he thought it would be helpful to run HAI titers on those drifted 
strains to determine whether there were large differences there as well. 
 
Dr. Bresee (SME) asked whether a similar study was planned for next year and in future years 
to have more than a single year of data.  He agreed that characterizing these strains 
antigenically would be important to better understanding the data. 
 
Dr. Hachey replied that they would be willing to conduct more studies if they were funded to do 
so.  This study was part of the requirement imposed by FDA as part of the licensure process for 
individuals 50 years of age and above.  It just happened to occur during a mismatch year. 
 
Dr. Gemmill (NACI) asked whether it might be possible to expect or hope for a vaccine that 
offers broader coverage generally for more strains, or if they were just looking at a vaccine that 
helped to avoid eggs and offers more antigen in each dose.  He thought the ideal vaccine would 
be one that lasts a long time and has coverage of all of the strains that might be circulating. 
 
Dr. Hachey responded that everybody hopes for a universal vaccine.  Unfortunately, that has 
eluded everyone thus far.  One nice thing with recombinant technology is that a vaccine can be 
developed quickly in a matter of weeks that would represent a drifted strain.  At this point, they 
are limited to about 6 million doses of vaccine.  That is clearly not enough for the US population.  
For example, that particular year, they could have easily produced vaccine for the drifted strain.  
However, it would have been in limited amounts. 
 
Dr. Decker (Sanofi Pasteur) referred to a slide showing HAI immune response Days 0 and 28 
GMTs.  He did not understand why for three of the four strains included in the vaccine, the 
Flublok® antibody response was actually lower than the IIV response—not significantly, but 
numerically lower.  It was materially higher for H3N2, but not for any of the other strains.  He 
wondered if Dr. Hachey had any idea why that might be. 
 
Dr. Hachey responded that historically, Flublok® has been statistically comparable, but not any 
better, than the inactivated vaccine for B strains.  In prior studies, the serologies for the H1 
strains were better than the reference strains.  However, it is important to keep in mind that with 
this particular season, essentially all of the A strains were H3N2.  There were 6 non-typeable A 
strains.  Other than that, the H1N1 was grossly under-represented.  It may be a question of the 
number of samples. 
 
Dr. Decker (Sanofi Pasteur) noted that Flublok® was superior to IIV4 for those 50 through 64 
years of age, but not for those 65 years of age and older.  He wondered whether Dr. Hachey 
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Dr. Hachey responded that this was true for PCR-defined.  The culture-confirmed is a much 
more stringent test and showed a relative efficacy of 43%.  In an assessment of a subgroup of 
subjects 75 years of age or older, efficacy continues even with the PCR-confirmed. 
 
Dr. Decker (Sanofi Pasteur) noted that for all four strains, Flublok® includes 45 mcg of protein 
and Dr. Hachey referred to that as a high-dose vaccine. 
 
Dr. Hachey clarified that he called it a “higher than the standard dose vaccine.” 
 
Dr. Decker (Sanofi Pasteur) said he was not sure how dose was measured, but looking at 
immunogenicity, standard IIV egg-based has 15 mcg.  He wondered why it takes three times as 
much of the synthetic protein to get more or less the same response as with the egg-based 
protein. 
 
Dr. Hachey responded that the RIV4 does get a better response than the egg-based.  In the 
initial clinical trials with the trivalent vaccine, there were statistically superior responses to the 
H1 and H3 strains.  Particularly in the 65 years of age and older group, when Fluzone® standard 
dose is compared with Flublok®, the improvement in serology, particularly in the elderly 
population, is almost identical to the high-dose Fluzone® vaccine.  The two results are 
essentially the same. 
 
Dr. Decker (Sanofi Pasteur) said that he did not have those results in front of him and was 
looking at the results just presented. 
 
Influenza Vaccination and Egg Allergy  
 
John M. Kelso, MD 
Division of Allergy, Asthma and Immunology 
Scripps Clinic, San Diego and 
Clinical Professor of Pediatrics and Internal Medicine  
University of California San Diego School of Medicine 
 
Dr. Kelso presented information on the use of influenza vaccines in egg-allergic recipients, 
emphasizing that he has a particular interest in adverse reactions to vaccines.  During this 
session, he discussed the risk of withholding influenza vaccine and the safety of IIV in egg-
allergic recipients, current guidelines regarding IIV and LAIV in egg-allergic recipients, new 
studies on administration of LAIV to egg-allergic recipients, and his personal recommendations. 
 
Regarding the risk of withholding vaccine, an average of 294,128 persons are hospitalized each 
year in the US because of influenza, including an average of 21,156 hospitalizations in children 
less than 5 years of age.  An average of 23,607 deaths occur each year in the US as a result of 
influenza, including an average of 124 children.  Egg allergy is believed to affect 1.3 % of 
children and 0.2 % of adults1.  There are 73.7 million children in the US 2, meaning that there 
are approximately 1 million egg-allergic children [1The Center for Food Safety and Applied 
Nutrition Food and Drug Administration US Department of Health and Human Services; 
2www.childstats.gov/americaschildren]. 
 
Most influenza vaccines are still grown in eggs, literally, and contain measurable quantities of 
egg protein, typically measured as ovalbumin—the particularly allergenic egg protein that is in 
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someone who is allergic to egg protein.  In terms of whether giving influenza vaccine causes 
systemic reactions when injected into egg-allergic patients, 27 studies have now been published 
on this that have collectively involved over 4100 egg-allergic subjects receiving influenza 
vaccine without any serious reactions, including respiratory distress or hypotension.  There has 
been a very low rate of minor reactions (hives, mild wheezing), but this was exactly the same as 
in non-egg-allergic recipients [Des Roches A, et al. Egg-allergic patients can be safely 
vaccinated against influenza. J Allergy Clin Immunol 2012;130:1213-1216]. 
 
Thus, the occasional child who receives an influenza vaccine may have a couple of hives or 
may wheeze a little, but whether they are egg-allergic does not determine the rate of those 
reactions. 
 
Regarding the subset of children who have particularly severe egg allergy, most studies have 
specifically included patients with histories of severe anaphylaxis (n = 513) with egg ingestion, 
and these patients also tolerate the vaccine.  So, it appears that even severely egg-allergic 
patients can safely receive IIV.  
 
In terms of why no serious reactions are being reported, manufacturers of injectable IIV report 
that the maximum amount of ovalbumin is less than 1 µg per 0.5 mL dose.  The measured 
amounts in independent laboratories are usually much lower than the claimed amounts.  Thus, 
the vaccine does not appear to contain enough ovalbumin to cause a reaction. 
 
In terms of the current state of US allergy guidelines, allergy guidelines are typically published 
by the Joint Task Force on Practice Parameters.  The current US guidelines state the following 
[Annals of Allergy, Asthma & Immunology 2013; 111:301-2]: 
 
“All patients with egg allergy of any severity, including anaphylaxis, should receive IIV 
annually, using any age-approved brand of IIV in an age-appropriate dose.” 
 
“Special precautions regarding medical setting and waiting periods after administration 
of IIV to egg-allergic recipients beyond those recommended for any vaccine are not 
warranted.” 
 
“Language that describes egg-allergic recipients as being at increased risk compared 
with non-egg-allergic recipients or requiring special precautions should be removed from 
guidelines and product labeling." 
 
Dr. Kelso shared a draft document, the International Consensus (ICON) on Allergic Reactions to 
Vaccines,  for which he had been given permission to share excerpts from  current international 
allergy guidelines on allergic reactions to vaccines that includes the following allergy 
organizations:  World Allergy Organization (WAO); European Academy of Allergy and Clinical 
Immunology (EAACI); American Academy of Allergy, Asthma, and Immunology (AAAAI); and 
American College of Allergy, Asthma, and Immunology (ACAAI).  This document will state the 
following:  
 
“Egg allergy does not impart increased risk of anaphylactic reaction to immunization with 
either inactivated or live attenuated influenza vaccines” 
 
“Although cases of immediate hypersensitivity reactions such as urticaria may occur, 








In terms of vaccine guidelines, the current National Advisory Committee on Immunization 
(NACI) guideline states the following: 
 
“Regarding administration of influenza vaccine to egg allergic persons, after careful 
review, NACI has concluded that egg allergic individuals may be vaccinated against 
influenza using TIV without prior influenza vaccine skin test and with the full dose, 
irrespective of a past severe reaction to egg and without any particular consideration, 
including immunization setting.” 
 
These guidelines have been in place in Canada since 2014, and they have not observed any 
uptick in adverse reactions or safety signals in monitoring since putting these recommendations 
in place where they removed any precautions regarding administration of influenza vaccine to 
egg-allergic patients. 
 




This algorithm basically says that if someone can eat eggs and nothing happens, they are not 
allergic and can get an influenza vaccine.  If someone eats eggs and just gets hives, they can 
get an influenza vaccine, but it has to be administered in a physician’s office and they have to 
be monitored for 30 minutes following vaccine.  Alternatively, such patients can receive the 
recombinant vaccine that does not contain egg protein.  The algorithm goes on to say that those 
who have had a more severe reaction to the ingestion of eggs, should go to an allergist’s office 





Advisory Committee on Immunization Practices (ACIP)                                               Summary Report                                             February 24, 2016 
 
 
The ACIP guidelines go on to pay particular attention to LAIV to state that, “ACIP will continue to 
review safety data for use of LAIV in the setting of egg allergy.”  There are several studies 
pertaining to this issue.  The first of these included 68 children 2 through 16 years of age with 
egg allergy defined as a history of having not only  an allergic reaction to the ingestion of eggs, 
but also the presence of IgE allergic antibody to eggs.  Importantly, 40% of children were 
laboratory and clinically allergic to egg and had a history of anaphylactic reaction to egg.  In 
addition, 55 children without egg allergy were included in this study.  Participants were 
administered LAIV FluMist® in the usual manner, which contains less than 0.24 µg of ovalbumin 
per dose, and were observed for 1 hour.  No patients developed an allergic sign or symptom 
during the hour of observation.  These authors concluded that, “LAIV is a safe alternative to TIV 
in children with known egg allergy. It was not surprising that there were no immediate IgE-
mediated reactions after vaccination of the children with egg allergy because the quantity of 
ovalbumin in LAIV is comparable with that of TIV, which has previously been shown to be safe 
in patients with egg allergy” [Safe vaccination of patients with egg allergy by using live 
attenuated influenza vaccine; Des Roches A, Samaan K, Graham F, Lacombe-Barrios J, 
Paradis J, Paradis L, et al. J Allergy Clin Immunol Pract 2015; 3:138-9]. 
 
The next study included a larger number of chilren—this time 282 children 2 through 17 years of 
age with egg allergy.  The reason that most of these studies include children is because egg 
allergy is much more common in children.  Egg allergy in this study is defined either as:  1) 
positive food challenge result to egg within the last 12 months under medical supervision; 2) 
previous convincing clinical reaction within 12 months and current sensitization (skin test or 
specific IgE); or 3) current sensitization with a greater than 95% likelihood of clinical reaction 
even if they had never eaten egg.  Of the participants, 115/282 (41%) had prior anaphylaxis.  
Participants were administered LAIV FluMist® containing less than 0.24 µg of ovalbumin per 
dose in the usual manner, and were observed for 1 hour.  In this case, 151/282 received a 
second dose 4 weeks later for a total of 433 doses given.  No anaphylaxis occurred.  Possible 
allergic reactions occurred in 8/282 (2.8%) within one hour of vaccine receipt.  These included 6 
rhinitis, 1 localized urticaria, and 1 gastrointestinal discomfort.  All of these reactions were mild 
and self-limiting.  The authors concluded that, “These data have demonstrated a safety profile in 
terms of systemic allergic reactions to LAIV in children with egg allergy, including those with a 
prior history of anaphylaxis, similar to that previously reported for children without egg allergy” 
[Safety of live attenuated influenza vaccine in atopic children with egg allergy; Turner PJ, 
Southern J, Andrews NJ, Miller E, Erlewyn-Lajeunesse M, Doyle C, et al; J Allergy Clin 
Immunol; 2015; 136:376-81]. 
 
Finally, the largest of these studies included 779 children 2 through 18 years of age with a 
current doctor diagnosis of egg allergy.  Of these children, 270 (34.7%) had a history of 
anaphylaxis to egg.  Participants were administered LAIV in the usual manner and were 
observed for 30 minutes.  No systemic allergic reactions occurred.  Possible allergic reactions 
occurred in 9/779 (1.2%) within 30 minutes. These included 4 rhinitis, 4 localized/contact 
urticaria, and 1 oropharyngeal itch.  Again, all were mild and self-limiting.  The authors 
concluded that, “Children with an egg allergy can be safely vaccinated with LAIV in any setting” 
[Turner PJ, Southern J, Andrews NJ, Miller E, Erlewyn-Lajeunesse M. ; BMJ 2015;351:h6291; 
BMJ 2015;351:h6291]. 
 
Collectively, of the three studies just covered, published reports now describe 1129 children with 
confirmed egg allergy, including 412 with a history of anaphylaxis to egg ingestion, who have 
been given LAIV without any immediate systemic reactions.  As with the data on the IIV, the 








To put this in perspective, in the allergy world where the ingestion of allergenic foods and the 
likelihood of causing a reaction are contemplated, the lowest observed-adverse effect level 
(LOAEL) is taken into consideration.  The LOAEL is the lowest amount of the offending food that 
would elicit mild, objective symptoms (e.g., mild urticaria, erythema, and oral angioedema) in 
the most sensitive individuals.  It has been determined that 0.35% of patients allergic to egg 
may react to 130 µg of egg-white proteins.  This is more than 100-fold more than the amount in 
influenza vaccine.  Injecting and ingesting vaccine are different, but to put this in to perspective, 
it would take a lot more ovalbumin by ingestion to provoke symptoms, even in the most 
exquisitely allergic patients [Taylor SL, et al. Factors affecting the determination of threshold 
doses for allergenic foods: how much is too much? J Allergy Clin Immunol 2002;109:24-30]. 
 
On the other end of the spectrum is allergic reactions after egg-free recombinant influenza 
vaccine reported to VAERS.  A report was published last year of 12 patients who described 
signs and symptoms that were consistent with acute hypersensitivity reactions after 
administration of RIV3, which cannot possibly contain any ovalbumin.  The cases were all 
considered to be possible anaphylaxis.  Just like all other vaccines, about 1 per million cases of 
anaphylaxis occur after influenza vaccine regardless of whether the recipient is egg-allergic or 
whether the vaccine contains egg.  A patient with a history of a prior allergic reaction to 
influenza vaccination, not egg, should be evaluated prior to subsequent vaccinations [Allergic 
reactions after egg-free recombinant influenza vaccine: reports to the US Vaccine Adverse 
Event Reporting System; Woo EJ; Clin Infect Dis 2015;60:777-780]. 
 
In terms of what precautions are advised to mitigate the risk of anaphylaxis with any vaccine, 
ACIP’s General Recommendations currently state as they always have that: 
 
“Although anaphylactic reactions are rare after vaccination, their immediate onset and 
life-threatening nature require that all personnel and facilities providing vaccinations 
have procedures in place for anaphylaxis management.  All vaccination providers should 
be familiar with the office emergency plan and be currently certified in cardiopulmonary 
resuscitation.  Epinephrine and equipment for maintaining an airway should be available 
for immediate use.” 
 
These recommendations are not peculiar to influenza vaccines or egg allergies.  These are 
recommendations that have always been made for any vaccine. 
 
Turning to his more personal thoughts, Dr. Kelso said that he wondered whether the algorithm is 
needed.  It implies that egg allergy increases the risk for an anaphylactic reaction after influenza 
immunization, but an extensive body of data says this is not the case.  It implies that children 
with severe reactions to egg ingestion are at increased risk for reactions, but hundreds of such 
children have been vaccinated uneventfully.  It implies that RIV is safer than IIV or LAIV for egg-
allergic recipients, but all vaccines rarely cause anaphylaxis.  It is inconsistent with US and 
international allergy guidelines.  It is inconsistent with Canadian vaccine guidelines.  It is an 
unnecessary barrier to immunization.  Egg-allergic children and some adults are going 
unimmunized because practitioners do not want to take the risk.  Many hospitalizations and 
some deaths occur among the unimmunized.  With that in mind, Dr. Kelso indicated that his 









1. No restriction on the use of the LAIV in egg-allergic recipients (i.e., treat LAIV like IIV); 
2. No special precautions for the administration of any influenza vaccine (IIV or LAIV) to 
any egg-allergic recipient (i.e., no special medical setting or waiting period beyond those 
recommended for any vaccine recipient); and 




Dr. Karron clarified what is done with a child who has a history of anaphylaxis to egg.  The 
guidance does not recommend sending that child to an allergist.  Instead, it says that such a 
child should be vaccinated by someone who is comfortable dealing with anaphylaxis.  The 
argument can be made that anyone who offers vaccines anywhere, anytime should be prepared 
to deal with anaphylaxis.  She said she thought that if the algorithm set up a barrier at all, it set 
up a barrier for those highly allergic children who have had an anaphylactic event.  She would 
hope that those children are under an allergist’s care.  Whether they need to receive their 
vaccines under that supervision is a different issue.  For the average child who has had a mild 
event, the guidance is to go ahead and vaccinate. 
 
Dr. Kelso agreed that the guidance states that a physician with experience in treating severe 
allergic reactions, which he thought most people would translate to mean allergist.  If in fact it 
does not mean anything beyond the expertise that any vaccine provider can offer, he would 
argue that it can be covered by the General Recommendations rather than a special box. 
 
Dr. Kempe asked how many of these studies assessed younger children, and how much 
experience there is in Canada with repetitive immunization in children with anaphylaxis. 
 
Dr. Kelso responded that most of these studies went down to age 2.  Some of the 27 studies on 
injectable vaccines included infants.  Because many of the studies included children, they also 
included children who needed a booster dose a month later.  So, in many of the injectable 
vaccine studies and at least one of the LAIV studies, the investigators specifically assessed 
booster doses given at least a month later and did not observe a risk with that. 
 
Proposed Recommendations for 2016-2017 
 
Lisa Grohskopf, MD 
Influenza Division 
National Center for Immunization and Respiratory Diseases 
Centers for Disease Control and Prevention 
 
Dr. Grohskopf reiterated the core influenza recommendation, with no changes proposed by the 
WG: 
 
Annual influenza vaccination is recommended for all persons of persons 6 months of 
age and older. 
 
 
A licensed, age-appropriate influenza vaccine should be used 
Recommendations for different vaccine types and specific populations discussed 
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In the past four months, the WG has discussed timing of vaccination and decided that the 
available data did not indicate that the language should be changed substantially.  The previous 
language in 2015-2016 read:  
 
Optimally, vaccination should occur before onset of influenza activity in the community. 
Healthcare providers should offer vaccination by October, if possible. Vaccination should 
continue to be offered as long as influenza viruses are circulating. Children aged 6 
months through 8 years who require 2 doses (see "Vaccine Dose Considerations for 
Children Aged 6 Months through 8 Years") should receive their first dose as soon as 
possible after vaccine becomes available, and the second dose ≥4 weeks later.  
 
The statement that “Healthcare providers should offer vaccination by October, if possible. 
Vaccination should continue to be offered as long as influenza viruses are circulating” was 
clarified in the proposed 2016-2017 language as follows: 
 
Optimally, vaccination should occur before onset of influenza activity in the community. 
Healthcare providers should offer vaccination by the end of October, if possible. Children 
aged 6 months through 8 years who require 2 doses (see "Vaccine Dose Considerations 
for Children Aged 6 Months through 8 Years") should receive their first dose as soon as 
possible after vaccine becomes available, and the second dose ≥4 weeks later. 
Vaccination should continue to be offered as long as influenza viruses are circulating 
and unexpired vaccine is available. 
 
Some WG members were concerned that people would interpret “by October” to mean August 
or September while the spirit of the recommendation was October.  The other change shown in 
red is a minor modification to the duration of the time during which vaccination should be 
offered. 
 
With regard to egg allergies, the 2015-2016 recommendations takes a stratified approach based 







Hives only to eggs = mild allergy  
Any other symptoms = severe allergy 
LAIV is not recommended for egg allergy 
Until recently, there have been limited specific data on LAIV in this population 
A 30-minute post-vaccination period has been recommended since 2012 to 
observe for signs of allergic reaction, based largely on other allergy literature 
rather than post-vaccination AEs 
 
In terms of the discussion within the WG over the course of several calls to explain the 
proposed language and the published data, including data discussed by Dr. Kelso earlier in the 
session, and potential language discussed in the Influenza WG and with investigators of the 
Clinical Immunization Safety Assessment (CISA) project.  Major considerations included the 
overall rarity of anaphylaxis following vaccination in general, and because it is a rarity, events 
may be missed in small studies.  For example, a paper by McNeil (2015) which describes VSD 
results noted 33 anaphylaxis cases after 25,173,965 doses of all vaccines combined for a rate 
of about 1.31 (95% CI 0.90-1.84) per million doses.  In this paper, 10 anaphylaxis cases 
occurred after IIV3 was administered alone.  With over 7,434,628 doses, the rate was 1.83 
(95% CI 0.22-6.63) per million doses.  That speaks to the relative rarity of these events in 
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Some members thought it resulted in a false sense of security as severe reactions can occur 
after 30 minutes.  In the same study by McNeil, the onset of symptoms was within 30 minutes in 
only 8 of 33 cases [McNeil MM et al, J Allergy Clin Immunol 2015].  Also discussed was the fact 
that since the recommendations were changed for the 2011-2012 season, there continue to be 
occasional VAERS reports of anaphylaxis following influenza vaccination of egg-allergic 
individuals.  In not all cases is it known that this was due to egg, and it is probably not always 
possible to know that for certain.  A stepwise approach such as has been taken in the past 
permits assessment of additional reports over seasons subsequent to change in 
recommendations.  Similar to last time the WG discussed changing the recommendations, the 
discussion for those who are most severely allergic, the understanding was that these events 
are very rare and are probably not terribly likely.  However, in the event that something 
happens, the feeling was that those with more severe allergy perhaps should be in a medical 
setting.  This is the reason for the proposed recommendations. 
 
In terms of the proposed recommendations for 2016-2017, the WG agreed that LAIV appears to 
be a low risk similar to that of inactivated vaccine and based on the data probably should not be 




A number of WG members wanted to call attention to the fact that the 15-minute waiting period 
recommended for all persons still applies, particularly adolescents, in case syncope occurs.  
This is pointed out in the current draft of the egg allergy language and would be pointed out in 
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In terms of the language that would accompany the algorithm, the first two points would not 
change from the previous recommendations 
 
1. Regardless of a recipient’s allergy history, all vaccines should be administered in 
settings in which personnel and equipment for rapid recognition and treatment of 
anaphylaxis are available. 
 
2. A previous severe allergic reaction to influenza vaccine, regardless of the component 
suspected of being responsible for the reaction, is a contraindication to future receipt of 
the vaccine. 
 
3. Persons with a history of egg allergy who have experienced only hives after exposure to 
egg should receive influenza vaccine. Any licensed influenza vaccine (i.e., any form of 
IIV, LAIV, or RIV) that is otherwise appropriate for the recipient’s age and health status 
may be used. 
 
4. Persons who report having had reactions to egg involving symptoms other than hives, 
such as angioedema, respiratory distress, lightheadedness, or recurrent emesis; or who 
required epinephrine or another emergency medical intervention, may similarly receive 
any licensed influenza vaccine (i.e., any form of IIV, LAIV, or RIV) that is otherwise 
appropriate for age and medical conditions.  The selected vaccine should be 
administered in a medical setting in which a healthcare provider with experience in the 
recognition and management of severe allergic conditions is immediately available.  
 
5. A 30 minute post-vaccination observation period, previously recommended following 
vaccination of egg-allergic recipients, is no longer recommended. However, regardless 
of allergy history, vaccine providers should consider observing all patients, particularly 
adolescents, with patients seated or lying down for 15 minutes after vaccination to 
decrease the risk for injury should syncope occur (24). 
 
6. For persons with no known history of exposure to egg, but who are suspected of being 
egg-allergic on the basis of previously performed allergy testing, the recommendations in 
3) immediately above may be followed.  
 
Items 3, 4, and 5 reflect the changed language in the algorithm.  With regard to retention of the 
algorithm, it has been found in the past that generally people seem to want one.  It is possible to 
represent these recommendations wholly in text, but the reaction that tends to occur when 
discussing not having an algorithm for this and the 1- versus 2-dose question for young children 
has typically been that people like to have the algorithm to place in the ED or wherever else a 




Dr. Moore said she was struggling with the idea of what the endpoint would be at which one 
would determine that an algorithm is no longer necessary.  A number of studies have been 
presented with evidence of absence of an issue.  VAERS is great for hypothesis generation, but 
does not suggest anything causal as is well-known from all sorts of things that can be reported 
to VAERS.  She wondered at what point they decide there is enough evidence of absence of a 
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Programmatically, the algorithm results in many people not getting vaccinated either because 
they are afraid of getting vaccinated because they have an egg allergy and they have heard that 
it is dangerous to get the influenza vaccine, or mass clinics, pharmacies, and school-located 
clinics have to spend a tremendous amount of time evaluating for this and then determining 
what to do.  Many of them simply do not do that and decide that if there is an egg allergy 
question, they will skip it.  This becomes quite a barrier to access for those folks. 
 
Dr. Grohskopf replied that if a recommendation treated everyone the same way, an algorithm is 
probably not needed.  In terms of getting to that step, the issue is that while there are data, the 
studies are relatively small and this is already known to be a rare event.  While VAERS has 
obvious limitations, there has been a small number of cases in several seasons since the 
recommendations were originally changed in 2011-2012.  Not enough to consider changing the 
recommendations back, but some of those cases have been discussed and it could never be 
determined with certainty whether those cases had more of a likelihood to do with egg than not.  
The general philosophy of the approach since 2011-2012 has been a season of data is 
reviewed, and perhaps a change is made.  These particular recommendations, at least as they 
are presented at this point, there is no longer a waiting period which is an important barrier in a 
lot of clinical settings.  Also, it still means that everybody can be vaccinated and not even an 
allergy-experienced person would be required to be there. 
 
Dr. Kempe pointed out that this is basically a power issue and the confidence intervals are 
needed around the estimates.  To her knowledge, nobody has assembled these data in a 
systematic review.  That is why she was asking about the Canadian experience and whether 
there is anything where this has been done routinely that could help ACIP with larger numbers. 
 
Dr. Gemmill (NACI) indicated that the work was done primarily in the province of Quebec, by Dr. 
De Serres who presented earlier on meningococcal B, in conjunction with the Quebec 
Association of Allergists.  He said they feel very confident that they made the right decision so 
far.  While the trickle down has not happened completely yet because it takes a while for 
practice to change once a recommendation has been made, there have been absolutely no 
signals.  They have been in touch with their safety representatives to confirm that point.  
Perhaps more details can be provided in writing at a later time. 
 
Dr. Byington (AAP) noted that the language regarding physician versus other providers may be 
very limiting in some cases if nurse practitioners, physicians assistants, et cetera are 
administering the vaccine.  She wondered if provider could be substituted or physician was 
required. 
 
Dr. Grohskopf responded that the WG discussed this at length and the final thinking was to 
include the word physician. 
 
Dr. Karron added that there was a diversity of opinions among the WG members. 
 
Regarding the power issue raised by Dr. Kempe, Ms. Pellegrini said that if they are looking for 
reactions that are literally 1 in a million, it seemed to her that there is simply no way to conduct a 
study that is going to turn those up in a methodical way.  Furthermore, there is no way to write 
an algorithm that is going to effectively screen for a 1 in a million event.  Therefore, it was not 
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Dr. Kempe said she did not think they were looking for 1 in a million.  If they had the numbers 
from Canada, an assessment could be done over a reasonable period what the point estimate 
could be with that number of people, and then make a more rational decision. 
 
Dr. Grohskopf noted that something raised in the past when recommendations are changed, 
prior to changing there may be less use of something because it was not recommended to use 
it.  This was brought up when it was recommended to start using the inactivated vaccine.  Might 
more cases be seen in VAERS once it is recommended that it is okay to give the vaccine.  One 
point that was raised was that LAIV is currently not recommended, so there may be more use 
and more reports in VAERS as a result. 
 
It sounded to Dr. Messonnier that there may be more data that might be helpful to the ACIP 
members in thinking this through.  The WG seemed to be suggesting a stepwise approach, 
gather additional data, and then reassess.  There are other data that could be assembled, such 
as missed opportunities, to give the members some kind of confidence intervals.  Because the 
data were not available during this meeting, the group could opt to table the recommendation 
until the next meeting when those data could be provided.  Alternatively, they could take the 
incremental steps at some level that the WG was recommending, and hear further data at the 
next meeting or the meeting after that.  Or, they could go all the way during this meeting. 
 
Dr. Karron said that if they kept some type of algorithm, she would suggest removing the 
language “if a vaccine other than RIV is used” for two reasons:  1) RIV is not used in children, 
and 2) anaphylaxis can occur with RIV. 
 
Dr. Kimberlin (AAP) said he was reading Item 4 on slide 9 as meaning that people with 
reactions to egg involving angioedema and so forth may receive the vaccine, and he would 
consider someone needing epinephrine or another emergency medical intervention to be pretty 
severe.  Item 2 states “A previous severe allergic reaction to influenza vaccine, regardless of the 
component suspected” which might mean egg allergy or egg protein is a contraindication to 
receive the vaccine in the future.  This seemed like a discrepancy to him. 
 
Dr. Grohskopf clarified that Item 4 reflects symptoms following exposure to egg, while Item 2 
reflects symptoms following exposure to vaccine.  Regardless of allergy history, having a 
previous severe reaction to a vaccine is a contraindication for further receipt of that vaccine.  
This point does not refer specifically to egg, but has been in the recommendations since 2011-
2012 because it was felt important to remind people of that.  There was a specific request to 
insert that.  Contextually, since most of the section talks about egg allergy, it probably does not 
fit as well. 
 
Due to a time constraint pertaining to the Zika Virus session, Dr. Bennett suspended the 









Upon returning to the influenza discussion, Dr. Bennett reported that in speaking with the WG, 
putting the vote off until June would not be suitable due to the MMWR publication timeline.  
Moreover, it is unlikely that any additional information would be available by June.  As a result, 
she asked whether anyone had a motion regarding the 2016-2017 recommendations. 
 
Dr. Karron indicated that during the break, she caucused among the other ACIP Influenza WG 
members and the WG wished to propose the following changes based upon the earlier 
discussion: 
 
1) Remove the algorithm figure entirely 
2) Retain Items 1, 2, and 3 because they are just making general statements that are not 
controversial and merely reiterate what ACIP has said often 
3) Retain Item 4, but strike the phrase “if a vaccine other than RIV is used,” state “The 
selected vaccine should be administered in a medical setting in which a healthcare 
provider with experience in the recognition and management of severe allergic 
conditions is immediately available,” and change physician to healthcare practitioner  
4) Eliminate Item 5 in its entirety, because observation of people following influenza 
vaccine should not differ from the General Recommendations and is redundant here 
5) Eliminate Item 6 because this was added due to one famous case in the CISA literature 
in a child who was not suspected of being egg-allergic; that child had anaphylaxis and 
then was discovered upon skin testing to be egg-allergic and it was hypothesized that 
the vaccination sensitized the child, so that child would not have been discovered 
following this recommendation 
 
Dr. Baker said that as a pediatrician, but not representing the AAP, she thought the suggested 
changes were perfect and that it should be kept simple.  While it would be nice to have more 
data in the future, the data presented during this session were enough at this point. 
 
Dr. Weber (SHEA) noted that if RIV is allowed, it could be given by anyone.  If there is a 
requirement that a trained physician must be present to deal with anaphylaxis, that may mean 
someone who is approved to intubate a patient, which means it is going to be limited to ED and 
the intensive care unit (ICU) physicians.  It would eliminate all family practice physicians, 
nurses, and clinics in his facility who are not licensed for intubation. 
 
Dr. Bennett clarified that the recommendation was to change physician to healthcare provider. 
 
Dr. Moore thought the changes were wonderful and would make implementation much easier 
programmatically.  In terms of the statement regarding administration in a setting where people 
can handle anaphylaxis, in general anyone who gives an immunization should be capable of 
responding and reacting to someone who has signs of anaphylaxis because any vaccine can 
cause that.  She wondered whether something specific should be called out here, similar to Item 
6 which is already in the General Recommendations making it redundant to say it again here.  
Perhaps it would not be necessary to restate the provision here, because any vaccine can 
cause anaphylaxis. 
 
Dr. Karron pointed out that this would be a major change to the existing language, and this 
would provide a way to do it in a stepwise manner.  It may be that over time, there are no 
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Dr. Moore clarified that, for example, a pharmacy that is equipped to respond to someone who 
has anaphylaxis after administration of a drug should not be administering to this person.  She 
was concerned about how to translate that to people who want to know where someone should 
go. 
 
It was noted that the intent of the discussion in the WG was that it be in a healthcare setting 
where there is someone who can manage it, not in a local drug store. 
 
In particularly, Dr. Karron noted that the WG talked about the fact that they did not necessarily 
want children with a previous history of anaphylactic responses to be vaccinated in the school 
setting. 
 
Dr. Ezeanolue suggested saying “go to a healthcare setting.”  This was not clear to him based 
on the language. 
 
Dr. Moore suggested clarifying the language by stating “inpatient or outpatient medical setting.” 
 
Dr. Harriman thought Item 1 addressed emergency management and that it did not need to be 
in both places. 
 
It was noted that perhaps some language could be borrowed from the General 
Recommendations to be put in that area. 
 
Dr. Grohskopf replied that they plan to add the list from the General Recommendations once 
that is further along. 
 
Dr. Kempe thought it would be hard for doctors to understand this change without any 
explanation.  She wondered if they should state “based on more recent data” to set the ground 
work for a change that is based on something. 
 
Dr. Bennett thought that was a good suggestion, but pointed out that the group did not have to 
vote on that specifically.  It could be part of the narrative. 
 
Dr. Grohskopf noted that that is a substantial part of the narrative before these bullets. 
 
Dr. Savoy (AADP) asked if they were suggesting that the local CVS that has an office where 
there is a nurse practitioner who potentially has the equipment needed could or could not give a 
vaccine to an egg-allergic child.  It sounded like some people were saying “yes” and the WG 
was saying “no.” 
 
Dr. Foster (APhA) assumed “equipment” was referring to epinephrine, which is what most 
guidelines require.  Perhaps the wording would be better if the word drugs was used rather than 
equipment.  Most places do not have equipment, but pharmacists are trained to handle these 
types of reactions as part of the pharmacist training program.  He did not think that would 
exclude people from getting vaccines in pharmacies. 
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Dr. Karron clarified that the intent of the WG was that for those children who had a previous 
episode of anaphylaxis, that perhaps more of a medical environment would be appropriate.  She 
wondered whether they were struggling over a problem that was truly a problem in the sense 
that a child who has had an anaphylactic response is not a child that is likely to be vaccinated in 
a pharmacy or a school setting.  They would be more likely to be vaccinated in a healthcare 
setting. 
 
Dr. Belongia wondered whether it would help to say clinical practice setting instead of medical 
setting to be clearer. 
 
Dr. Savoy (AAFP) did not understand why a patient would think that a pharmacy-based or 
school-based clinic is not a healthcare, medical care, or provider-based setting.  Aside from it 
not being inpatient, which is fairly obvious, it was not apparent how any of the words being 
suggested would clarify that. 
 
Dr. Kempe thought this was a scope of practice issue.  A well-equipped pharmacy clinic with a 
nurse practitioner who has handled anaphylaxis, that is probably within her scope of practice.  
She was not sure they could be more specific about the scope of practice for a provider in a 
given setting. 
 
Dr. Bennett asked whether there was language in the General Recommendations that they 
could duplicate and place into this recommendation, or if they could refer back to the General 
Recommendations. 
 
Dr. Messonnier thought that the problem was that this language was very similar to Item 1.  It 
seemed that they were trying to say that additional precautions should be taken with these 
children with a history of anaphylaxis.  One way to fix that might be instead of putting it here, to 
put the language with Item 1.  The issue is not specific to this.  Item 1 says everyone should get 
a vaccine in a place where they could have recognition and treatment of anaphylaxis.  A 
sentence could be added there to say, “Patients with a history of anaphylaxis should take 
special care to make sure that this is available.”  That would be a more general statement than 
trying to attach it to an influenza vaccine. 
 
An inquiry was posed regarding whether that would also remove the stratification.  Dr. 
Messonnier clarified that she was not suggesting removing the stratification.  She was just 
noting that there were two sentences, both of which recommended the setting in which vaccine 
should be given.  It might make more sense to combine them, because they were trying to make 
the contrast between Item 1 and Item 4 in which they were trying to say that this should be a 
more stepped up setting. 
 
Dr. Rubin asked for clarification regarding whether Dr. Messonnier was suggesting that they 
move the language in Item 4 and make it part of Item 1. 
 
Dr. Messonnier said she felt that the WG was trying to contrast that in general, everybody 
should get a vaccine in a certain setting but that patients with a history of anaphylaxis to egg 
should have more precautions.  She thought the language would work better if it was included in 
Item 1. 
 
Dr. Karron amended her motion to move the language under Item 4 to become paragraph 2 in 








Dr. Bennett clarified that there would still be 4 bullets, as only part of Item 4 would be moved. 
 
Dr. Messonnier thought they were trying to achieve parallelism between a setting for everybody 
and setting for people with a history of egg allergies. 
 
Dr. Belongia thought there appeared to be a contradiction.  The last part of Item 4 seemed to 
imply that that was the situation for people who have reported having had bad reactions to eggs 
in the past.  They can get any vaccine, but those people should receive vaccines in that setting.  
However, Item 1 says that everybody should receive a vaccine in that setting.  That was 
discordant. 
 
Dr. Bennett thought that if they could craft it in Item 1 it might be easier than trying to have it in 
two different places and be slightly different. 
 
To clarify, Dr. Cohn suggested moving the paragraph in Item 4 that read, “The selected vaccine 
should be administered in a medical setting in which a healthcare provider with experience in 
the recognition and management of severe allergic conditions is immediately available” and 
move it to Item 1, but tailor/finalize the language slightly to reflect that same message in Item 1 
after the vote and send it around to everyone for approval before it is published. 
 
Dr. Grohskopf said she was somewhat confused, because if they moved the last sentence from 
Item 4 and placed it in Item 1, there would be no difference specified between the two classes of 
individuals.  Basically, 3 and 4 would be the same after that. 
 
Dr. Karron agreed, noting that there were some general statements in the bullets that apply to 
everybody.  Everybody should receive vaccines in settings where appropriate expertise is 
available.  Anyone who has a reaction to influenza vaccine should not get it again.  Then there 
are two categories of people:  A, people who have had mild reactions (Item 3) and Category B, 
people who have had more severe reactions (Item 4).  She thought to move information from 
Item 4 would not follow that logical flow. 
 
Dr. Messonnier thought where people were getting stuck was understanding the categories, but 
not understanding what they were trying to convey would be different about people in Item 4.  
Pharmacists might say that now there are clinics where there are providers with experience in 
recognition and management of severe allergic reactions.  Therefore, if someone has had a 
severe allergy, she wondered what they were suggesting they do. 
 
Dr. Karron clarified that Item 1 said “in a setting where” and Item 4 said “medical setting,” which 
was the WG’s attempt to say that this should be a clinical setting. 
 
Dr. Bennett asked whether it would be possible in Item 1 to delineate these specific groups just 
outlined clearly and directly. 
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Dr. Rubin pulled up a document from the AAP from Pediatrics 2007 titled “Preparations for 
Emergencies in the Offices of Pediatricians and Primary Care Providers.”  In part, the paper 
stratifies how close an office is to a hospital (within 10 minutes, longer than 10 minutes).  That 
stratification results in the type of equipment / expertise that is appropriate for the office, 
including airway management.  He thought they were talking about the same thing.  Airway 
management equipment was not as likely to be available in a pharmacy.  That might change 
with more data. 
 
Dr. Kempe thought they were getting two things confused.  Item 1 pertained to generally being 
ready for anaphylaxis.  This is about a belief on many people’s part in the past, which was 
probably false, that egg allergies specifically cause anaphylaxis with influenza vaccine.  This is 
about people who have already had a severe allergic reaction.  If they were known to have a 
reaction to influenza vaccine, it wouldn’t be given to them again.  They were trying to uncouple 
the egg allergy issue from the influenza issue, and she thought it needed to be more explicit.  
Item 4 was not the same as Item 1. 
 
Dr. Rubin was not clear that they were ready to make that step.  If they were, the document 
would become a lot simpler. 
 
Dr. Fryhofer (AMA/ACP) indicated that she was part of the WG and this was a long discussion 
during the WG meeting.  Part of the reason they left physician was because that changed the 
context of the type of medical setting.  The way the conversation was going, they might as well 
for Item 3 say “children with an egg allergy of any severity can get any of the vaccines.”  
However, she did not think that was the WG’s intent. 
 
Dr. Riley’s understanding was exactly what Dr. Rubin said, which was that they were not ready 
to jump all the way to “don’t worry about it.”  However, she thought she was hearing that the 
concern was that someone might still have anaphylaxis, so what they really wanted was 
availability of airway management.  Why not just put that in?  She would not try to lump that 
together with Item 1, because it would be confusing.  The progression was general, mild allergy, 
then severe allergy. 
 
Dr. Belongia thought that would address the ambiguity to a great degree if that term was used 
specifically. 
 
Dr. Netoskie (AHIP) agreed with Dr. Riley.  It seemed to him that under the topic of egg allergy, 
the most important message to begin with is that “you may administer vaccine to people who 
have had egg allergy issues.”  He thought that should be first, followed by the conditions where 
there may be various levels of concern.  From the physician education perspective, that is the 
key message that should come across first. 
 
Dr. Schaffner (NFID) expressed concern that they were drifting into the ultimate management of 
anaphylaxis.  From his point of view, the place where vaccines are administered need two 
pieces of equipment:  an epi pen and a cell phone. 
 
Dr. Rubin pointed out that the critical difference in Items 3 and 4 was that in 3 the vaccine 
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Dr. Moore emphasized that the data from allergists suggest that there is not even a biological 
plausibility to this causing anaphylaxis because of the minutia.  She said she understood the 
difference in injection versus ingestion, but that that is difficult to make a case for.  Perhaps they 
could state “Out of an abundance of caution” and then say that there is no evidence at this point 
that there are a lot of people who are having anaphylactic reactions to influenza vaccines who 
have a history of egg allergy. 
 
Dr. Grohskopf responded that that is discussed in the background section that precedes this 
recommendation, in addition to the literature, including all of the literature discussed by Dr. 
Kelso.  Going back the last several years, one of the concerns has been that there is a 
recommendation from the allergy community as well as the ACIP recommendation, which is for 
everybody.  One thing that has been voiced consistently over the last three or four years has 
been the venues and settings in which vaccination is occurring have expanded and are much 
more diverse.  There was overall some concern that there may be some settings that, even 
though it is repeatedly recommended that certain equipment should be available, it might not 
be.  Perhaps including some particular language would help. 
 
Dr. Bennett said she thought they needed to go to vote, but that they needed to clarify what they 
would be voting on since they had gone back and forth.  Her proposal was to vote on what they 
had at the moment, and then if there was a wording change the WG felt should be made, they 
trust them to make the changes and review them after the fact.  She did not think that continuing 
the discussion was going to get them anywhere, as they seemed to be going around in circles.  
She said if anyone adamantly objected, she would be happy to listen, but she thought they 
needed to move forward. 
 
Ms. Pellegrini emphasized that they wanted to get this right.  It is important and is a big change 
that would take a long time for physicians, patients, and families to get used to.  She did not 
understand exactly what they had to do during this meeting, and whether they were under 
pressure for something to be published. 
 
Dr. Bennett responded that they must approve these recommendations so that the MMWR 
could be published in a timely manner.  What they did not have to do was approve the exact 
wording.  They merely had to approve it in spirit. 
 
Dr. Fryhofer (AMA/ACP) noted that she is a practitioner who sees patients.  When she saw the 
word “equipment” it meant to her that she needs to have an anesthesiologist there to intubate 
the patient.  She thought this was creating a barrier that was an unintended consequence.  
Adding the airway management will make people think they have to be ready to intubate a 
patient.  That is not a reality. 
 
Dr. Bennett clarified that she was proposing that they vote without that, as it was added after the 
original language.  She proposed they vote on the amended motion.  She emphasized that 
there was no way this would be perfect by the end of the day, and that they should move 
forward with the sense that there would be an opportunity to see the specific wording and make 
comments on it after the WG has a chance to incorporate the comments.  She said she had 









Vote:  Influenza Vaccine Recommendations for 2016-2017 
 
Dr. Karron made a motion to approve the 2016-2017 Influenza Vaccine Recommendations for 
2016-2017 with the changes as proposed.  Dr. Walter seconded the motion.  The motion carried 
with 11 affirmative votes, 0 negative votes, and 3 abstentions.  The disposition of the vote was 
as follows: 
 
11 Favored: Bennett, Harriman, Karron, Kempe, Moore, Pellegrini, Romero, Reingold, Riley, 
Rubin, Walter 
  0 Opposed: N/A  





Update on CDC’s Response to Zika Virus 
 
Toby L. Merlin, MD 
Director, Division of Preparedness and Emerging Infections 
National Center for Emerging and Zoonotic Infectious Diseases 
Centers for Disease Control and Prevention 
 
Dr. Merlin provided an update on CDC’s response to Zika Virus.  He summarized the current 
situation, CDC’s response activities, and the challenges and opportunities for vaccine 
development. 
 
The Zika virus outbreak has grown in size and reach and is attracting interest from public and 
the media abroad, as well as in the US.  In response to this emerging public health threat, CDC 
activated its Emergency Operations Center (EOC) on January 22, 2016 to help coordinate the 
public health response.  On February 1, 2016, the WHO declared a Public Health Emergency of 
International Concern (PHEIC) because of clusters of microcephaly and other neurological 
disorders in some areas affected by Zika. 
 
On February 8, 2016, CDC elevated its EOC activation to a Level 1, the highest level.  President 
Obama also announced a request for $1.8 billion in emergency funds for several agencies to 









Characterize the effects of Zika Virus infection (Zika) in the current outbreak 
Effects of Zika in pregnant women, including the risk of fetal loss and congenital 
malformations, including microcephaly 





























Promote and evaluate interventions to prevent Zika, particularly in at-risk populations 
(pregnant women) 
 
Personal protective measures (insect repellant, contraception) 
Vector control  
Prevention of transmission via blood and transplantation 
Travel advisories 
Enable detection of Zika by development and distribution of Zika laboratory diagnostics 
 
Current CDC investigations and collaborations include the following: 
Brazil 
Retrospective case-control study for risk of fetal Zika infections, potential co-factors, 
and microcephaly 
Retrospective case-control study for risk of GBS 
Columbia (protocols pending approval) 
Prospective pregnancy cohort study to define spectrum of fetal outcomes associated 
with Zika infection 
Virus persistence in semen, urine 
 
Domestic (particularly Puerto Rico)  
Pregnancy registry and follow-up of cases 
Other studies  
Histopathologic examination of tissues from affected pregnancies 
 
Prior to 2015, Zika outbreaks occurred in Africa, Southeast Asia, and the Pacific Islands.  In 
May 2015, the first locally-acquired cases in the Americas were reported in Brazil.  Currently, 
outbreaks are occurring in many countries in the Americas and US territories, including Puerto 
Rico, American Samoa, and the US Virgin Islands.  Thus far, local mosquito-borne transmission 
of Zika has not been reported in the continental US.  Since 2011, there have been laboratory-
confirmed Zika virus disease cases identified in travelers returning to the US from areas with 
local transmission.  With current outbreaks in the Americas, cases among US travelers will most 










Imported cases may result in virus introduction and local spread in some areas of the US where 
Aedes mosquitos are present.  CDC is not able to predict how much Zika virus will spread in the 
continental US.  However, recent chikungunya and dengue outbreaks in the continental US 
suggest that Zika outbreaks may be limited to small, geographic clusters. 
 
The following maps depict the approximate distribution of Aedes aegypti and Aedes albopictus 
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Aedes aegypti mosquitoes have been identified across the southern half of the US from 
California to Florida, while Aedes albopictus has been identified throughout much of the 
Southern and Eastern US.  Imported cases may result in virus introduction and local spread in 
some areas of the US where Aedes mosquitos are present. 
 
CDC is not able to predict how much Zika virus would spread in the continental US.  The spread 
of Zika is most likely due to the movement of people, not the movement of mosquito 
populations.  For Zika to cause an outbreak in the continental US people infected with the virus 
need to enter the US.  An Aedes mosquito must bite the infected person during the relatively 
short time that the virus can be found in the person’s blood.  The infected mosquito must live 
long enough for the virus to multiply and for the mosquito to bite another person. 
 
The best way to prevent diseases spread by mosquitoes is to protect against mosquito bites 






Wear long-sleeved shirts and long pants 
Stay in places with air conditioning or that use window and door screens to keep mosquitoes 
outside 
 






When used as directed, these insect repellents are proven safe and effective even 
for pregnant and breastfeeding women 
 
Insect repellents should not be used in babies younger than 2 months of age  
Products containing higher than 30% N,N-diethyl-meta-toluamide (DEET) should not 
be used in children, and products containing para-menthane-diol (PMD) should not 





Use mosquito netting to cover babies younger than 2 months of age in carriers, strollers, or 
cribs to protect them from mosquito bites 
 
Do not use oil of lemon eucalyptus in children younger than 3 years of age 
 
Sleep under a mosquito bed net if air conditioned or screened rooms are not available or if 
sleeping outdoors 
 
Recent chikungunya and dengue outbreaks in the continental US suggest that Zika outbreaks in 
the US mainland may be limited to small, geographic clusters.  Better housing construction, less 
crowding, regular use of air conditioning, use of window screens and door screens, and state 
and local mosquito-control efforts have helped to limit transmission of these mosquito-borne 
viruses. 
 
Currently, there is no vaccine or medication to prevent infection or disease.  Developing safe 
and effective vaccines for the prevention of emerging infectious diseases, such as Zika, is a 
priority for the US government.  Preliminary evidence indicates that a vaccine could be effective 
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appears to show minimal antigenic and genetic variation across strains.  Moreover, there are 
limited data revealing neutralization across viral strains. 
 
Plans are under development to leverage existing infrastructure to provide a coordinated and 
collaborative framework to support the accelerated development of Zika vaccines.  Ongoing 
partnerships between National Institutes of Health / National Institute of Allergy and Infectious 
Diseases (NIH / NIAID), the Biomedical Advanced Research and Development Authority 
(BARDA), CDC, FDA, and the DoD’s Walter Reed Army Institute of Research (WRAIR), and 
industry partners will provide a coordinated and collaborative framework to support the 
accelerated development of Zika vaccines.  There are many approaches and technologies 
being put forth, including recombinant, live-attenuated, live-chimeric with other flavivirus 
components, nucleic acid, whole-inactivated virions, and other virus-vectored platforms.  These 
vaccine candidates are all in exploratory stages of development. 
 
The President’s emergency funding request includes support for vaccine research and 
diagnostic development and procurement.  The request includes funding for research, rapid 
advanced development, and commercialization of new vaccines and diagnostic tests for Zika 
virus.  There is also some funding for the US Agency for International Development (USAID) to 
create new incentives for the development of vaccines and diagnostics. 
  
Vaccine Development Update 
 
Bruce Gellin, MD, MPH 
Director, National Vaccine Program Office 
Department of HHS, Public Health and Science 
 
Dr. Gellin further described the vaccine development process and development pertaining to 
Zika virus.  He first explained that the Public Health Emergency Medical Countermeasure 
Enterprise (PHEMCE) coordinates federal efforts to enhance chemical, biological, radiological, 
and nuclear threats (CBRN) and emerging infectious diseases (EID) preparedness from a 
medical countermeasure (MCM) perspective.  He explained that he wanted to put Zika virus 
vaccine development in the context of the PHEMCE, given that it is “all hands on deck” 
regarding who has equities they can provide. 
 
The PHEMCE is led by the HHS Office of the Assistant Secretary for Preparedness and 
Response (ASPR) and includes three primary HHS internal agency partners: CDC, FDA, and 
NIH.  Also included are several interagency partners:  DoD, VA, the Department of Homeland 
Security (DHS), and the US Department of Agriculture (USDA).  PHEMCE Agency Lead roles 




























Identify, create, develop, manufacture, and procure critical MCM 
Establish and communicate clear regulatory pathways to facilitate MCM development and 
use 
Develop logistics and operational plans for optimized use of MCM at all levels of response 
Address MCM gaps for all sectors of the American civilian population 
 
The HHS priorities on MCM for Zika virus include the following: 
Detect Zika Infection 
 Support advanced development of rapid serological diagnostics, including point of 
care, for the detection of antibodies in persons previously infected with Zika virus 
Prevent Zika Infection 
NIH/DOD/BARDA collaboration for USG-developed, manufactured, and evaluated 
Zika virus vaccine 
NIH and BARDA to support private sector development of vaccine through federal 
funding opportunities 
HHS to support international collaborations, including vaccine production at the 
Butantan Institute in Brazil  
Secure and Protect Blood Supply 
 Support advanced development of high throughput molecular diagnostics for 
screening blood supply  
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The current Zika virus vaccine development landscape as of February 16, 2016 is depicted in 




It is important to understand that the vaccine and drug development pipeline is expensive, risky, 
and lengthy.  This is illustrated by the following graphic that highlights the progress with Zika 
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It is clear that there is a significant amount of interest in Zika virus vaccine development, and 
there are numerous technologies that could be utilized.  There are a number of key questions 


























Pre-existing immunity to Zika, YF, dengue, and vaccine platforms 
Is there a potential for antibody dependent enhancement? 
Intended Usage 
General usage (GUP) and post-exposure (PEP) prophylaxis 




Vaccine components (e.g., E protein, whole virus, adjuvants, other viruses) 
Level and type of elicited immunity 
Kinetics of vaccine immunity 
Duration of immunity (Heterologous Prime/Boost Approach) 
Routes of administration 
Platform technology maturity 
Manufacturing process maturity (potency assays, vaccine stability) 
 
Zika Virus Natural and Adaptive Immunity in Animals and Humans 
Correlates of protective immunity 
Immunogenicity and protection study design 
Assays and reagents  
 
There have been several workshops since early February 2016, and there are additional 
upcoming workshops of interest: 
 
March 1-2, 2016 in Washington, DC 
PAHO Meeting on the Zika virus research agenda and its public health implications in the 
Americas 
 
March 28-29, 2016 in Washington, DC 
HHS Stakeholders meeting on Zika virus and Medical Countermeasures 
 
Contact information of interest pertaining to Zika virus vaccine development includes the 
following: 
Request a Tech Watch Meeting Through www.medicalcountermeasures.gov 















BARDA Broad Agency Announcement 
BAA-16-100-SOL-00003 will support innovation through development of platform 
technologies that enhance capabilities for development and manufacturing of MCMs. 
Technical Point of Contact: Mark Craven: mark.craven@hhs.gov 
 
NIH Federal Funding Opportunity 







Arthur Reingold, MD 
University of California, Berkeley 
Chair, ACIP Cholera Vaccine Work Group 
 
Dr. Reingold reminded everyone that the Cholera Vaccine WG was formed in August 2015.  
During the October 2015 ACIP meeting, the WG presented an overview of cholera background 
and epidemiology.  PaxVax filed a BLA with the FDA in October 2015 with a request for priority 
review for the use of its vaccine CVD 103-HgR.  The vaccine is currently undergoing a fast-track 
review, which the FDA is anticipated to complete by June 2016.  The plan is to call for an ACIP 
vote on recommendations for use of CVD 103-HgR in June 2016 for use in adults. 
 
Since October 2015, the ACIP Cholera Vaccine WG has drafted policy questions, identified 
important and critical outcomes for review, conducted a systematic literature review, completed 
an initial GRADE evaluation of the evidence, and discussed considerations for 
recommendations for use.  This is a somewhat unusual vaccine in that some of the studies are 
actually challenge studies in which the organism is intentionally introduced. 
 
Dr. Reingold indicated that during this session, Dr. Danzig from PaxVax would present clinical 
data on CVD 103-HgR, Dr. Wong from CDC would summarize the GRADE evaluation and WG 
plans, and that presentations would include the information and background needed for 
discussion about cholera vaccine to inform ACIP decisions during upcoming meetings. 
 
Vaxchora™ Clinical Data 
 
Lisa Danzig, MD 
VP Clinical Development and Medical Affairs 
PaxVax 
 
Dr. Danzig presented pivotal data that have been filed in support of the BLA for PaxVax CVD-
103-HgR vaccine called Vaxchora™.  She briefly reviewed the background on CVD-103-HgR 
and the clinical re-development program that included human challenge studies in which 
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PaxVax is a privately held global specialty vaccines company with a mission to develop, 
manufacture, and commercialize innovative vaccines against infectious diseases in a socially 
responsible manner.  PaxVax has approximately 180 dedicated employees who work across 
locations in the US and Europe.  The PaxVax headquarters is in Redwood City, California.  Its 
research and development site is in San Diego, California.  The Thörishaus, Switzerland site 
includes multiple manufacturing, office, and laboratory spaces for Vivotif® production, quality 
testing, product release, and supply chain. 
 
PaxVax is initially focused on delivering vaccines for the travelers’ markets, with the following 
products:  Vivotif®, which is a typhoid vaccine live oral Ty21a; Vaxchora™, which is the oral 
cholera vaccine that is under FDA review; an Ad4 vector program that has included programs in 
HIV, influenza, anthrax, and Ad4/7; and new research and development that focuses on travel 
and specialties, including Zika virus vaccine. 
 
Vibrio cholerae (V. cholera) O1 biotypes are the most common (Classical, El Tor).  Each biotype 
has two distinct serotypes.  The transmission route is via contaminated water and food.  It 
causes a toxin-mediated secretory diarrhea, which if severe can be rapidly fatal if untreated.  
This is known as cholera gravis.  It is endemic in over 50 countries and is found primarily in Asia 
and Africa.  In addition, there has recently been extensive disease burden in the Caribbean.  
Approximately 3 to 5 million cases are estimated to occur per year, with more than 100,000 
deaths.  It is estimated that the majority (80%) of mild to moderate diarrhea cases do not come 
to medical attention, and therefore go unreported.  Everyone is susceptible, but there is an even 
greater risk with blood group O and probably hypochlorhydria, but the reasons are unknown [Ali 
M, Nelson AR, Lopez AL, Sack DA. Updated global burden of cholera in endemic countries. 
PLoS Negl Trop Dis 2015;9(6):e0003832]. 
 
There is no licensed cholera vaccine in the US.  Because cholera causes explosive diarrhea, 
infection can be rapidly fatal.  If untreated, in its severest form cholera makes headlines.  CVD 
103-HgR is not a new vaccine.  It is a live, attenuated V. cholerae serogroup 01, serotype Inaba, 
classical biotype strain in which the toxigenic A1 ADP-ribosylating subunit of cholera toxin was 
deleted and only the non-toxic immunogenic B binding subunit of cholera toxin is synthesized.  
The first lots were tested in volunteers in 1988.  It was available in 1994 through Berna 
commercially as Orochol®, Mutacol®, and Orochol® E (the higher dose).  It was licensed in 
Switzerland, Canada, Argentina, Australia, and New Zealand in the 1990s.  In 1997, Berna 
submitted a BLA to the FDA.  There was a VRBPAC in 1998 that included a discussion of the 
design of the challenge studies that would be needed to support licensure in the US.  The 
endpoints were discussed at that time, and a challenge study was redesigned that would be 
able to support the demonstration of an efficacy claim in a non-endemic population such as US 
travelers. 
 
For unrelated business reasons in 2004, the production at Berna ceased.  Subsequently, when 
Crucell bought Dukoral® in 2006, they returned the rights of the cholera vaccine to the Center 
for Vaccine Development (CVD) from which PaxVax acquired the right to re-develop CVD-103-
HgR in 2010.  The PaxVax BLA for an adult indication was submitted on October 16, 2015 and 
was accepted for filing on December 15, 2015 with a review classification of “Priority.”  The 
review goal date June 15, 2016 and this is on track.  Proposed labeling feedback is anticipated 
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The commercial experience is more than 500,000 doses distributed over 10 years.  The vaccine 
was well-tolerated, with an excellent safety profile.  There have been more than 35 scientific 
publications between 1988 and 2010, which have been provided to the WG.  Summarized 
briefly, efficacy in non-endemic populations was demonstrated in healthy volunteer cholera 
challenge studies with a number of cholera strains.  The challenges ranged from 8 days to 6 
months following vaccination1.  There were field efficacy studies in endemic populations2.  
Safety, immunogenicity, and dose-finding studies were conducted in developed and developing 
countries3.  Orochol E is a 1 log higher dose, which is not included in the current vaccine 
formulation or application.  Special populations include pediatric and HIV4, and concomitant 
yellow fever (YF), malaria prophylaxis, and oral polio vaccination (OPV)5 were also studied. 
Safety and immunogenicity of re-immunization at 2.5 and 3.5 years6 following vaccination were 
also studied and published.  Interestingly, since there are no data on persistence, the 
seroconversion by serum vibriocidal antibody (SVA) following primary immunization was 81%.  
 
Following re-immunization, SVA was 57% at 2.5 years and 65% at 3.5 years.  Fecal antibodies 
also decreased at 2.5 versus 3.5 years.  This suggests that primary immunization elicited long-
term local immunologic memory [1 Orochol Historical Studies: Table 1. North America Challenge 
Studies – (El Tor Inaba, El Tor Ogawa, Classical Inaba strains tested); 2 Orochol Historical 
Studies: Table 5. Studies in Cholera Endemic Areas; 3 Orochol Historical Studies: Table 2. RCT 
N. America or European Adults, Table 6: Non-pivotal Safety/Immunogenicity Studies; 4 Orochol 
Historical Studies: Table 3: Pediatric Studies, Table 4: Special Populations; 5 Orochol Historical 
Studies: Table 6: Non-Pivotal Safety/Immunogenicity Studies and Other Studies of Relevance; 
and 6Kollaritsch et. al. Vaccine 18 (2000) 3031-3039; Levine BMC Biology 2010, 8:129].  
 
The following table offers an overview of the current clinical program: 
  
 
Study Objective(s) Design & Type of Control 





















5 x 108 CFU/dose; oral 
Phase 3 







1 x 109 CFU/dose; oral 
Phase 3 
Older Adult  
005 
Demonstrate 
equivalence in immune 
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The Phase 1 study has been published.  It confirmed the safety and immunogenicity of the 
earlier formulation.  There was limited shedding and there was no transmission to household 
contacts.  The household contacts of the study recipients received fecal swab stool culture and 
antibody tests to determine whether they were exposed to the organism when the vacinee 
brought it home [Clinical and Vaccine Immunology; p. 66 –73; January 2014; Volume 21; 
Number 1]. 
 
That supported moving forward with the PXVX-VC-200-003 challenge study to demonstrate 
efficacy at two time points.  This pivotal efficacy challenge study used a closely monitored 
human infection model involving the ingestion of virulent V. cholerae O1 El Tor Inaba strain 
N16961 strain at 1 x105 colony forming units (CFU).  The primary objective was to determine 
whether a single dose of PXVX0200 provides significant protection against a challenge with 
virulent cholera.  The challenge was given at 10 days and 3 months after vaccination.  The 
primary endpoint was the development of moderate to severe diarrhea or moderate to severe 
cholera, which was equal to or greater than 3.0 liter purge for the illness.  “Severe” was defined 
as a 5.0 liter purge, and “moderate” was defined as 3.0 liter purge.  Without rehydration therapy, 
this endpoint would be potentially life-threatening because the plasma volume for an average 
person is 2.5 liters.  The success criterion was that the lower two-sided 95% confidence bound 
on protective efficacy must be greater than or equal to 30%.  The secondary objectives were to: 
1) evaluate the impact of vaccination on disease severity, total stool volume by weight, 
incidence of diarrhea of any severity, incidence of fever, incidence of fecal shedding of wild type 
V. cholerae, peak concentration V. cholerae detected in stool; and 2) evaluate the tolerability of 
the vaccine. 
 
In terms of the data, the attack rate for moderate cholera for 3.0 liter liquid stool was 6% in the 
vaccine group challenged after 10 days.  Relative to the placebo group at 59%, that is a 
significant reduction.  Vaccine efficacy was 90%, with a lower bound of 63%.  At the 3-month 
challenge, the attack rate was 12%.  Vaccine efficacy was 80%.  This study met the primary 
endpoints, with the lower bound over 30%.  The subgroup analyses on the primary endpoints 
did not show major differences between blood groups O or non-O, males or females, or black or 
white.  Not everyone was selected to be challenged, so there was a group who was followed for 
safety. 
 
Protection was demonstrated for secondary endpoints including diarrhea of any severity 
(defined as >4 loose stools within a 24 hour period), volume of diarrhea, number of loose stools, 
number of days passing loose stools, and a 99% reduction in shedding of the challenge strain in 
the vaccine versus placebo groups during the 11 days following challenge. 
 
Vibriocidal antibodies are a measure of immunity and have been inversely correlated with 
infection with cholera1.  In terms of the SVA against classical Inaba prior to challenge for the 
placebo and challenge groups, peak titers reached about 100-fold greater than baseline at 10 
days after study.  While they subsequently declined, there is persistence of the antibody level 
above the placebo or the baseline level [1M. Pasetti and M. Levine, Clinical and Vaccine 










These are the peak antibody titers, this time expressed as the fold increase from baseline on 
the x-axis against cumulative diarrhea by volume on the y-axis.  Each subject is marked with a 
P in blue or a V in red, which represents the challenged subjects who received a placebo or 
vaccine.  The vaccine recipients had high fold increases on the right and low stool volumes, in 
contrast to placebo recipients whose fold increases did not exceed 4-fold and who had high 
stool volumes. 
 
The serum vibriocidal fold-increase measured on Day 11 was a predictor of protection against 
development of moderate to severe cholera following challenge in Study 003. As expected, 
since the vibriocidal response is thought to be mediated by the LPS, similar results were 
attained when vibriocidal assays were performed with strains representing the other major 
biotypes and serotypes.  The GMT percent 4-fold rise for vaccinees and placebos were similar 
to those with the Classical Inaba strain as shown in the following table: 
 
 Vibriocidal GMT 
Day 11  (95% CI) 
Percent With 4-fold Vibriocidal Rise at 
Day 11 
Cholera Strain 








N = 94 
Placebo 
N=102 
Classical Inaba  4313*  65 89%* 2% 
El Tor Inaba 6898* 63 90%* 4% 
Classical 
Ogawa 2324
* 94 86%* 3% 






Challenge Study 003 Post-immunization  
Vibriocidal GMT and Percent 4-Fold Rise 
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Equivalence was demonstrated in lot consistency for three lots with approximately 900 subjects 
per group, given that the geometric mean ratios for each pair of lots was 0.78-1.20 which was 
within the pre-specified interval of 0.67-1.5.  Safety was also assessed in this 3000 subject 
study (004 Safety Profile).  The single dose of cholera vaccine was well-tolerated in this study.  
Reactogenicity signs and symptoms after vaccine administration were reported by 51.90% of 
vaccine and 43.15% of placebo recipients (p=0.0024).  There was slightly more reactogenicity in 
the vaccine group, but there were no meaningful differences in reactogenicity across lots.  
 
There were no significant differences between vaccine and placebo recipients with exception of: 
1) headache reported in 28.93% (791 of 2734) vaccine recipients and 23.62% of (81 of 343) 
placebo recipients (p=0.0419); most were mild (516 vaccine, 50 placebo) or moderate (261 
vaccine, 30 placebo); and 2) diarrhea, which although rare in both vaccine and placebo groups 
was reported 3 times more frequently in vaccine (3.88%) versus placebo (1.17%) (p=0.0079) 
recipients. 
 
Most diarrhea was mild or moderate (defined as ≥4 or ≥5 loose stools/24h respectively); severe 
diarrhea was defined as ≥ 6 loose stools/24h and was reported in 0.8% (22 of 2789) vaccine 
recipients and 0.0% (0 of 350) placebo recipients.  The median duration of diarrhea was 1 day 
and resolved in all subjects within 2 days of onset.  The median day of onset was 2 days after 
vaccination (range 1-7 days).  There was one death during the study, which was a suicide that 
was considered to be unrelated, and 20 subjects reported at least one SAE (17 Vaccine, 3 
Placebo) which were all considered to be unrelated to the study. 
 
Since a 4-fold rise in serum vibriocidal titer was correlated with protection, this was used to 
bridge the immune response from an older population to a younger population in which efficacy 
was demonstrated in study PXVX-VC-200-005.  This study met the primary endpoints by 
demonstrating with 95% confidence that the seroconversion rate in older adults was within 10% 
of the rate in younger adults, and that the seroconversion rate in older adults was at least 70%, 
which was the pre-specified endpoint. 
 
In terms of the overall reactogencity across all of the Phase 3 studies combined, 3325 vaccine 
and 563 placebo recipients participated in one of the Phase 3 studies.  “Any” reactogenicity was 
reported in 50% of vaccinees and 46% of placebo subjects (p=0.06).  Most reactogenicty was 
mild or moderate.  The breakdown of the solicited post-immunization reactions within 7 days in 







Malaise 30.0% 29.4% 0.8 
Headache 27.8% 26.0% 0.4 
Abdominal Pain 18.3% 17.0% 0.5 
Nausea 17.4% 15.6% 0.3 
Anorexia 15.6% 16.8% 0.4 
Diarrhea (≥4 
loose stools/24h) 3.8% 1.6% 0.008 








The vaccine was well-tolerated and there were no significant differences between groups, with 
the exception of an approximately 2% increase in diarrhea more frequently in the vaccine group.  
However, that was mostly mild or moderate and was presented because a contributing element 
of that was from the consistency trial. 
 
Adverse events were collected through Day 29 for most studies, with a follow-up period of up to 
181 days in subsets of all of the studies.  The most common AEs described are show in the 















No meaningful differences were observed between the rates of vaccine and placebo recipients 
reporting unsolicited AEs during study.  No SAEs were considered to be related to vaccine. 
The efficacy demonstrated in the human challenge correlates with the vibriocidal immune 
response at 11 days following vaccination.  Vibriocidal titers were plotted for the subset of 
subjects from whom blood was taken at Days 29, 91, and 181.  At all time points, titers 
remained well above the placebo and respective baseline. 
 
Primed antigen-specific B cells also become memory B cells, which differentiate into antigen 
antibody secreting cells upon antigen re-exposure.  Immunoglobulin G (IgG) and 
Immunoglobulin A (IgA) memory B cells from LPB toxin b-subunit (CTb) and toxin co-regulated 
pilus subunit (TcpA) have previously been found in cholera-infected patients for up to a year 
following disease [Harris, J. Infection and Immunity 2009].  The percent of anti-LPS IgA memory 
B cells measured in peripheral blood pre-challenge correlated with protection in the vaccinated 
subjects who were immunized over a challenge on Day 91.  For comparison, there were some 
unchallenged vaccinees also in whom memory B cells appear to be induced.  For reference, in 
the placebo group who was followed for safety and was not challenged at 170 days post-
challenge, there was also a strong induction of memory B cells.  So anti-LPS memory B cells 
increase and remain elevated at Day 181, which likely demonstrates an anamnestic response at 
6 months. 
 
In summary, PaxVax redeveloped CVD 103-HgR (PXVX0200, Vaxchora®).  It was well-
tolerated, with no related SAEs; a slight (~2%) increase in diarrhea, most of which was mild to 
moderate; and a similar profile to Orochol®.  Protective efficacy against challenge was 90% at 
10 days following vaccination and 80% at 3 months following vaccination.  The vaccine was 
found to be immunogenic in healthy adults 18 through 45 years of age and 46 through 65 years.  
There was 90% to 94% seroconversion by SVA to Classical Inaba.  Seroconversion also was 
demonstrated by SVA with other biotypes and serotypes (Classical Ogawa, El Tor Inaba, El Tor 
Symptom Vaxchora n=3235 
Placebo 
n=562 
Headache 2.5% 2.7% 
Fatigue 2.2% 3.2% 
URI 2.1% 2.1% 
Back pain 1.4% 1.1% 
Flatulence 1.1% 1.8% 
Abdominal pain 1.1% 0.9% 
Diarrhea (≥4 loose 
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Ogawa).  Vibriocidal serocoversion correlates with efficacy.  Vibriocidal Ab levels remained well 




Dr. Stephens asked whether Dr. Danzig could comment further on shedding in terms of other 
family members. 
 
Dr. Danzig replied that in the Phase 1 studied, two subsets were measured every other day for 
the first week and shedding was demonstrated in the vacinees.  All household contacts were 
measured with blood draws and fecal swabs or stool cultures, and no transmission of the 
shedding was demonstrated. 
 
Cholera Vaccine GRADE Evaluation and Work Group Plans 
 
Karen K. Wong, MD, MPH 
Medical Officer 
Division of Foodborne, Waterborne, and Environmental Diseases 
National Center for Emerging and Zoonotic Infectious Diseases 
Centers for Disease Control and Prevention 
 
Dr. Wong presented the results of the cholera vaccine GRADE evaluation.  She reiterated that 
no cholera vaccine is currently available in the US.  Vaccines are available outside the US, but 
these require two doses.  CVD 103-HgR, a live-attenuated, single dose oral cholera vaccine 
was previously licensed in other industrialized countries and marketed as Orochol® or Mutacol®, 
before manufacture ceased for business reasons.  The company PaxVax acquired the license 
to re-develop this vaccine as Vaxchora™, which Dr. Wong referred to in this presentation as the 
newer formulation of the vaccine.  As noted earlier, a BLA was filed in October 2015 for adults 
18 years of age or older, with an FDA action date expected in mid-June 2016. 
 
The WG examined the following policy question for the GRADE evaluation: 
 
“Should live attenuated oral cholera vaccine CVD 103-HgR be recommended for use in 
adults 18 years of age or older who are at risk of travel-related exposure to toxigenic 
Vibrio cholerae O1?” 
 
The population includes adults who live in the US and are traveling to cholera-affected areas. 
The intervention is CVD 103-HgR administered as a single oral dose.  The current option is that 
no oral cholera vaccine is currently recommended or available to adults in the US. 
 
Prior to reviewing the evidence, the WG selected outcome measures to be included in the 
evidence profile.  Preventing cholera death, life-threatening cholera diarrhea, and severe 
cholera diarrhea were classified as critical outcomes.  Preventing cholera diarrhea of any 
severity and inducing a vibriocidal antibody response were considered to be important 
outcomes.  Serious and systemic adverse events and decrease in the effectiveness of co-
administered vaccines or medications were considered to be critical outcomes. 
 
The WG conducted a systematic review of PubMed and Embase papers in any language 
published between 1988, when the vaccine was first developed, and January 2016.  Efforts 
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reviewed for additional studies of interest.  Articles were included if they presented data on CVD 
103-HgR and involved human subjects, reported primary data, included data relevant to the 
outcome measures being assessed, and included data for a relevant dose. 
 
In the initial review, 77 studies were identified.  Of these, 49 were excluded (41 that either did 
not include CVD 103-HgR data or any primary data, 8 pediatric studies, and 1 cost-benefit 
analysis).  This left 28 studies in the GRADE evaluation.  Of the 28 studies, there were 3 studies 
of the newer formulation, all of which were RCTs.  There were 25 studies of the older 
formulation, including 18 RCTs and 7 observational studies.  Of the 28 studies, 5 were cholera 
challenge studies, including 3 RCTs (1 of which used the new formulation) and 2 observational 
studies.  The following table summarizes the number of studies, by type, that were available to 




Outcomes for which limited data were available included preventing cholera death, preventing 
life-threatening cholera diarrhea, and decreasing the effectiveness of co-administered vaccines 
or medications. 
 
The GRADE evidence scoring method begins with an initial evidence type of 1 for RCTs and 3 
for observational studies.  Criteria for moving the evidence type down by 1 or 2 points include: 
risk of bias, inconsistency, indirectness, imprecision, and publication bias.  Criteria for moving 
up by 1 or 2 points include:  strength of association, dose response gradient, and opposing 







1 corresponds to evidence from RCTs or overwhelming evidence from observational 
studies 
2 corresponds to RCTs with important limitations, or exceptionally strong evidence from 
observational studies 
3 corresponds to observational studies, or RCTs with notable limitations 
4 corresponds to clinical experience and observations, observational studies with 








The WG attempted to assess prevention of cholera death as an outcome of vaccination. 
However, cholera challenge studies are not designed to assess this outcome.  There was one 
large field study that showed no difference in deaths from diarrhea of any etiology between 
vaccinated and comparison populations.  Cause of death was assessed by verbal autopsy in an 
Indonesian population monitored over 4 years.  The following table summarizes the challenge 




The WG felt that there was insufficient evidence to assess prevention of cholera death by the 
vaccine.  There was insufficient evidence to assess prevention of cholera death.  Most criteria 
were unable to be assessed. 
 
One RCT addressed the outcome of prevention of life-threatening cholera diarrhea [Chen, 
Cohen et al, 2014].  This study was with the new formulation of the vaccine.  Challenge with 
toxigenic V. cholerae O1 in vaccinated and comparison groups was performed at 10 days or 3 
months after vaccination.  The risk ratio was less than 1, which suggests a protective effect of 
the vaccine.  There was strong evidence from 1 RCT with the newer formulation of vaccine that 
CVD 103-HgR prevents life-threatening cholera diarrhea.  The overall evidence type was 1. 
 
There were 3 RCTs that addressed prevention of severe cholera diarrhea [Chen, Cohen et al, 
2014; Tacket et al, 1999; and Richie et al, 2000].  There were 2 challenge RCTs, one of which 
assessed the outcome at multiple time points, that showed a strong consistent reduction in 
severe cholera diarrhea among vaccinated versus comparison individuals.  There was one field 
RCT that found no significant difference in severe cholera diarrhea in vaccinated versus 
unvaccinated individuals.  This study was conducted in Indonesia among children and adults.  In 
this study, individuals rather than clusters were randomized.  Cholera outcomes were assessed 
by sentinel surveillance over 4 years.  Incidence of cholera was low during the study period, 
making detection of an effect difficult.  The evidence type for prevention of severe cholera 
diarrhea was downgraded for inconsistency, given that the 1 large field trial showed no effect.  
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that the vaccine prevents severe cholera diarrhea.  The overall evidence type was determined 
to be 1. 
 
There were 4 RCTs [Chen, Cohen et al, 2014; Richie et al, 2000; Tacket et al, 1999; and Levine 
et al, 1988] and 3 observational studies [Calain et al, 2004; Losonksy et al, 1993; and Tacket et 
al, 1992] that addressed prevention of cholera diarrhea of any severity.  There were 5 challenge 
studies, some of which included multiple time points.  Of these, 4 showed a statistically 
significant reduction in the proportion of vaccinated versus comparison groups developing 
cholera diarrhea, corresponding to VE ranging from 51% to approaching 100%.  In these 
studies, challenge occurred from 8 days to up to 6 months post-vaccination.  There was 1 field 
RCT [Richie et al, 2000] that found no difference between vaccinated and comparison 
populations in cholera diarrhea detected by sentinel surveillance over 4 years.  Another study 
describing a mass vaccination campaign [Calain et al, 2004] during a cholera outbreak found 
that incidence of cholera diarrhea was lower in vaccinated versus comparison populations.  The 
evidence type for prevention of cholera diarrhea of any severity was downgraded for 
inconsistency, as 1 large field trial showed no effect.  There was strong evidence from other 
studies with old and new vaccine formulations that CVD 103-HgR prevents cholera diarrhea of 
any severity.  The overall evidence type was 1. 
 
Vibriocidal antibodies are the best available marker for protection against cholera.  They 
correlate with serogroup-specific (O1 or O139) protection, but protect against both biotypes (El 
Tor, Classical) and both serotypes (Inaba, Ogawa).  There were 19 RCTs and 3 observational 
studies that assessed immunogenicity.  This figure shows the proportion demonstrating a 
vibriocidal antibody response in vaccinated persons, shown in red, versus comparison persons, 
shown in blue:   
 
 
Each row in the above graph represents a study population.  Some studies assessed the 
outcome in more than one group or at multiple time points.  Some studies did not report 
serology results in an unvaccinated comparison group.  There is a horizontal separation 
between results from the vaccinated and comparison groups.  This indicates a consistent 
vibriocidal antibody response seen in studies with both the older and newer formulations of the 
vaccine.  The vaccine efficacy for induction of vibriocidal antibody response from studies with 
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vaccine formulation were downgraded for indirectness.  However, there was strong evidence 
from studies with old and new formulations that the vaccine induces a vibriocidal antibody 
response.  The overall evidence type was 1. 
 
There were 20 RCTs, 4 observational studies, and post-marketing surveillance data that 
examined AEs from the vaccine.  For SAEs, there was 1 field RCT that found no difference in 
overall mortality in the vaccinated versus comparison population over 4 years.  Overall, there 
were no differences detected between vaccinated and comparison populations for any SAEs. 
For systemic adverse events, there was 1 unpublished RCT with the new vaccine formulation 
that found a slightly higher proportion with diarrhea in vaccinated versus comparison persons. 
Overall, the evidence indicates that systemic adverse events occur at similar rates in vaccinated 
and comparison populations. 
 
Post-marketing, spontaneously reported, serious unexpected adverse events were rare for 
Orochol®, the older formulation of this vaccine.  Of more than 500,000 Orochol® doses 
distributed, events included hospitalization with fever, gastroenteritis, vomiting, hemorrhagic 
cerebrospinal fluid in an 11-month old infant; 1 report of Guillain-Barre Syndrome (GBS) in a 
person who received multiple travel vaccines; 1 report of Angioedema; and 1 report of loss of 
hair.  Of more than 200,000 Orochol® E doses distributed, there were no spontaneously 
reported adverse reactions. 
 
Most evidence for serious and systemic adverse events came from studies of an older 
formulation of the vaccine; thus, the evidence type was downgraded for indirectness.  There 
have been relatively few recipients of the newer formulation of the vaccine.  The evidence type 
for these RCTs was downgraded for imprecision.  Overall, SAEs were uncommon, and studies 
with old and new formulations of the vaccine suggest that AEs occur at similar rates in 
vaccinated and comparison populations.  The final evidence type was 3 for RCTs and 4 for 
observational studies, and the overall evidence type was 3. 
 
There were 3 RCTs and 1 observational study that evaluated evidence for decrease in the 
effectiveness of co-administered vaccines and medications.  No effect was identified on 
antibody response to live attenuated oral typhoid vaccine when co-administered with CVD 103-
HgR.  Of people given both vaccines, 62% to 83% developed anti-Typhi antibodies versus 66% 
of people given typhoid vaccine alone.  No effect was identified on antibody response to YF 
vaccine when co-administered with CVD 103-HgR.  Of people given both vaccines, 100% 
developed anti-YF antibodies.  There was 1 additional study that evaluated CVD 103-HgR in 
combination with typhoid, YF, and OPV vaccines, as well as mefloquine, chloroquine, and 
proguanil.  There was lower vibriocidal seroconversion in response to the cholera vaccine when 
chloroquine was co-administered with CVD 103-HgR versus CVD 103-HgR alone. 
 
For typhoid or YF vaccine, the evidence type was downgraded for indirectness, as these studies 
used the older formulation of the vaccine.  There was no suggestion that CVD 103-HgR 
decreases the effectiveness of typhoid or YF fever vaccines.  There was insufficient evidence to 
determine the effect on other co-administered vaccines or medications.  The RCTs received a 
final evidence type of 2, and one observational study received a final evidence type of 4.  The 
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Overall, there was insufficient evidence to determine whether the vaccine prevents cholera 
death.  The evidence suggests that the vaccine prevents life-threatening and severe cholera 
diarrhea, as well as cholera diarrhea of any severity, with an overall evidence type of 1.  The 
evidence suggests that the vaccine induces a vibriocidal antibody response, with an overall 
evidence type of 1.  The evidence did not suggest an association between the vaccine and any 
serious or systemic adverse events, with an overall evidence type of 3.  The evidence, which 
was available with respect to oral live-attenuated typhoid vaccine and YF vaccine, did not 
suggest that CVD 103-HgR decreases the effectiveness of co-administered vaccines or 
medications.  The overall evidence type for this outcome was 2. 
 
In terms of considerations for formulating recommendations for use, cholera is rare in the US.  
Fewer than 25 cases per year have been reported since 2012; however, other years have had 
more cases.  There were 42 cases reported in the US in 2011 during a cholera epidemic in 
Haiti, and there was a large outbreak on a flight from Argentina to Peru to the US in 1992. 
Cholera cases in the US are likely underreported.  Infections that occur while traveling that 
Outcome Studies Initial evidence 
Risk of 










4 RCTs 1 N/A N/A N/A Very serious (-2) N/A N/A N/A Insufficient evidence to 
evaluate 














3 RCTs 1 No serious 
Serious 









4 RCTs 1 No serious 
Serious 






3 Obs 3 Serious (-1) No serious 
Serious 















3 Obs 3 No serious No serious 
Serious 








20 RCTs 1 No serious No serious Serious (-1) Serious (-1) No serious None 3 
3 







3 RCTs 1 No serious No serious Serious (-1) No serious No serious None 2 
2 
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resolve before return to the US are not captured by US surveillance.  Cholera has a short 
incubation period, and little information is available about cases that occur while traveling. 
 
Cholera can be severe and rapidly life-threatening.  The overall risk of cholera is very low for 
most US travelers, and it is treatable if medical services are readily available.  However, certain 
populations may be at higher risk of exposure.  These may include HCP, outbreak response 
workers, persons visiting friends or relatives, and persons traveling or living in cholera-affected 
areas for extended periods.  Certain populations also may be at higher risk of poor outcomes, 
including those with low gastric acidity or blood type O, or persons without ready access to 
medical services.  It is important to note that sanitation, hygiene, and safe water and food 
remain critical to preventing cholera and other enteric infections. 
 
Overall, the evidence type is 1 for prevention of cholera diarrhea and induction of a vibriocidal 
antibody response.  Overall, the evidence type is 3 for safety as assessed by serious and 
systemic adverse events and 2 for decreasing the effectiveness of co-administered vaccines 
and medications.  There are insufficient data to evaluate whether CVD 103-HgR prevents death 
from cholera.  Also, there are no data currently available on the safety and efficacy of this 
vaccine in pregnant women.  In terms of the balance between benefits and harms, there is 
strong evidence that CVD 103-HgR prevents cholera diarrhea.  SAEs were uncommon with the 
older formulation of vaccine.  Limited evidence suggests that SAEs are also uncommon with the 
newer formulation.  Systemic adverse events occur at similar rates in vaccinated and 
comparison groups. 
 
High value is placed on the ability to prevent a severe, life-threatening illness in travelers at risk 
of cholera exposure or severe cholera illness, especially if medical care is not readily 
accessible.  Cost-effectiveness was not evaluated in this review.  Risk of cholera is very low for 
most travelers to cholera-affected areas.  Travel vaccines are usually paid for by employers or 
by the travelers themselves, depending upon the circumstances. 
 
The WG has discussed options for draft recommendations.  One option is a broad 
recommendation: to recommend or consider the vaccine for adults planning to travel to a 
cholera-affected area.  Another option is more targeted: to recommend or consider for adults 
who are at high risk of exposure (for example, cholera outbreak response workers) or at risk for 
severe illness. 
 
Based upon review of the evidence for critical and important outcomes, the WG concluded that 
the vaccine is safe and effective.  The WG is continuing to discuss a Category A versus 
Category B recommendation, and whether specific risk groups should be emphasized in the 
recommendations.  The WG is evaluating evidence for duration of protection and for re-
immunization.  Evidence is being evaluated from selected subgroups, such as 
immunocompromised persons, separately from this GRADE review.  The WG also is evaluating 
pediatric studies separately from this GRADE review, as a summary of these data may be 
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In conclusion, Dr. Wong reminded everyone that the original policy question assessed by this 
GRADE evaluation was, “Should CVD 103-HgR be recommended for use in adults at risk of 
travel-related exposure to toxigenic Vibrio cholerae O1?”  As ACIP considers these questions, 
she asked the members also to consider whether within the policy option, specific risk groups 
should be emphasized, and whether there were additional data that would be helpful to ACIP to 




Dr. Karron asked whether a lot of data would be available on duration of protection beyond 6 
months. 
 
Dr. Danzig replied that with the historical formulation, she presented re-immunization data from 
2.5 to 3.5 years.  PaxVax currently is negotiating final labeling with the FDA.  They anticipate 
post-marketing commitments and will be designing them together with the FDA.  However, no 
studies have been initiated to date so no data will be forthcoming soon. 
 
Dr. Ezeanolue asked how soon data on pediatrics would be available.  He thought she 
mentioned that these data were already available. 
 
Dr. Danzig responded that PaxVax plans to submit the protocol to FDA by the end of 2016, so it 
will take a couple of years before the pediatric data with the new vaccine formulation are 
available. 
 
Dr. Wong responded that historical data with the older formulation of the vaccine are available 




Dr. Jeanne M. Santoli 
Immunization Services Division 
National Center for Immunization and Respiratory Diseases 
Centers for Disease Control and Prevention 
 
During this session, Dr. Santoli presented an update on Pentacel® vaccine.  In December 2015, 
Sanofi Pasteur announced a manufacturing delay with Pentacel® vaccine.  As a result, Sanofi 
Pasteur is only able to meet approximately 70% of historical Pentacel® vaccine demand 
throughout the first half of 2016.  At this time, sufficient supplies of the relevant individually 
administered vaccines DAPTACEL®, ActHIB®, and IPOL® are available to address the 
anticipated gap in Pentacel® supply. 
 













Julie Lindberg, Pregnant Mother 
Delivered in Person and by Letter Submitted to ACIP for the Record 
 
713 Berkeley Ave NW, Atlanta, GA 30318 
julielindberg@yahoo.com  
Injury and Death by Vaccines February 24, 2016  
 
First of all, I want to thank you for your expertise.  Thank you for listening to these public 
comments.  It is a privilege to be able to speak to you today.  
 
I am here to talk about your recommendations in general, but first I want to share with you 
something new that affects me personally today.  I am pregnant, and my health care provider 
follows your advice to recommend the inactivated flu vaccine and the Tdap.  The CDC website 
tells me that the flu shot is safe for me and my child and that it has been shown to protect us 
from the flu.  Unfortunately, the manufacturers for every single flu vaccine on the market today 
publicly state the exact opposite, in writing.  Currently, Novartis, GlaxoSmithKline, Sanofi 
Pasteur, Protein Sciences Corporation, and bioCSL, state that safety and effectiveness of their 
flu vaccine have not been established for pregnant women.  The same is true for Tdap, 
according to Sanofi Pasteur and GlaxoSmithKline.  Both available Tdap vaccines, Adacel and 
Boostrix, contain high levels of aluminum.  The World Health Organization states that one of the 
risk factors of heavy metal exposure is that it can cause microcephaly. 
 
But I am not here to talk about the flu vaccine or Tdap.  Or Brazil.  I want to speak to you about 
all your recommendations.  I am asking you today to slow down, maybe stop altogether, and 
reexamine the injury and death that all kinds of vaccines have caused.  
 
Historically, this advisory committee has recommended vaccines that have not undergone 
safety testing with a true placebo, not another vaccine as a placebo, but a placebo that does 
nothing to the human body.  You have recommended vaccines that are not tested for long-term 
effectiveness, vaccines that severely disable and kill.  Your recommendations are being applied 
in deceptive, abusive, forceful ways, in our own country and across the globe.  True informed 
consent is being sidestepped and ignored.  This is wrong. I am asking you today to stop and 
challenge one another to look at these issues in the face.  
 
The history of vaccines, from 1850 to today, particularly in the U.S., does not show that 
vaccines are responsible for the major decline of disease and death.  Clean water, proper 
nutrition, effective sanitation, holistic medicine, and compassionate quarantine have saved 
millions of lives.  I am asking you to stop and look at a broader view of history.  
 
You have been given a position of authority and influence.  You shape the beliefs and actions of 
people across the world.  You influence the law and the economy.  Take some time and turn 
your eyes away from the money and the power and the illusions.  Both diseases and vaccines 
have ruined lives.  Smallpox, polio, diphtheria, pertussis, and SIDS have not been reduced. 
They have been renamed.  Prod one another to greater honesty.  Take courage and walk away 
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heartbreak in the vaccine industry.  We can wait for you.  We have a multitude of safe options to 
prevent sickness while you take the time to “First Do No Harm.”  
 
Disease exists in many forms.  But it will not win in the end.  Be courageous and ask for deeper 
wisdom in these matters.  Thank you for your time. 
 
Mara Berger 
Parent of Adam Berger, Deceased 
Letter Submitted to ACIP for the Record 
 
February 8, 2016 
 
From:  Mara Berger, mother of Adam Berger, deceased 
Address:  5801 N. Sheridan Road, Chicago, IL  60660 
Email: maraberger@hotmail.com 
 
Subject:  To Recommend the Conjugate Vaccine to the Adult Population concerning Neisseria 
Meningitidis strain C 
 
This is the third time I'm requesting that the ACIP recommends the conjugate vaccines 
Menactra and Menveo for routine usage in healthy adults 21-55 years old and to healthcare 
personnel for the purpose of protecting them from contracting meningococcal disease/Neisseria 
meningitidis bacterial strains A, C, Y and W135.  The ACIP and CDC have never targeted or 
recommended the conjugate vaccines to them, which appears to be intentional and without 
explanation. The fact is that healthy adults and healthcare personnel do contract meningococcal 
disease and can suffer sequelae or die.  The ACIP, CDC and HHS are aware that one of them 
who died two years ago was my son, Adam age 44, who was healthy and a nursing student. He 
had contracted Neisseria meningitidis strain C and died within hours. After he died, I did 
extensive research and learned that Neisseria meningitidis is a vaccine preventable disease, 
which would have prevented his untimely and needless death. The ACIP and CDC cannot 
continue to turn a blind eye and ignore the fact that healthy adults as well as those in the 
healthcare field are at risk for meningococcal disease. Unbeknownst to me, many health 
facilities such as the prestigious teaching hospital that Adam worked at in Chicago didn't 
mention meningococcal disease to Adam or recommend the conjugate vaccines for strains A, 
C, Y and W135 because they follow the CDC, which doesn’t recommend the vaccines to adults 
over 21 years or healthcare personnel for routine use.  Healthy adults without medical 
conditions are just as at risk to contract meningococcal disease. Does the ACIP and CDC want 
healthy adults to believe that because they're healthy, that they won't contract the 
disease?   Anyone, anytime and anywhere can contract dangerous Neisseria meningitidis 
suddenly and even with proper care, can die within hours.  That is why it’s most important to 
prevent the disease before it starts with vaccination and adults should have that choice and 
know the risk of not getting vaccinated.  I never heard of meningococcal disease or Neisseria 
meningitidis prior to Adam’s death.  I feel duped by the CDC.  Since the government’s top health 
agencies don’t recommend the vaccine to protect us, why would they educate the public about 
the disease and vaccines to prevent it.  They wouldn’t.  Therefore, healthy adults and healthcare 
personnel are at risk for the disease.  The ACIP and CDC are supposed to make sound medical 
decisions and protect all people and save lives. The conjugate vaccine Menactra was approved 
by the FDA in 2005 for 9-month to 55 year olds for routine usage and Menveo was approved in 
2010 for 9-month to 55 year olds for routine usage.  The ACIP and CDC never recommended 
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the scientific or medical reason that the ACIP and CDC have never recommended those 
conjugate vaccines to them.  In my opinion, any other excuse or reason would be egregious and 
irresponsible.  They refuse to recommend the vaccines, yet, the CDC’s website states that 
Neisseria meningitidis is the leading cause of infectious disease in the United States; that the 
vaccine is safe, immunogenic and effective; that vaccination in adults is low and that there has 
been no decrease of incidence in adults.  My research written by an expert in a reputable 
medical journal states that the average age to contract meningococcal disease is 45 years old 
and male although women contract it also. In terms of incidence of the disease resulting in 
mortality or morbidity, the greatest burden of disease is among adults 25-64 years old in which 
60% of the cases and 70% of fatalities occur. The ACIP and CDC omitting that information on 
their website is very troubling because omission is a lie. The federal government appoints 
individuals to represent and protect the public and physicians take an oath to “Do No Harm.”  In 
my opinion, much harm has been done over the years.  What I already knew, but Health 
Secretary Burwell confirmed in a letter to me stated that “Based on its comprehensive analysis 
of the available evidence, it is possible that ACIP might not recommend an FDA-licensed 
vaccine for routine use. However, physicians or other healthcare providers would still be able to 
administer the FDA-licensed vaccine according to the labeled indications.”  Therefore, it 
appears that physicians can act in their patients’ best interests and bring up the subject of 
meningococcal disease and the vaccine to prevent it to their healthy patients and those persons 
entering the healthcare field.  If physicians don’t want to supply and store the vaccine, they can 
send their patients to the pharmacy for the inoculations.  In my opinion, someone must be held 
accountable and responsible for the intentional and irrational decision to not recommend a life-
saving vaccine to prevent maiming and death.  In memory of Adam, I’m going to educate adults 
about the risks of meningococcal disease and the conjugate vaccines to prevent it.  I say to the 
ACIP…It’s time to recommend the meningococcal conjugate vaccines to healthy adults 21-55 
and healthcare personnel for routine usage. 
 
Frankie Milley 
Founder / National Director  
Meningitis Angels 
Letter Submitted to ACIP for the Record 
 
   Meningitis Angels 
 
Website www.Meningitis-Angels.org   
Address PO Box 448, Porter, Texas 77365 
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Ref: Meningococcal B Vaccines 
 
Dear Dr. Nancy Bennett and ACIP Committee: 
 
First let me say thank you for you service to all of us for your most important work on vaccines.  
The work you all do insures our country and the world we will be protected from vaccine 
preventable diseases. 
 
Today, I am writing to ask you to strongly consider full recommendations for the use of 
MenACWY vaccines in HIV-infected persons and among men who have sex with men (MSM).  
At the same time though not on the agenda.  I am asking you to also reconsider stronger 
recommendations for the use of the meningococcal B vaccines among teens and young adults.   
The US, as you know, is still experiencing outbreaks with the most recent in California.  Each 
time this happens another life is at risk.  Another family may have to bury a child, as I did 
needlessly, or care for one severely disabled.  
 
The current recommendation for this age group is not working as well as it should.  It leaves 
health care providers confused and afraid of the liability of giving a vaccine not fully 
recommended by the ACIP Committee.  The permissive recommendations do NOT allow for 
proper education on the disease and vaccines.  Affordability and accessibility due to permissive 
recommendations as always are an issue.  
 
I am asking the committee to please once and for all to do the right thing.  Please give strong 
recommendations for all 3 of the high risk groups listed above.  The decision to protect lives 
from disease and death are never the wrong ones.  
 
Respectfully, Thank You, Frankie Milley, Mom to Ryan,  
Meningitis Angels, National Executive Director 
 
Hollie Smith and Laura Matrka 
Letter Submitted to ACIP for the Record 
 
NOTICE OF DENIAL 
 (To Hollie Smith) 
Dear  
 
Catamaran, an OptumRx company ("OptumRx"), on behalf of L Brands Inc, is responsible 
for reviewing pharmacy services provided to L Brands Inc members. OptumRx received a 
request on 2/1/2016 and reviewed it to provide the following medication, GARDASIL INJ, at 
a zero dollar cost to you.  
 http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-
specificlindex.html for specific details).  
 
The reason(s) OptumRx did not approve this medication can be found above. This denial 





Why was my request denied?  
This request was denied because you did not meet the following clinical requirements:  
In order for the plan to cover a vaccine at zero copay, the requested vaccine must 
be listed as recommended per the Advisory Committee on Immunization 
Practices (ACIP) guidelines (see




What if I need help understanding why my request was denied?  
Contact OptumRx at 8776656609 for assistance with understanding this letter and the 
decision to deny you a service or coverage.  
 
How can I obtain the material(s) used to review this request?  
You may request, free of charge, a copy of the drug coverage policy, actual benefit 
provision, guideline, protocol or other similar criterion on which the denial decision is 
based, including the diagnosis code and the treatment code and their corresponding 
meanings, by calling OptumRx at 8776656609, or by writing to OptumRx at the address 
below:  
 
OptumRx Prior Authorization 
Department  
P.O. Box 5252  
Lisle, IL 60532-5252  
 
All OptumlM trademarks and logos are owned by Optum, Inc. All other brand or product 
names are trademarks or registered marks of their respective owners.  
© 2016 Optum. Inc. All rights reserved.   
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To Whom it May Concern: 
 
I am writing to request coverage of the Gardasil vaccine for patient _____________ for the 
condition of Recurrent Respiratory Papillomatosis, caused by HPV strains 6 and 11, for the 
following reasons. 
 
1. Patients with RRP fail to clear the HPV virus, whereas normal people typically clear it 
within 9 months or so.  They have an incompletely-understood susceptibility to HPV that 
may put them at increased risk of other HPV-mediated disease such as infection with 
HPV 16 or 18 leading to oropharyngeal or cervical malignancy. 
2. Recent data indicates that RRP patients who receive the Gardasil vaccine have a 
decreased number of surgeries per year and a longer interval between surgeries.  The 
average interval between procedures in the non-vaccinated group was 271.2 days; after 
vaccination, this increased to 537.4 days.  The average number of surgeries per year 
prior to vaccination was 2.16; this dropped to 0.93 surgeries per year after vaccination. 
(Hocevar-Boltezar et al Eur Arch Otorhinolaryngol “Human papilloma virus vaccination in 
patients with an aggressive course of recurrent respiratory papillomatosis.” 
2014;271:3255–3262.) 
 
Decreased number of procedures would lead both to better health for these patients and 
obvious financial benefit to the insurance companies who cover them. 
 
Thank you for your consideration, 











Upon reviewing the foregoing version of the February 24, 2016 ACIP meeting minutes, Dr. 
Nancy Bennett, ACIP Chair, certified that to the best of her knowledge, they are accurate and 
complete.  Her original, signed certification is on file with the Management Analysis and 
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